

# SCIENTIFIC PROGRAMME

10° CONGRESSO NAZIONALE



**Italian Conference on  
AIDS and Antiviral Research**

Presidenza del Congresso  
**Massimo Andreoni**, Roma  
**Andrea Antinori**, Roma  
**Carlo Federico Perno**, Milano

**10  
ANNI  
VERSARY**

22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



Promosso da



e da

**INMI**, Istituto Nazionale per le Malattie Infettive

**ISS**, Istituto Superiore di Sanità

**AMCLI**, Associazione Microbiologi Clinici Italiani

**SIICA**, Società Italiana di Immunologia,  
Immunologia Clinica e Allergologia

**SIMaST**, Società Interdisciplinare per lo Studio  
delle Malattie Sessualmente Trasmissibili

**SITA**, Società italiana per la Terapia Antinfettiva

**SIV-ISV**, Società Italiana di Virologia - Italian  
Society for Virology

**ANLAIDS**, Associazione Nazionale per la lotta  
all'AIDS

**ARCIGAY**, Associazione LGBT Italiana

**EpaC Onlus**, Associazione EpaC Onlus

**LILA**, Lega Italiana per la lotta contro l'AIDS


**MARIO MIELI**, Circolo di Cultura Omosessuale


**NADIR**, Associazione Nadir Onlus

**NPS Italia Onlus**, Network Persone Sieropositive

**PLUS Onlus**, Persone LGBT sieropositive Onlus

Endorsements





## PROVIDER AND ORGANIZING SECRETARIAT



Via G.B. Giorgini, 16 - 20151 Milan, I  
Phone +39 02 3343281 - Fax +39 02 33496370  
icar2018@effetti.it  
www.effetti.it

## QUICK LINKS

**Organizing Secretariat** [icar2018@effetti.it](mailto:icar2018@effetti.it)  
**Abstract Secretariat** [abstract.icar2018@effetti.it](mailto:abstract.icar2018@effetti.it)  
**ICAR Website** [www.icar2018.it](http://www.icar2018.it)



[www.facebook.com/ICAR2018Roma](https://www.facebook.com/ICAR2018Roma)



[twitter.com/ICAR2018Roma](https://twitter.com/ICAR2018Roma)

## Promoted by

**SIMIT** Società Italiana di Malattie Infettive e Tropicali

## and by

**INMI**, Istituto Nazionale per le Malattie Infettive

**ISS**, Istituto Superiore di Sanità

**AMCLI**, Associazione Microbiologi Clinici Italiani

**SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

**SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

**SITA**, Società italiana per la Terapia Antinfettiva

**SIV-ISV**, Società Italiana di Virologia – Italian Society for Virology

**ANLAIDS**, Associazione Nazionale per la lotta contro l'AIDS

**ARCIGAY**, Associazione LGBT Italiana

**EpaC**, Educazione, Prevenzione e Ricerca sull'Epatite C

**LILA**, Lega Italiana per la lotta contro l'AIDS

**MARIO MIELI**, Circolo di Cultura Omosessuale

**NADIR**, Associazione Nadir Onlus

**NPS Italia Onlus**, Network Persone Sieropositive

**PLUS Onlus**, Persone LGBT sieropositive Onlus

## Endorsements

### INSTITUTIONS

**Ministero della Salute**

**AIFA**, Agenzia Italiana del Farmaco

**CNR**, Consiglio Nazionale delle Ricerche

**Città metropolitana di Roma Capitale**

**Fondazione PTV Policlinico Tor Vergata**

**Università degli Studi di Roma "Tor Vergata"**

**Università degli Studi di Milano**

### SCIENTIFIC SOCIETIES AND ASSOCIATIONS

**AIMI**, Associazione Infermieri Malattie Infettive

**AISF**, Associazione Italiana per lo Studio del Fegato

**Arcobaleno AIDS**

**ASA**, Associazione Solidarietà AIDS

**ASPE**, Associazione Studio Patologie Epatiche

**Aviralia**, Fondazione Aviralia Onlus

**C.I.C.A.** Coordinamento Italiano delle Case Alloggio per persone con HIV/AIDS

**Cittadinanzattiva**

**FeDerSerD**, Federazione Italiana degli Operatori dei Dipartimenti e dei Servizi delle Dipendenze

**Gay Center**

**SIM**, Società Italiana di Microbiologia

**SIMPIOS**, Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

**SIMSPe**, Società Italiana di Medicina e Sanità Penitenziaria

**SIPaD**, Società Italiana Patologie da Dipendenza

**Villa Maraini** Fondazione onlus



**IMPORTANTI OBIETTIVI TERAPEUTICI.**



**FARMACI INNOVATIVI.**



**CURE MIGLIORI.**

**Combattiamo patologie gravi.**

In Gilead applichiamo il meglio della scienza biofarmaceutica per creare medicinali innovativi che portino nuove speranze nella lotta contro l'HIV/AIDS, patologie del fegato e gravi patologie cardiovascolari e respiratorie.

**Superando gli attuali standard terapeutici.**

Stiamo sviluppando nuovi farmaci di maggiore efficacia, migliore profilo di resistenza, migliore indice di sicurezza e con schemi di dosaggio più semplici. Grazie ad ogni progresso nelle terapie, cerchiamo di migliorare significativamente la cura del paziente e la vita umana.



**GILEAD**

Advancing Therapeutics.  
Improving Lives.



## Scientific Committee

### CHAIRS

- Massimo Andreoni, Roma
- Andrea Antinori, Roma
- Carlo Federico Perno, Milano

### SCIENTIFIC SECRETARIAT

- Chiara Agrati, Roma
- Alessandra Bandera, Monza
- Marco Borderi, Bologna
- Andrea Calcagno, Torino
- Maria Rosaria Capobianchi, Roma
- Antonella Castagna, Milano
- Francesca Ceccherini - Silberstein, Roma
- Benedetto Maurizio Ceesia, Catania
- Valeria Cento, Milano
- Stefania Cicalini, Roma
- Antonella Cingolani, Roma
- Paola Cinque, Milano
- Nicola Coppola, Napoli
- Maria Luisa Cosmaro, Milano
- Andrea Cossarizza, Modena
- Gabriella d'Ettore, Roma
- Andrea De Luca, Siena
- Antonio Di Biagio, Genova
- Massimo Farinella, Roma
- Enrico Girardi, Roma
- Miriam Lichtner, Latina
- Sergio Lo Caputo, Bari
- Giordano Madeddu, Sassari
- Gaetano Maffongelli, Roma
- Franco Maggiolo, Bergamo
- Giulia Marchetti, Milano
- Cristina Mussini, Modena
- Giuseppe Nunnari, Messina
- Carmela Pinnetti, Roma
- Massimo Puoti, Milano
- Vincenzo Puro, Roma
- Stefano Rusconi, Milano
- Maria Santoro, Roma
- Loredana Sarmati, Roma
- Valentina Svicher, Roma
- Gloria Taliani, Roma
- Elisabetta Teti, Roma

## Government Bodies

### ICAR GOVERNMENT

#### Coordinator

- Andrea Antinori, Roma

#### Secretary

- Antonella d'Arminio Monforte, Milano

#### Members

- Massimo Andreoni, Roma
- Giulio Maria Corbelli, Bologna
- Massimo Galli, Milano
- Adriano Lazzarin, Milano
- Carlo Federico Perno, Roma
- Massimo Puoti, Milano
- Maurizio Zazzi, Siena

### SPC

#### (SCIENTIFIC PROGRAMME COMMITTEE)

- Massimo Andreoni, Roma
- Giocchino Angarano, Bari
- Andrea Antinori, Roma
- Guido Antonelli, Roma
- Francesco Benanti, Catania
- Marco Borderi, Bologna
- Michele Breveglieri, Verona
- Raffaele Bruno, Pavia
- Stefano Buttò, Roma
- Maria Capobianchi, Roma
- Antonella Castagna, Milano
- Francesco Castelli, Brescia
- Anna Maria Cattelan, Padova
- Antonio Chirianni, Napoli
- Paola Cinque, Milano
- Massimo Clementi, Milano
- Giulio Maria Corbelli, Bologna
- Andrea Cossarizza, Modena
- Antonella d'Arminio Monforte, Milano
- Andrea De Luca, Siena
- Maria Grazia Di Benedetto, Catania
- Giovanni Di Perri, Torino
- Margherita Errico, Milano
- Vincenzo Esposito, Napoli
- Carlo Ferrari, Parma
- Giovanni Battista Gaeta, Napoli
- Massimo Galli, Milano
- Ivan Gardini, Vercate MB
- Enrico Girardi, Roma
- Andrea Gori, Monza

- Giuseppe Ippolito, Roma
- Adriano Lazzarin, Milano
- Sergio Lo Caputo, Bari
- Paolo Maggi, Bari
- Franco Maggiolo, Bergamo
- Bruno Marchini, Roma
- Claudio M. Mastroianni, Latina
- Francesco Mazzotta, Firenze
- Cristina Mussini, Modena
- Giorgio Palù, Padova
- Carlo Federico Perno, Milano
- Massimo Puoti, Milano
- Giovanni Rezza, Roma
- Giuliano Rizzardini, Milano
- Stefano Rusconi, Milano
- Filippo von Schloesser, Roma
- Guido Silvestri, Atlanta USA
- Giulio Starnini, Viterbo
- Barbara Suligoi, Roma
- Gloria Taliani, Roma
- Carlo Torti, Catanzaro
- Stefano Vella, Roma
- Claudio Viscoli, Genova
- Maurizio Zazzi, Siena

### CSC (COMMUNITY SUB-COMMITTEE)

- Michele Breveglieri, Bologna (Arcigay)
- Giulio Maria Corbelli, Bologna (PLUS Onlus)
- Maria Grazia Di Benedetto, Catania (LILA)
- Margherita Errico, Milano (NPS Italia Onlus)
- Massimo Farinella, Roma (Circolo Mario Mieli)
- Ivan Gardini, Vercate MB (EpaC Onlus)
- Bruno Marchini, Roma (ANLAIDS)
- Filippo Schloesser, Roma (Nadir Onlus)

### ANNUAL PROGRAMME COMMITTEE

- Massimo Andreoni, Roma
- Andrea Antinori, Roma
- Guido Antonelli, Roma
- Michele Breveglieri, Bologna
- Margherita Errico, Milano
- Giuseppe Ippolito, Roma
- Claudio Maria Mastroianni, Roma
- Carlo Federico Perno, Milano



## Faculty

- **Isabella Abbate**, Roma
- **Chiara Agrati**, Roma
- **Claudia Alteri**, Roma
- **Laura Amato**, Roma
- **Massimo Andreoni**, Roma
- **Gioacchino Angarano**, Bari
- **Andrea Antinori**, Roma
- **Guido Antonelli**, Roma
- **Daniele Armenia**, Roma
- **Orlando Armignacco**, Roma
- **Sergio Babudieri**, Sassari
- **Patrizia Bagnarelli**, Ancona
- **Fausto Baldanti**, Pavia
- **Franco Baldelli**, Perugia
- **Alessandra Bandera**, Monza
- **Francesco Benanti**, Catania
- **Laura A. Benjamin**, Liverpool UK
- **Teresa Bini**, Milano
- **Isabella Bon**, Bologna
- **Paolo Bonfanti**, Lecco
- **Stefano Bonora**, Torino
- **Marco Borderi**, Bologna
- **Michele Breveglieri**, Bologna
- **Raffaele Bruno**, Pavia
- **Leonardo Calza**, Bologna
- **Fabio Cannone**, Roma
- **Maria Rosaria Capobianchi**, Roma
- **Giampiero Carosi**, Brescia
- **Antonio Cascio**, Palermo
- **Antonella Castagna**, Milano
- **Francesco Castelli**, Brescia
- **Anna Maria Cattelan**, Padova
- **Roberto Cauda**, Roma
- **Francesca Ceccherini – Silberstein**, Roma
- **Benedetto Maurizio Celesia**, Catania
- **Valeria Cento**, Milano
- **Ethel Cesarman**, New York USA
- **Antonio Chirianni**, Napoli
- **Antonella Cingolani**, Roma
- **Paola Cinque**, Milano
- **Massimo Clementi**, Milano
- **Mario Clerici**, Milano
- **Nicola Coppola**, Napoli
- **Giulio Maria Corbelli**, Bologna
- **Maria Luisa Cosmaro**, Milano
- **Andrea Cossarizza**, Modena
- **Claudia D'Agostino**, Roma
- **Antonella d'Arminio Monforte**, Milano
- **Gabriella d'Ettore**, Roma
- **Gianpiero D'Offizi**, Roma
- **Marina Davoli**, Roma
- **Alessia De Angelis**, Roma
- **Andrea De Luca**, Siena
- **Andrea De Maria**, Genova
- **Giuseppe Vittorio De Socio**, Perugia
- **Maria Grazia Di Benedetto**, Catania
- **Antonio Di Biagio**, Genova
- **Simona Di Giambenedetto**, Roma
- **Massimo A. Di Pietro**, Pistoia
- **Philippa Easterbrook**, Geneva CH
- **Margherita Errico**, Milano
- **Massimo Farinella**, Roma
- **Silvia Franceschi**, Aviano PD
- **Giovanni Battista Gaeta**, Napoli
- **Massimo Galli**, Milano
- **Cristina Gervasoni**, Milano
- **Valeria Ghesetti**, Torino
- **Andrea Giacometti**, Ancona
- **Nicola Gianotti**, Milano
- **Enrico Girardi**, Roma
- **Andrea Gori**, Milano
- **Giovanni Guaraldi**, Modena
- **Maria Rosaria Iardino**, Milano
- **Patrick Ingiliz**, Berlin D
- **Giuseppe Ippolito**, Roma
- **Giuseppe Lapadula**, Monza
- **Adriano Lazzarin**, Milano
- **Miriam Lichtner**, Latina
- **Giuseppina Liuzzi**, Roma
- **Sergio Lo Caputo**, Bari
- **Lucia Lopalco**, Milano
- **Giordano Madeddu**, Sassari
- **Paolo Maggi**, Bari
- **Franco Maggiolo**, Bergamo
- **Patrizia Magrini**, Roma
- **Michele Maio**, Siena
- **Giulia Marchetti**, Milano
- **Bruno Marchini**, Roma
- **Simone Marcotullio**, Roma
- **Javier Martinez-Picado**, Badalona E
- **Renato Maserati**, Pavia
- **Claudio Maria Mastroianni**, Roma
- **Sandro Mattioli**, Bologna
- **Giovanni Mazzola**, Palermo
- **Francesco Mazzotta**, Firenze
- **Jean-Michel Molina**, Paris F
- **Cristina Mussini**, Modena
- **Felice Alfonso Nava**, Padova
- **Silvia Nozza**, Milano
- **Giuseppe Nunnari**, Messina
- **Massimo Oldrini**, Como
- **Gian Piero Oliva**, Roma
- **Giorgio Palù**, Padova
- **Saverio Parisi**, Padova
- **Giustino Parruti**, Pescara
- **Carlo Federico Perno**, Milano
- **Carmela Pinnetti**, Roma

- **Guido Poli**, Milano
  - **Alessandro Porreca**, Bologna
  - **Massimo Puoti**, Milano
  - **Vincenzo Puro**, Roma
  - **Laura Rancilio**, Milano
  - **Maria Carla Re**, Bologna
  - **Stefano Regio**, Roma
  - **Giovanni Rezza**, Roma
  - **Diego Ripamonti**, Bergamo
  - **Giuliano Rizzardini**, Milano
  - **Paolo Rizzini**, Verona
  - **Stefano Rusconi**, Milano
  - **Maurizio Sanguinetti**, Roma
  - **Maria Santoro**, Roma
  - **Annalisa Saracino**, Bari
  - **Loredana Sarmati**, Roma
  - **Gabriella Scarlatti**, Milano
  - **Filippo von Schloesser**, Roma
  - **Laura Sighinolfi**, Ferrara
  - **Guido Silvestri**, Atlanta USA
  - **Maria Stagnitta**, Firenze
  - **Giulio Starnini**, Viterbo
  - **Gaetana Sterrantino**, Firenze
  - **Barbara Suligoi**, Roma
  - **Valentina Svicher**, Roma
  - **Gloria Taliani**, Roma
  - **Giuseppe Tambussi**, Milano
  - **Marcello Tavio**, Ancona
  - **Carlo Torti**, Catanzaro
  - **Ombretta Turriziani**, Roma
  - **Stefano Vella**, Roma
  - **Mario Venditti**, Roma
  - **Claudio Viscoli**, Genova
  - **Vincenzo Vullo**, Roma
  - **Mauro Zaccarelli**, Roma
  - **Erika Zampieri**, Roma
  - **Maurizio Zazzi**, Siena
  - **Rosa Rita Zortea**, Gorizia
- 
- ## Abstract reviewers
- **Chiara Agrati**, Roma
  - **Mauro Andreotti**, Roma
  - **Guido Antonelli**, Roma
  - **Alessandra Bandera**, Monza
  - **Marco Bartoli**, Roma
  - **Dario Bartolozzi**, Firenze
  - **Teresa Bini**, Milano
  - **Paolo Bonfanti**, Lecco
  - **Stefano Bonora**, Torino
  - **Marco Borderi**, Bologna
  - **Vanni Borghi**, Modena
  - **Maurizia Rossana Brunetto**, Pisa
  - **Andrea Calcagno**, Torino
  - **Anna Paola Callegaro**, Bergamo
  - **Leonardo Calza**, Bologna
  - **Maria Rosaria Capobianchi**, Roma
  - **Antonella Castagna**, Milano
  - **Francesco Castelli**, Brescia
  - **Francesca Ceccherini - Silberstein**, Roma
  - **Benedetto Maurizio Celesia**, Catania
  - **Valeria Cento**, Milano
  - **Massimo Cernuschi**, Milano
  - **Stefania Cicalini**, Roma
  - **Antonella Cingolani**, Roma
  - **Paola Cinque**, Milano
  - **Mario Clerici**, Milano
  - **Nicola Coppola**, Napoli
  - **Giulio Maria Corbelli**, Bologna
  - **Maria Luisa Cosmaro**, Milano
  - **Andrea Cossarizza**, Modena
  - **Gabriella d'Ettore**, Roma
  - **Gianpiero D'Offizi**, Roma
  - **Andrea De Luca**, Siena
  - **Andrea De Maria**, Genova
  - **Antonio Di Biagio**, Genova
  - **Giovanni Di Perri**, Torino
  - **Margherita Errico**, Milano
  - **Massimo Farinella**, Roma
  - **Carlo Ferrari**, Parma
  - **Giovanni Battista Gaeta**, Napoli
  - **Cristina Gervasoni**, Milano
  - **Nicola Gianotti**, Milano
  - **Enrico Girardi**, Roma
  - **Andrea Gori**, Milano
  - **Maria Rosaria Iardino**, Milano
  - **Giuseppe Lapadula**, Monza
  - **Miriam Lichtner**, Latina
  - **Giuseppina Liuzzi**, Roma
  - **Sergio Lo Caputo**, Bari
  - **Giordano Madeddu**, Sassari
  - **Gaetano Maffongelli**, Roma
  - **Paolo Maggi**, Bari
  - **Franco Maggiolo**, Bergamo
  - **Giulia Marchetti**, Milano
  - **Simone Marcotullio**, Roma
  - **Renato Maserati**, Pavia
  - **Claudio Maria Mastroianni**, Roma
  - **Alberto Matteelli**, Brescia
  - **Laura Monno**, Bari
  - **Cristina Mussini**, Modena
  - **Emanuele Nicastrì**, Roma
  - **Silvia Nozza**, Milano
  - **Giuseppe Nunnari**, Messina
  - **Giancarlo Orofino**, Torino
  - **Saverio Parisi**, Padova
  - **Giustino Parruti**, Pescara
  - **Stefania Piconi**, Milano
  - **Carmela Pinnetti**, Roma
  - **Massimo Puoti**, Milano
  - **Vincenzo Puro**, Roma
  - **Agostino Riva**, Milano
  - **Giuliano Rizzardini**, Milano
  - **Stefano Rusconi**, Milano
  - **Maria Santoro**, Roma
  - **Annalisa Saracino**, Bari
  - **Loredana Sarmati**, Roma
  - **Gabriella Scarlatti**, Milano
  - **Laura Sighinolfi**, Ferrara
  - **Alessandro Soria**, Monza
  - **Vincenzo Spagnuolo**, Milano
  - **Nicola Squillace**, Monza
  - **Gaetana Sterrantino**, Firenze
  - **Valentina Svicher**, Roma
  - **Gloria Taliani**, Roma
  - **Giuseppe Tambussi**, Milano
  - **Marcello Tavio**, Ancona
  - **Elisabetta Teti**, Roma
  - **Camilla Tincati**, Milano
  - **Carlo Torti**, Catanzaro
  - **Daria Trabattoni**, Milano
  - **Francesca Vichi**, Firenze
  - **Mauro Zaccarelli**, Roma

Dear Colleagues,

It is our great pleasure to welcome you to the **10<sup>th</sup> edition of ICAR, the Italian Conference on AIDS and Antiviral Research** which takes place this year in **Rome**.

In keeping with the tradition, ICAR 2018 preserves its characteristic of **abstract-driven Congress** based on the interaction among epidemiology, basic research, virology, clinical research and the needs of patient associations, providing great visibility to young researchers and community representatives. The Conference features supporting initiatives such as the **Young Investigators** and **Community Scholarships** and the **ICAR-CROI Awards** dedicated to the top young Italian investigators selected during the CROI 2018.

In the three days of the Conference, ICAR treats a wide range of topics including basic science, clinical and virological research and benefits from significant contributions from the Community of patient associations: 47 Scientific Sessions, 7 Keynote Lectures, 75 Oral Communications, 52 Poster Discussions and 5 Advanced Courses. We expect around 1.500 participants among physicians, researchers, members of patient associations and health professionals.

In terms of public health, ICAR 2018 wants to face the issues relating to cure and prevention of viral infections, opening up to societal and institutional players. In this field the following activities are reconfirmed: **RaccontART** Contest, the art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through different forms of expression; **HIV and HCV rapid tests** at the request of citizens.

Special thanks go to the **Scientific Secretariat** and the **Abstract Reviewers** for their commitment, to our **Faculty Members**, to the **ICAR Governing Board**, to **SIMIT, Institutions, Scientific Societies and Patient Associations**, to the **schools** and students, to the **Municipality of Rome** and to our Sponsors who enabled us to involve and host hundreds of young researchers and representatives of the Community of patient associations. We are greatly honored and pleased to welcome you in Rome and wish you a pleasant and interesting stay.

*Welcome to 10<sup>th</sup> ICAR Anniversary!*

Massimo Andreoni



*Massimo Andreoni*

The Chairs  
Andrea Antinori



*Antinori*

Carlo Federico Perno



*CFP*

## Il valore della collaborazione.

Innovazione significa anche mettere a disposizione di chi ne ha bisogno l'efficacia dei nostri farmaci. Per questo motivo Janssen collabora con le Istituzioni di tutto il mondo per facilitare l'accesso alle terapie, indipendentemente dalle realtà economiche dei Paesi in cui opera, creando relazioni che permettano di agevolare e tutelare i pazienti di ogni nazione.

Giorno dopo giorno, Janssen affronta sfide sempre più complesse nel campo della medicina, rimanendo al fianco dei pazienti nella sfida alle patologie più serie del nostro tempo, in molte delle aree terapeutiche principali: neuroscienze, infettivologia e vaccini, immunologia, malattie cardiovascolari e metaboliche, oncologia ed ematologia. Al tempo stesso promuove la sostenibilità del sistema salute con modelli innovativi di accesso e programmi di formazione e informazione.

Il valore della collaborazione è solo uno dei cardini su cui si basa l'operato di Janssen in Italia: da 40 anni al servizio della ricerca per un mondo più sano.

**Janssen. Più vita nella vita.**

janssen 




10° CONGRESSO NAZIONALE



Italian Conference on  
AIDS and Antiviral Research



22-24  
MAGGIO  
2018  
BERGIFE  
PALACE HOTEL,  
ROMA



PROGRAMME  
AT A GLANCE



# FARMACI INNOVATIVI PER MIGLIORARE LA VITA DELLE PERSONE, IN TUTTO IL MONDO.

Da oltre 25 anni sviluppiamo farmaci innovativi per migliorare la cura di patologie che mettono a rischio la vita delle persone. Tra queste anche l'**HIV/AIDS**.

**10 anni** di sostegno alla lotta contro l'**HIV** nei Paesi in via di sviluppo grazie ai progressi scientifici, ai programmi di prevenzione, screening e trattamento.

**10 milioni** di persone in trattamento con farmaci Gilead per l'**HIV** in questi Paesi, grazie alla collaborazione con istituzioni pubbliche e private.

Oltre **100 progetti** realizzati in Italia con Associazioni pazienti e Enti di ricerca per migliorare la qualità di vita delle persone affette da **HIV/AIDS**.




## Bibliografia

Riordan M. The Golden Age of Antiviral Drugs. Forbes, 27 October 2003. At: <http://www.forbes.com/global/2003/1027/090.html>

Robertson G. An Overview of Gilead's Developing World Access Program. 15 December 2011. At: <http://www.fgcasal.org/fgcasal/database/documentos/30VIH-Robertson.pdf>

Clinton Health Access Initiative. ARV Market Report. The State of the Antiretroviral Drug Market in Low- and Middle-Income Countries, 2014-2019. At: [http://www.clintonhealthaccess.org/content/uploads/2015/11/CHAI-ARV-Market-Report-2015\\_FINAL.pdf](http://www.clintonhealthaccess.org/content/uploads/2015/11/CHAI-ARV-Market-Report-2015_FINAL.pdf)


Gilead. Fellowship Program. At: <http://www.itfellowshipprogram.it/chisiamo/accessser/1/chi-siamo.html#.WK66KuQiyM8>




	AUDITORIUM	ORANGE 1	SPALATO	POLA	CESAREA	VOLUBILIS	PERGAMO
10.00 13.30	Secretariat opening and registration						
13.30 16.30	INCONTRO SCUOLE	PRE-CONFERENCE ADVANCED COURSE	PRE-CONFERENCE ADVANCED COURSE	PRE-CONFERENCE ADVANCED COURSE	PRE-CONFERENCE ADVANCED COURSE	PRE-CONFERENCE ADVANCED COURSE	SPECIAL EVENT
	 pag. 26	HIV Reservoir pag. 20	Le infezioni opportunistiche: sfide diagnostiche e problematiche cliniche pag. 20	La gestione della terapia antiretrovirale: nuove opzioni diagnostiche pag. 21	Prendere decisioni in sanità: l'approccio GRADE pag. 21	Competenze avanzate degli infermieri pag. 22	NADIR'S 20th: is Italy focused in achieving the 4th 90? pag. 23
16.30 17.30	SATELLITE SYMPOSIUM						
	Shaping the future in HIV pag. 28						
<b>AUDITORIUM</b>							
17.30 20.30	<b>ICAR 2018 Opening Session</b>						
	17.30-17.45 <b>Introducing ICAR 2018</b> pag. 28						
	17.45-18.30 <b>Authorities' welcome addresses</b> pag. 28						
	18.30-19.00 <b>Mauro Moroni Memorial Lecture</b> pag. 28						
	19.00-19.30 <b>ICAR-CROI Awards 2018 for young Italian HIV investigators</b> pag. 29						
19.30-20.30 <b>Opening Lectures</b> pag. 29							
20.30 22.30	<b>ICAR 2018 Welcome Reception</b>						



## PROGRAMME AT A GLANCE



AUDITORIUM						
09.00 10.00	<b>Keynote Lectures</b> <b>Cancer immunotherapy: a finally successful approach with potential implications in HIV therapy</b> Michele Maio (Siena) <b>New therapeutic options for new and old patients</b> Antonella Castagna (Milano) <i>pag. 30</i>					
AUDITORIUM	LEPTIS MAGNA	ORANGE 1	SPALATO	POLA	CESAREA	
10.10 11.55	SYMPOSIUM  <b>Towards the elimination of HCV and a cure for HBV</b> <i>pag. 30</i>	ORAL COMMUNICATION  <b>Antiretroviral Therapy: focus on Integrase inhibitor</b> <i>pag. 30</i>	ORAL COMMUNICATION  <b>Virology</b> <i>pag. 31</i>			
12.00 12.45	SPONSORED SYMPOSIUM  <b>Future Challenges in the Long Term Management of HIV</b> <i>pag. 32</i>	SATELLITE SYMPOSIUM  <b>Educate to Eradicate: from commitment to action</b> <i>pag. 33</i>				
12.50 13.35	SATELLITE SYMPOSIUM  <b>The Protease Inhibitor in present and future</b> <i>pag. 33</i>		EXPERT MEETING  <b>Towards HCV elimination program in PWID</b> <i>pag. 33</i>			
13.40 14.40			EXPERT MEETING  <b>Long-acting antimicrobial therapy for Gram-positive infections: new patient management scenarios</b> <i>pag. 34</i>	EXPERT MEETING  <b>Elimination of Hepatitis C in a target population: a tailored strategy</b> <i>pag. 34</i>	EXPERT MEETING  <b>Focus Group "Shaping the future in HIV once-daily therapy"</b> <i>pag. 34</i>	EXPERT MEETING  <b>New perspectives in the management of HIV infected person clinical path: The App Co.HIV</b> <i>pag. 35</i>
15.05 16.20	SYMPOSIUM  <b>Designing strategies for combination prevention</b> <i>pag. 35</i>	ORAL COMMUNICATION  <b>Clinical Hepatitis I</b> <i>pag. 35</i>	ORAL COMMUNICATION  <b>Immunology</b> <i>pag. 36</i>	POSTER DISCUSSION  <b>Clinical HIV</b> <i>pag. 37</i>		
16.25 17.40	SYMPOSIUM  <b>Tumors and chronic diseases in HIV infected patients: pathogenesis and clinical update</b> <i>pag. 38</i>	ORAL COMMUNICATION  <b>Hepatitis: basic science and virology</b> <i>pag. 38</i>	ORAL COMMUNICATION  <b>Social Science, Marginalized Population</b> <i>pag. 39</i>			
17.45 18.45		ORAL COMMUNICATION  <b>Comorbidities I</b> <i>pag. 40</i>	ORAL COMMUNICATION  <b>HIV epidemiology and prevention</b> <i>pag. 40</i>	POSTER DISCUSSION  <b>Social Science</b> <i>pag. 41</i>	POSTER DISCUSSION  <b>Immunology</b> <i>pag. 41</i>	



AUDITORIUM					
09.00 10.00	<b>Keynote Lectures</b> The role of microbiome in HIV acquisition and progression and response to cART Giulia Marchetti (Milano) Challenges with PrEP implementation: the French experience Jean-Michel Molina (Paris F) <i>pag. 43</i>				
AUDITORIUM	LEPTIS MAGNA	ORANGE 1	SPALATO	POLA	
10.10 11.55	SYMPOSIUM  New insights in viro-immunological pathogenesis in HIV <i>pag. 43</i>	ORAL COMMUNICATION  Clinical Hepatitis II <i>pag. 43</i>	ORAL COMMUNICATION  Virology and pharmacology <i>pag. 44</i>	POSTER DISCUSSION  Comorbidities <i>pag. 45</i>	
12.00 12.45	SATELLITE SYMPOSIUM  HIV & HCV: moving forward through tailored approaches <i>pag. 46</i>				
12.50 13.35	SATELLITE SYMPOSIUM  Innovation in the treatment of HIV: definition and medical needs identification <i>pag. 46</i>				
13.45 15.00	ORAL COMMUNICATION  Clinical HIV <i>pag. 47</i>	ORAL COMMUNICATION  Comorbidities II <i>pag. 48</i>	ORAL COMMUNICATION  Finding the undiagnosed and preventing new infections <i>pag. 48</i>	POSTER DISCUSSION  Hepatitis <i>pag. 49</i>	POSTER DISCUSSION  Basic science and virology <i>pag. 50</i>
AUDITORIUM					
15.00 16.15	SYMPOSIUM <b>Management of HIV therapy in Special Populations</b> <i>pag. 51</i>				
16.15 16.45	<b>ICAR 2018 Best Poster and SIMIT Special Awards</b> <i>pag. 51</i>				
16.45 17.00	<b>Closing remarks</b> <i>pag. 51</i>				



# Il nostro impegno contro l'**HIV**



## LA RICERCA

- **Rispondere ai bisogni non soddisfatti** di chi vive con l'HIV in Italia e in tutto il mondo è il nostro obiettivo.
- **Ricerca e innovazione** guidano la nostra strada per sviluppare nuove cure, facilitare l'aderenza ai trattamenti, minimizzare il rischio di resistenze, consentire una gestione più semplice dell'infezione.



## LA RESPONSABILITÀ SOCIALE

- Nel mondo con il programma Positive Action sosteniamo oltre **350 progetti per le comunità** collaborando con più di **230 partner**.
- In **Italia** collaboriamo al progetto EPIICAL, consorzio internazionale di ricerca nell'HIV pediatrico, che coinvolge **26 istituzioni accademiche in 4 continenti**.



## L'ACCESSO ALLE TERAPIE

- Per favorire l'accesso ai farmaci assicuriamo prezzi preferenziali e not for profit nei Paesi in via di sviluppo.
- Con il programma di licenze volontarie **14 molecole antiretrovirali** possono essere prodotte da aziende locali nelle aree meno sviluppate.

**ViiV**  
Healthcare

ViiV Healthcare, unica azienda al mondo  
dedicata al 100% all'HIV



## Il valore della ricerca.

Avere soluzioni terapeutiche innovative significa migliorare la vita delle persone dal punto di vista umano, sociale ed economico. Ma non sarebbe possibile senza nuove e incoraggianti scoperte in ambito farmaceutico: per questo motivo Janssen sostiene la ricerca globale all'interno dei propri laboratori e collabora con le realtà accademiche, scientifiche, industriali, istituzionali.

Giorno dopo giorno, Janssen affronta sfide sempre più complesse nel campo della medicina, rimanendo al fianco dei pazienti in molte delle principali aree terapeutiche: neuroscienze, infettivologia e vaccini, immunologia, malattie cardiovascolari e metaboliche, oncologia ed ematologia. Al tempo stesso promuove la sostenibilità del sistema salute con modelli innovativi di accesso e programmi di formazione e informazione.

Il valore della ricerca è solo uno dei cardini su cui si basa l'operato di Janssen in Italia: da 40 anni al servizio della ricerca per un mondo più sano.

**Janssen. Più vita nella vita.**

janssen 


10° CONGRESSO NAZIONALE



Italian Conference on  
AIDS and Antiviral Research



22-24  
MAGGIO  
2018  
BERGIFE  
PALACE HOTEL,  
ROMA



PRE-CONFERENCE  
ADVANCED COURSES



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



## PRE-CONFERENCE ADVANCED COURSE 13:30-16:00

## SALA ORANGE 1

### HIV Reservoir

Moderatori: S. Rusconi (Milano), M. Santoro (Roma)

*La terapia antiretrovirale ha indubbiamente portato ad un allungamento della vita ed a un miglioramento della stessa per le persone HIV-positive che seguiamo in ambulatorio, ma, altrettanto sicuramente, il controllo della replicazione di HIV nel plasma non ha corrisposto ad un controllo altrettanto valido nei serbatoi anatomici e cellulari. Ciò rappresenta il maggiore ostacolo all'eradicazione di HIV. Questo corso ha l'obiettivo di approfondire le tematiche innovative legate alla persistenza del reservoir di HIV, dal punto di vista virologico, laboratoristico e clinico-terapeutico.*

#### Dove si nasconde HIV: tessuti, incluso il sistema nervoso centrale, e serbatoi cellulari

13.30-13.50	<b>Il punto di vista del clinico</b>	Paola Cinque (Milano)
13.50-14.10	<b>Il punto di vista del virologo</b>	Claudia Alteri (Roma)
14.10-14.20	<b>Discussione</b>	

#### I marcatori virologici per monitorare il reservoir virale nelle persone HIV-positive

14.20-14.40	<b>Il punto di vista del clinico</b>	Carmela Pinnetti (Roma)
14.40-15.00	<b>Il punto di vista del virologo</b>	Isabella Bon (Bologna)
15.00-15.10	<b>Discussione</b>	

#### Come colpire il reservoir di HIV durante l'infezione acuta

15.10-15.30	<b>Il punto di vista del clinico</b>	Gabriella d'Ettore (Roma)
15.30-15.50	<b>Il punto di vista del virologo</b>	Isabella Abbate (Roma)
15.50-16.00	<b>Discussione</b>	

## PRE-CONFERENCE ADVANCED COURSE 13:30-16:00

## SALA SPALATO

### Le infezioni opportunistiche: sfide diagnostiche e problematiche cliniche

Moderatori: C.M. Mastroianni (Roma), C. Mussini (Modena)

*Negli ultimi anni le linee di attività dei ricercatori e clinici si sono concentrate, peraltro con notevole successo, sul miglioramento delle strategie di terapia antiretrovirale e prevenzione dell'infezione da HIV. D'altra parte è diminuita l'attenzione sul primo capitolo della storia dell'HIV/AIDS, le infezioni opportunistiche, che ancora oggi rappresentano una importante causa di morbidità e mortalità soprattutto nei pazienti con diagnosi tardiva di infezione da HIV. Di qui la necessità di rinvigorire l'attenzione e l'esperienza per le patologie infettive opportunistiche AIDS-correlate. Lo scopo del corso è quello di fornire aggiornamenti sugli aspetti diagnostici e di gestione clinica delle principali infezioni opportunistiche in corso di AIDS.*

13.30-14.00	<b>Diagnosi delle infezioni opportunistiche nella nuova era della microbiologia</b>	Maurizio Sanguinetti (Roma)
14.00-14.30	<b>Diagnostica e gestione clinica della sifilide</b>	Antonella Cingolani (Roma)
14.30-15.00	<b>Micosi invasive emergenti</b>	Claudia D'Agostino (Roma)
15.00-15.30	<b>Infezioni opportunistiche del SNC</b>	Paola Cinque (Milano)
15.30-16.00	<b>Patologie opportunistiche tropicali</b>	Antonio Cascio (Palermo)



**PRE-CONFERENCE ADVANCED COURSE** 13:30-16:00

**SALA POLA**

**La gestione della terapia antiretrovirale: nuove opzioni diagnostiche**

Moderatori: A. Di Biagio (Genova), F. Maggiolo (Bergamo)

*L'evoluzione della patologia da HIV richiede un aggiornamento costante del processo gestionale dei pazienti sieropositivi. Il management deve adattarsi alle condizioni del paziente, sia di tipo infettivologico che legate all'invecchiamento o alle diverse co-morbidità. Lo sfruttare le nuove tecnologie di laboratorio, il rivalutare parametri da tempo utilizzati, l'approfondire aspetti peculiari e lo sfruttare nuove opportunità tecnologiche fanno parte di questo aggiornamento.*

13.30-14.00	<b>Recupero immunologico: linfociti CD4 e cosa altro?</b>	Alessandra Bandera (Monza)
14.00-14.30	<b>Viremia residua a basse copie: dalla definizione alla gestione</b>	Saverio Parisi (Padova)
14.30-15.00	<b>Frailty nei pazienti HIV: come definirla e quantizzarla?</b>	Marco Borderi (Bologna)
15.00-15.30	<b>Co-morbidità emergenti: focus su ipertensione</b>	Giuseppe Vittorio De Socio (Perugia)
15.30-16.00	<b>Nuovi strumenti gestionali: calcolatori online, punteggi ed applicazioni informatiche</b>	Sergio Lo Caputo (Bari)

**PRE-CONFERENCE ADVANCED COURSE** 13:30-16:00

**SALA CESAREA**

*Unrestricted educational grant of Gilead Sciences*

**Prendere decisioni in sanità: l'approccio GRADE**

Moderatori: E. Girardi (Roma), G. Madeddu (Sassari), L. Sarmati (Roma)

*Il metodo GRADE (Grading of Recommendations Assessment, Development and Evaluation) nasce dalla necessità di standardizzare e rendere trasparente il processo con cui vengono valutate la qualità delle prove disponibili e la forza delle raccomandazioni per la produzione di linee-guida. Nato nel 2000, è diventato lo strumento di riferimento per la formulazione di raccomandazioni cliniche basate sulle evidenze. Un aspetto peculiare del metodo GRADE è l'integrazione della valutazione della qualità metodologica delle prove disponibili con altri aspetti quali: fattibilità e trasferibilità dell'intervento proposto; benefici e rischi attesi e la loro rilevanza; implicazioni organizzative, economiche, sociali e finanziarie. Lo scopo di questo corso è presentare le caratteristiche principali di questo metodo ed illustrare alcuni casi concreti della sua applicazione nell'ambito delle malattie infettive.*

13.30-13.45	<b>Introduzione</b>	Enrico Girardi (Roma)
13.45-14.05	<b>Il metodo GRADE: principi generali</b>	Marina Davoli (Roma)
14.05-14.25	<b>Il metodo GRADE per la produzione di raccomandazioni cliniche</b>	Laura Amato (Roma)
14.25-14.50	<b>Formulare un quesito: il metodo PICO e le linee guida Italiane di terapia antiretrovirale</b>	Enrico Girardi (Roma)
14.50-15.15	<b>Valutare le evidenze con GRADE: analisi di pubblicazioni scientifiche</b>	Loredana Sarmati (Roma)
15.15-15.40	<b>GRADE dall'evidenza all'indicazione: guidance ECDC sulla prevenzione e il controllo delle malattie trasmissibili nelle carceri</b>	Giordano Madeddu (Sassari)
15.40-16.00	<b>Discussione e conclusioni</b>	Enrico Girardi (Roma), Giordano Madeddu (Sassari), Loredana Sarmati (Roma)



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



## PRE-CONFERENCE ADVANCED COURSE 13:30-16:00

## SALA VOLUBILIS

### Competenze avanzate degli infermieri

Moderatori: G.P. Oliva (Roma), E. Zampieri (Roma)

*Le competenze avanzate degli infermieri sono, nei fatti, una realtà incontestabile e dalla quale non si può più retrocedere in considerazione dell'accordo Stato-Regioni del 2013 e del comma 566 della Legge di stabilità 2015. Il corso precongressuale vuole con i suoi contenuti dimostrare come gli infermieri mettono già in campo le competenze avanzate acquisite, sia nella pratica clinica che in quella gestionale e di ricerca, con l'obiettivo di dare da un lato qualità all'utente e dall'altro far riconoscere le suddette competenze agli altri componenti del gruppo curante, di cui l'infermiere è una figura cruciale.*

13.30-13.45 **Saluti e presentazione del corso** Gian Piero Oliva (Roma), Erika Zampieri (Roma)

#### La complessità assistenziale infermieristica in ambito infettivologico

13.45-14.15 **Una esperienza di rilevazione con ICA-DAMI nell'INMI Spallanzani** Alessia De Angelis (Roma)

14.15-14.45 **Distress Management scale: l'esperienza della UOC Immunodeficienze virali dell'INMI Spallanzani** Fabio Cannone (Roma)  
Gian Piero Oliva (Roma)

#### La gestione dei pazienti affetti da lesioni cutanee difficili

14.45-15.15 **Appropriatezza nella continuità assistenziale al paziente con lesioni cutanee difficili** Rosa Rita Zortea (Gorizia)

15.15-15.45 **Il paziente affetto da lesioni cutanee difficili infette da germi multiresistenti: un caso clinico** Erika Zampieri (Roma)

15.40-16.00 **Discussione e conclusioni** Gian Piero Oliva (Roma), Erika Zampieri (Roma)

13:30-16:00

**SALA PERGAMO**



## SPECIAL EVENT

### **NADIR'S 20th: Is Italy focused in achieving the 4th 90?**

*Chairs:* F. Schloesser (Roma), S. Vella (Roma)

*In Italy HIV therapy is available and free of charge to people living with the infection. Nearly the 90% of people in treatment achieve the viral load suppression. By consequence, a health related good quality of life should be the crucial target for the care-giving system. Is this commitment a shared target in Italy? Are all the stakeholders involved in this social and health process? Nadir, twenty years after its foundation, in accordance to its constitutional goals, is exploring this new HIV infection social approach to find a common playing field with all the stakeholders to follow up the settlement of the UNAIDS 4th 90 challenge.*

13.30-13.40 **Welcome**

Filippo Schloesser (Roma), Stefano Vella (Roma)

#### **Are we losing the importance of the 4<sup>th</sup> 90?**

*Chairs:* M. Cascio (Palermo), A. Lazzarin (Milano), B. Marchini (Roma)

13.40-13.55 **Managing comorbidities in real life. Is it a challenge?**

Simone Marcotullio (Roma)

13.55-14.10 **Self-Perceived quality of life. Is this a neglected issue?**

Sandro Mattioli (Bologna)

14.10-14.25 **PLWH rights. Where are we going?**

Massimo Oldrini (Como)

14.25-14.40 **What can SIMIT (Italian Society of Infectious and Tropical Diseases) do for ensuring the 4th 90?**

Massimo Galli (Milano)

#### **Round Table: identifying pragmatic goals for reaching the 4th 90**

*Chairs:* M. Andreoni (Roma), M.L. Cosmaro (Milano), M. Stagnitta (Firenze)

14.40-15.40 **Commenting on the previous lectures:**

- on managing comorbidities
- on self-perceived quality of life
- on PLWH rights

Giovanni Guaraldi (Modena)

Andrea Antinori (Roma)

Cristina Mussini (Modena)

**Remarks from the room**

#### **Let's not forget Italian "detectable" PLWH**

*Chairs:* M.G. Di Benedetto (Catania), M. Farinella (Roma), L. Rancilio (Milano)

15.40-15.55 **Are Italian multi-class resistant patients becoming a neglected population?**

Antonella Castagna (Milano)

15.55-16.00 **Conclusions and final remarks**

Filippo Schloesser (Roma), Stefano Vella (Roma)


10° CONGRESSO NAZIONALE



Italian Conference on  
AIDS and Antiviral Research



22-24  
MAGGIO  
2018  
PALACE HOTEL,  
ROMA



SCIENTIFIC  
PROGRAMME



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



13:30-16:30

**AUDITORIUM**

## **INCONTRO SCUOLE "RACCONTART HIV"**

Moderatori: F. Ceccherini-Silberstein (Roma), M. Errico (Milano)

13.30-14.00 **Introduzione, obiettivi dell'incontro, presentazione della Giuria Artistica e Scientifica**

F. Ceccherini-Silberstein (Roma), M. Errico (Milano)

### **La Giuria Artistica**

- **Gianfilippo Corticelli**, Direttore fotografia
- **Antonello Dose**, Conduttore radiofonico
- **Alessandro Gottardo (alias Shout)**, Illustratore
- **Enzo Porcelli**, Produttore cinematografico
- **Guido Silvestri (Silver)**, Fumettista
- **Francesco Suriano**, Scrittore di teatro, sceneggiatore e regista

### **La Giuria Scientifica**

- **Massimo Andreoni**, Università degli Studi di Roma Tor Vergata
- **Andrea Antinori**, INMI "Lazzaro Spallanzani" IRCCS, Roma
- **Antonella Cingolani**, Fondazione Policlinico Universitario Agostino Gemelli, Roma
- **Paola Cinque**, Università Vita-Salute San Raffaele, Milano
- **Francesca Ceccherini-Silberstein**, Università degli Studi di Roma Tor Vergata
- **Giovanni Del Bene**, ANLAIDS, Milano
- **Margherita Errico**, NPS Italia, Milano
- **Massimo Farinella**, Circolo di Cultura Omosessuale Mario Mieli, Roma
- **Rosario Galipò**, ANLAIDS Lazio, Roma
- **Bruno Marchini**, ANLAIDS, Roma
- **Luca Modesti**, Conigli Bianchi, Roma
- **Simona Nasta**, NPS sezione Sicilia, Palermo
- **Carlo Federico Perno**, Università degli Studi di Milano
- **Stefano Rusconi**, ASST Fatebenefratelli Sacco, Università degli Studi di Milano
- **Domenico Salierno**, NPS sezione Campania, Napoli
- **Filippo Schloesser**, NADIR, Roma



14.00-16.00 **Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici:**

- IIS Luigi Einaudi, Ferrara
- IIS Via dei Papareschi, Roma
- IS Puecher Olivetti, Rho
- Istituto Istruzione Superiore Luigi Einaudi, Magenta (MI)
- Istituto di Istruzione Superiore Gandhi, Besana in Brianza (MB)
- Istituto di Istruzione Superiore Statale Cine-tv Roberto Rossellini, Roma
- Istituto Domizia Lucilla, Roma
- Istituto Istruzione Superiore Francesco Orioli, Viterbo
- Istituto Istruzione Superiore Rosina Salvo, Trapani
- Istituto Professionale di Stato Ciro Pollini, Mortara (PV)
- Istituto Statale di Istruzione Scientifica e Tecnica Aldo Moro, Rivarolo Canavese (TO)
- ITET Mantegna Mantova, Mantova
- ITI Michael Faraday, Roma
- Liceo Artistico Statale Ripetta, Roma
- Liceo Classico e delle Scienze Umane Benedetto da Norcia, Roma
- Liceo Lucio Anneo Seneca, Roma
- Liceo Scientifico Alessandro Tassoni, Modena
- Liceo Scientifico Statale Louis Pasteur, Roma
- Liceo Statale Gian Battista Vico, Corsico (MI)
- Liceo Statale Vittoria Colonna, Roma
- Liceo Virgilio, Milano

16.00-16.30 **Premiazione delle Opere vincitrici**

Massimo Andreoni (Roma), Andrea Antinori (Roma),  
Francesca Ceccherini-Silberstein (Roma), Margherita Errico (Milano),  
Carlo Federico Perno (Milano)



22-24  
MAGGIO  
2018 ERGIFE  
PALACE HOTEL,  
ROMA



## **SATELLITE SYMPOSIUM** 16.30-17.30

Unrestricted educational grant of Gilead Sciences

### **Shaping the future in HIV**

Chair: A. d'Arminio Monforte (Milano)

HAART therapy has completely transformed the future of PLWHIV giving them the same life expectancy than general population. Today ARV drugs are easy to take, powerful, well tolerated and safe. But do we have all the picture clear and under control?

The aim of the symposium is to understand if there are other parameters we are missing or we should understand more in depth such as residual viremia, inhibitory quotient of drug combinations, inflammation, what happens in reservoir, etc. The final objective of therapy today should also consider QoL and long term Health. In this context triple therapy is still the Standard of Care and the backbone is the key for durability.

16.30-16.45 **Building blocks for a solid ART**

16.45-17.00 **What else do we need to complete the image?**

17.00-17.15 **ART today: endpoint or starting line?**

17.15-17.30 **Discussion of Symposium issues**

## **AUDITORIUM**

Sergio Lo Caputo (Bari)

Marco Borderi (Bologna)

Franco Maggiolo (Bergamo)

## **ICAR 2018 OPENING SESSION**

## **AUDITORIUM**

17.30-18.45

### **Introducing ICAR 2018**

M. Andreoni (Roma), A. Antinori (Roma), C.F. Perno (Milano)

17.45-18.30

### **Authorities' welcome addresses**

Marta Branca, Direttore Generale INMI L. Spallanzani, Roma

Massimo Galli, Presidente SIMIT, Milano

Stefano Vella, Presidente AIFA, Roma

18.30-19.00

### **Mauro Moroni Memorial Lecture**

Chairs: G. Antonelli (Roma), A. Lazzarin (Milano)

**HIV persistence and approaches to cure** Javier Martinez-Picado (Badalona E)

19.00-19.30

## ICAR-CROI Awards 2018 for young Italian HIV investigators

Chairs: A. De Luca (Siena), G. Silvestri (Atlanta USA)

### Selected Italian Investigators:

- Impaired gut tight junction but preserved and microbial translocation in acute HIV Elvira Stefania Cannizzo (Milano)
- Cardiac ventricular dysfunction in young vertically infected HIV patients Eugenio Nelson Cavallari (Roma)
- Beneficial effect of 6 months of probiotics on asymptomatic neurocognitive impairment Luigi Celani (Roma)
- Modulation of HIV restriction factors by blocking CCL2/CCR2 in vitro and in vivo Daniela Angela Covino (Roma)
- Specific CSF viral escape findings compared to pre-cART HIV encephalitis Valentina De Zan (Milano)
- Variability of HIV-1 V2 Env domain for integrin binding: clinical correlates Claudia Fabrizio (Bari)
- Impact of previous M184V on virological outcome of switch to 3TC-based dual therapies Roberta Gagliardini (Siena)
- No change in neurocognitive function after switching from efavirenz to rilpivirine Giuseppe Lapadula (Monza)
- HCV and liver disease increase risk of neurocognitive impairment in HIV+ individuals Ilaria Mastrorosa (Roma)
- Impact of determinants of increased vascular risk on neurocognition in HIV+ patients Ilaria Mastrorosa (Roma)
- Peripheral and CSF immune activation and inflammation in HIV+ patients starting cART Esther Merlini (Milano)
- HIV specific IgM memory B cells dominate in seronegative early-treated children Elena Morrocchi (Roma)
- Hepatic expression of hsa-miR-125a-5p and fibrosis in overt and occult HBV infection Lorenzo Onorato (Napoli)
- Risk and predictors of asymptomatic and symptomatic CSF viral escape in HIV+ patients Carmela Pinnetti (Roma)
- Gain of positive charges in HBsAg C-terminus correlates with HBV-induced liver cancer Romina Salpini (Roma)
- HIV-RNA in the olfactory mucosa of HIV-positive patients Mattia Trunfio (Torino)

19.30-20.30

## OPENING LECTURES

Chairs: M. Galli (Milano), M.R. Iardino (Milano), G. Ippolito (Roma)

- |             |   |                                  |
|-------------|---|----------------------------------|
| 19.30-20.00 | <b>Global perspectives on HCV eradication</b>     | Philippa Easterbrook (Geneva CH) |
| 20.00-20.30 | <b>Challenges in reaching the 4th 90 in Italy</b> | Filippo Schloesser (Roma)        |

20.30-22.30

## ICAR 2018 Welcome Reception



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



09:00-10:00

## KEYNOTE LECTURES

Chairs: R. Cauda (Roma), A. d'Arminio Monforte (Milano), V. Vullo (Roma)

- 09.00-09.30 **Cancer immunotherapy: a finally successful approach with potential implications in HIV therapy**
- 09.30-10.00 **New therapeutic options for new and old patients**

**AUDITORIUM**

Michele Maio (Siena)  
Antonella Castagna (Milano)

**SYMPOSIUM** 10:10-11:55

## Towards the elimination of HCV and a cure for HBV

Chairs: G. Angarano (Bari), C.M. Mastroianni (Roma), M. Puoti (Milano)

*The availability of pangenotypic oral antivirals has made possible the elimination of HCV; a crucial role will be played by the elimination of virus reservoirs in marginalized populations; thus, the treatment of PWID and prisoners will have pivotal role in any plan for eradication of HCV infection. The lifelong administration of anti HBV drugs allows only a suppression of viral replication, so it is important to understand if they could be stopped in some patients and if new treatment options may allow to cure HBV infection and eradicate delta coinfection and which are the lab tools to define these new strategies.*

- 10.10-10.25 **HCV in PWID and prison setting**
- 10.25-10.40 **When can we stop NUCs in patients with Chronic Hepatitis B?**
- 10.40-10.55 **New biomarkers for the management of Chronic Hepatitis B**
- 10.55-11.10 **Update on Hepatitis B cure and emerging issues in Hepatitis D?**
- 11.10-11.55 **Discussion of Symposium issues**

**AUDITORIUM**

Massimo Andreoni (Roma)  
Gloria Taliani (Roma)  
Valentina Svicher (Roma)  
Giovanni Battista Gaeta (Napoli)

**ORAL COMMUNICATION** 10.10-11.55

## Antiretroviral therapy: focus on integrase inhibitor

Chairs: F. Castelli (Brescia), N. Gianotti (Milano), L. Sighinolfi (Ferrara)

- 10.10-10.25 **The new frontier in HIV drug resistance: the integrase inhibitors**

Daniele Armenia (Roma)

**OC 1** 10.25-10.35 **Durability of integrase inhibitors (INSTI) regimens in the clinical setting: data from the Icona Foundation Cohort**

A. d'Arminio Monforte<sup>1</sup>, A. Cozzi-Leperi<sup>2</sup>, S. Lo Caputo<sup>3</sup>, S. Rusconi<sup>4</sup>, N. Gianotti<sup>5</sup>, A. Di Biagio<sup>6</sup>, G. Marchetti<sup>1</sup>, V. Mazzotta<sup>7</sup>, G. Mazzarello<sup>6</sup>, A. Costantin<sup>8</sup>, A. Castagna<sup>5</sup>, A. Antinori<sup>7</sup> for the Icona Foundation Study Group

<sup>1</sup>ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Milan, Italy, <sup>2</sup>Institute for Global Health, University College London, United Kingdom, <sup>3</sup>Clinic of Infectious Diseases, Polyclinic of Bari, Bari, Italy, <sup>4</sup>Infectious Diseases Unit, ASST FBF-Sacco, DIBIC "L. Sacco", University of Milan, Milan, Italy, <sup>5</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy, <sup>6</sup>Infectious Diseases Unit, Hospital Policlinico San Martino, University of Genoa, Genoa, Italy, <sup>7</sup>HIV/AIDS Department, INMI "L. Spallanzani" IRCCS, Rome, Italy, <sup>8</sup>Clinical Immunology Unit, Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy

**OC 2** 10.37-10.47 **Virological response and resistance profile in virologically suppressed HIV-1 infected patients switching to integrase inhibitors based treatment in clinical practice**

D. Armenia<sup>1</sup>, C. Gori<sup>2</sup>, F. Forbici<sup>2</sup>, V. Borghi<sup>3</sup>, M. Zaccarelli<sup>2</sup>, A. Bertoli<sup>1</sup>, C. Alteri<sup>1</sup>, W. Gennari<sup>3</sup>, G. Berno<sup>2</sup>, A. Giannetti<sup>2</sup>, A. Vergori<sup>2</sup>, I. Mastrorosa<sup>2</sup>, V. Mazzotta<sup>2</sup>, G. Maffongelli<sup>4</sup>, M. Colafigli<sup>5</sup>, I. Pozzetto<sup>6</sup>, M. Lichtner<sup>6</sup>, M. Andreoni<sup>4</sup>, C. Mussini<sup>3</sup>, A. Antinori<sup>2</sup>, C.F. Perno<sup>2,7</sup>, F. Ceccherini-Silberstein<sup>1</sup>, M.M. Santoro<sup>1</sup>

<sup>1</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>2</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, <sup>3</sup>Polyclinic of Modena, Modena, Italy, <sup>4</sup>Polyclinic of Rome "Tor Vergata", Rome, Italy, <sup>5</sup>San Gallicano Dermatological Institute, IRCCS, Rome, Italy, <sup>6</sup>La Sapienza University Polo Pontino, Latina, Italy, <sup>7</sup>University of Milan, Milan, Italy

**OC 3** 10.49-10.59 **Comparison of raltegravir (RAL) and boosted darunavir (DRV/b) versus dolutegravir (DTG) both associated with tenofovir/emtricitabine (TDF/FTC) in primary HIV infection (PHI): virological efficacy of two different integrase inhibitors (INSTI)-based treatment strategies**

A. Mondì<sup>1,2</sup>, C. Pinnetti<sup>1</sup>, P. Lorenzini<sup>1</sup>, M.M. Plazzi<sup>1</sup>, I. Abbate<sup>3</sup>, G. Rozero<sup>3</sup>, C. Agrati<sup>4</sup>, R. Libertone<sup>1</sup>, S. Menichetti<sup>1</sup>, I. Mastrorosa<sup>1</sup>, A. Ammassari<sup>1</sup>, A. Antinori<sup>1</sup>

<sup>1</sup>HIV/AIDS Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>Unit of Infectious Diseases, Macerata General Hospital, Macerata, Italy, <sup>3</sup>Laboratory of Virology, National

Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>4</sup>Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

**OC 4 11.01-11.11 Efficacy of switching to Raltegravir from a virologically effective regimen in HIV/HCV coinfecting patients, with and without resistance to NRTIs**

A. Lai<sup>1</sup>, A. Giacomelli<sup>1</sup>, M. Franzetti<sup>2</sup>, W. Gennari<sup>3</sup>, F. Saladini<sup>4</sup>, F. Lombardi<sup>5</sup>, S. Di Giambenedetto<sup>6</sup>, G. Punzi<sup>6</sup>, V. Borghi<sup>3</sup>, D. Bartolozzi<sup>7</sup>, L. Monno<sup>6</sup>, A. Callegaro<sup>8</sup>, A. Di Biagio<sup>9</sup>, S. Rusconi<sup>1</sup>, N. Gianotti<sup>10</sup> on behalf of the ARCA Mentor School

<sup>1</sup>Department of Biomedical and Clinical Sciences 'L. Sacco', University of Milan, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, 'A. Manzoni' Hospital, Lecco, Italy, <sup>3</sup>Microbiology and Virology Unit, University Hospital Policlinic, Modena, Italy, <sup>4</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>5</sup>Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart of Rome, Rome, Italy, <sup>6</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>7</sup>Infectious and Tropical Disease Unit, Careggi University Hospital, University of Florence, Florence, Italy, <sup>8</sup>Virology Laboratory, ASST PG-23, Bergamo, Italy, <sup>9</sup>Infectious Disease Clinic, IRCCS San Martino – IST Hospital, Genoa, Italy, <sup>10</sup>Infectious Diseases, IRCCS San Raffaele, Milan, Italy

**OC 5 11.13-11.23 Patient-Reported Outcomes (PROs) evaluation among HIV-infected (HIV+) patients (pts) starting elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)**

I. Mastrorosa<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, E. Girardi<sup>3</sup>, A. Calcagno<sup>4</sup>, G. Madeddu<sup>5</sup>, A. Maddaloni<sup>6</sup>, M. Farenga<sup>7</sup>, A. Cristaudo<sup>8</sup>, P. Meraviglia<sup>9</sup>, A. Antinori<sup>1</sup>, A. d'Arminio Monforte<sup>10</sup>, A. Cingolani<sup>11</sup>, for the Icona Foundation Study Group

<sup>1</sup>Clinical Department, National Institute for Infectious Diseases L Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Institute for Global Health, University College London, United Kingdom, <sup>3</sup>Unit of Epidemiology, National Institute for Infectious Diseases L Spallanzani, IRCCS, Rome, Italy, <sup>4</sup>Unit of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Torino, Italy, <sup>5</sup>Unit of Infectious Diseases, University of Sassari, Sassari, Italy, <sup>6</sup>Unit for Immunodeficiencies and Gender Infectious Diseases, AO Dei Colli Cotugno Hospital, Naples, Italy, <sup>7</sup>Division A of Infectious Diseases, Amedeo di Savoia Hospital Torino, Italy, <sup>8</sup>Infectious Dermatology and Allergology Unit, IFO San Galliciano Institute (IRCCS), Rome, Italy, <sup>9</sup>1st Division of Infectious Diseases, ASST FBF-Sacco, Milan, Italy, <sup>10</sup>Clinic of Infectious and Tropical Diseases, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, <sup>11</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy

**OC 6 11.25-11.35 Dolutegravir + lamivudine as simplification cART in patients with suppressed HIV-RNA: long term analysis of a multicenter cohort**

L. Comi<sup>1</sup>, C. Mussini<sup>2</sup>, R. Gulminetti<sup>2</sup>, L. Pagnucco<sup>2</sup>, M. Digaetano<sup>3</sup>, E. Di Filippo<sup>1</sup>, D. Valenti<sup>1</sup>, F. Maggiolo<sup>1</sup>

<sup>1</sup>Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, <sup>2</sup>Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, <sup>3</sup>Division of Infectious Diseases, University of Modena, Modena, Italy

**OC 7 11.37-11.47 Effectiveness of dolutegravir (DTG)-based regimens as either first line or switch antiretroviral therapy (ART): data from the Icona cohort**

A. Mondì<sup>1,2</sup>, A. Cozzi-Lepri<sup>3</sup>, A. Tavelli<sup>4</sup>, S. Rusconi<sup>5</sup>, F. Vichi<sup>6</sup>, B. Menzaghi<sup>7</sup>, F. Ceccherini-Silberstein<sup>8</sup>, A. Calcagno<sup>9</sup>, F. Maggiolo<sup>10</sup>, G. Marchetti<sup>11</sup>, A. Antinori<sup>1</sup>, A. d'Arminio Monforte<sup>11</sup> on behalf of Icona Foundation Study Group

<sup>1</sup>HIV/AIDS Department, INMI "L. Spallanzani" IRCCS, Rome, Italy, <sup>2</sup>Unit of Infectious Diseases, Macerata General Hospital, Macerata, Italy, <sup>3</sup>Institute for Global Health, University College London, London, UK, <sup>4</sup>Icona Foundation, Milan, Italy, <sup>5</sup>Infectious Diseases Unit, ASST FBF-Sacco, DIBIC "L. Sacco", University of Milan, Milan, Italy, <sup>6</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, Italy, <sup>7</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy, <sup>8</sup>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, <sup>9</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Amedeo di Savoia Hospital, Turin, Italy, <sup>10</sup>Unit of Infectious Diseases, ASST-PG23, Bergamo, Italy, <sup>11</sup>ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Department of Health Sciences, Milan, Italy

**ORAL COMMUNICATION 10.10-11.55**

**ORANGE 1**

**Virology**

Chairs: M.R. Capobianchi (Roma), V. Ghisetti (Torino), M.C. Re (Bologna)

**10.10-10.25 The clinical virology laboratory in the management of patients with maximal virologic suppression**

Ombretta Turriziani (Roma)

**OC 8 10.25-10.35 Impact of GSS and viral tropism on cART outcomes during primary HIV infection**

A. Giacomelli<sup>1</sup>, M. Fabbiani<sup>2</sup>, I. De Benedetto<sup>3</sup>, S. Nozza<sup>3</sup>, E. Focà<sup>4</sup>, B.M. Celesia<sup>5</sup>, G. Marchetti<sup>6</sup>, C. Mussini<sup>7</sup>, A. Antinori<sup>8</sup>, G. d'Ettore<sup>9</sup>, G. Madeddu<sup>10</sup>, A. Bandera<sup>2</sup>, A. Muscatello<sup>2</sup>, S. Rusconi<sup>1</sup> on behalf of the INACTION study group

<sup>1</sup>Divisione Malattie Infettive, DIBIC Luigi Sacco, Università degli Studi di Milano, <sup>2</sup>Divisione Malattie Infettive, Ospedale San Gerardo, Università degli Studi di Milano-Bicocca, <sup>3</sup>Divisione Malattie Infettive, Ospedale San Raffaele IRCCS, Università Vita-Salute, Milano, <sup>4</sup>Divisione Malattie Infettive, Spedali Civili, Università degli Studi di Brescia, <sup>5</sup>U.O.C. Malattie Infettive, ARNAS Garibaldi, Catania, <sup>6</sup>Divisione Malattie Infettive, Dipartimento di Scienze della Salute, Università degli Studi di Milano, <sup>7</sup>Divisione Malattie Infettive, Università degli Studi di Modena e Reggio Emilia, Modena, <sup>8</sup>U.O.C. Immunodeficienze virali, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS, Roma, <sup>9</sup>Divisione Malattie Infettive, Università degli Studi La Sapienza, Roma, <sup>10</sup>Divisione Malattie Infettive, Università degli Studi di Sassari, Italy

**OC 9 10.37-10.47 Viro-immunological characterization of primary HIV-1 infection in SIREA study**

G. Rozera<sup>1</sup>, G. Ferrari<sup>1</sup>, C. Pinnetti<sup>2</sup>, R. Libertone<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>3</sup>, A. Amendola<sup>1</sup>, M.R. Capobianchi<sup>1</sup>, N. Orchi<sup>4</sup>, G. De Carli<sup>4</sup>, I. Abbate<sup>1</sup>

<sup>1</sup>Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>2</sup>HIV/AIDS Clinical Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>3</sup>Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, <sup>4</sup>AIDS Referral Centre and Epidemiology Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

**OC 10 10.49-10.59 Resistance mutations in the reverse transcriptase of HIV-1 in recent infections do not affect the replicative capacity of the virus, in contrast to those in non-recent infections**

S. Caucci<sup>1</sup>, P. Bagnarelli<sup>1</sup>, M. Franzetti<sup>2</sup>, M. Andreoni<sup>3</sup>, C. Balotta<sup>2</sup>, S. Menzo<sup>1</sup>



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



<sup>1</sup>Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, <sup>2</sup>Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Milano, <sup>3</sup>Clinica di Malattie Infettive, Università di Tor Vergata, Roma, Italy

**OC 11 11.01-11.11 Virological and immunological efficacy of antiretroviral regimens containing elvitegravir in patients in clinical practice**

D. Redi<sup>1</sup>, E. Giombini<sup>2</sup>, S. Modica<sup>1</sup>, R. Gagliardini<sup>1</sup>, A. Bezenchek<sup>3</sup>, D. Di Carlo<sup>4,5</sup>, F. Maggiolo<sup>6</sup>, S. Di Giambenedetto<sup>7</sup>, F. Lombardi<sup>7</sup>, A. Callegaro<sup>8</sup>, M.R. Gismondo<sup>9</sup>, M. Zazzi<sup>1</sup>, A. De Luca<sup>1,10</sup>, B. Rossetti<sup>10</sup>, N. Gianotti<sup>11</sup>

<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, <sup>2</sup>National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, <sup>3</sup>InformaPRO, Rome, Italy, <sup>4</sup>University of Milan, Pediatric Clinical Research Center "Romeo and Erica Invernizzi", Milan, Italy, <sup>5</sup>University of Pavia, Department of Biology and Biotechnology, Pavia, Italy, <sup>6</sup>Infectious Diseases Unit, Bergamo Hospital, Bergamo, Italy, <sup>7</sup>Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, <sup>8</sup>Microbiology and Virology Unit, Bergamo Hospital, Bergamo, Italy, <sup>9</sup>Microbiology Unit, Ospedale L. Sacco, Milan, Italy, <sup>10</sup>Infectious Diseases Unit, AOU Senese, Siena, Italy, <sup>11</sup>Infectious Diseases, IRCCS San Raffaele, Milan, Italy

**OC 12 11.13-11.23 LTR-5' genetic variability and correlation with HIV-DNA burden modification during cART**

C. Alteri<sup>1</sup>, R. Scutari<sup>1</sup>, M.C. Bellocchi<sup>1</sup>, G. Maffongelli<sup>2</sup>, C. Stingone<sup>2</sup>, M. Brugnati<sup>1</sup>, L. Carioti<sup>1</sup>, D. Di Carlo<sup>3,4</sup>, F. Continenza<sup>5</sup>, F. Falasca<sup>6</sup>, S. Martini<sup>7</sup>, A. Bertoli<sup>1</sup>, O. Turriziani<sup>8</sup>, N. Coppola<sup>7</sup>, M. Andreoni<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C.F. Perno<sup>8</sup>, V. Svicher<sup>1</sup>

<sup>1</sup>University of Rome Tor Vergata, Department of Experimental Medicine and Surgery, Rome, Italy, <sup>2</sup>University Hospital of Rome Tor Vergata, Infectious Diseases Unit, Rome, Italy, <sup>3</sup>University of Milan, Paediatric Clinical Research Center "Romeo and Erica Invernizzi", Milan, Italy, <sup>4</sup>University of Pavia, Department of Biology and Biotechnology, Pavia, Italy, <sup>5</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>6</sup>University of Rome La Sapienza, Department of Molecular Medicine, Rome, Italy, <sup>7</sup>Second University of Naples, Infectious Diseases Unit, Naples, Italy, <sup>8</sup>University of Milan, Department of Oncology and Haemato-Oncology, Milan, Italy

**OC 13 11.25-11.35 Characterization of virological failure in HIV-1 infected patients switching to dual therapy with DTG plus one RTI (NRTI or NNRTI)**

N. Galizzi<sup>1</sup>, A. Polo<sup>2</sup>, A. Castagna<sup>1,2</sup>, L. Galli<sup>2</sup>, C. Muccini<sup>1</sup>, A. Mastrangelo<sup>1</sup>, R. Dell'Acqua<sup>3</sup>, M. Maillard<sup>2</sup>, S. Bossolasco<sup>2</sup>, P. Cinque<sup>2</sup>, A. Lazzarin<sup>2</sup>, N. Gianotti<sup>2</sup>

<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>San Raffaele Scientific Institute, Milano, Italy, <sup>3</sup>University Hospital Policlinico, Bari, Italy

**OC 14 11.37-11.47 Historical genotype predicts virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort**

F. Lombardi<sup>1</sup>, A. Borghetti<sup>1</sup>, A. D'Avino<sup>1</sup>, D. Moschese<sup>1</sup>, A. Bezenchek<sup>2</sup>, A. Shallvari<sup>2</sup>, A. Di Biagio<sup>3</sup>, F. Del Puente<sup>3</sup>, S. Bonelli<sup>3</sup>, M. Trezzi<sup>4</sup>, M. Zazzi<sup>5</sup>, De Luca<sup>5,6</sup>, S. Di Giambenedetto<sup>1</sup>

<sup>1</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, <sup>2</sup>InformaPRO, Rome, Italy, <sup>3</sup>Clinica Malattie Infettive, Ospedale San Martino di Genova, <sup>4</sup>Grosseto Hospital Grosseto Italy, <sup>5</sup>Department of Medical Biotechnologies, University of Siena, Siena, <sup>6</sup>Infectious Diseases Unit, AOU Senese, Siena, Italy

**SPONSORED SYMPOSIUM 12:00-12:45**

**AUDITORIUM**

Sponsored by ViiV Healthcare

**Future Challenges in the Long Term Management of HIV**

Chair: A. d'Arminio Monforte (Milano)

*The challenge in the fight against HIV is constantly evolving, and both the clinical management of long-term ARV therapy and the needs of the HIV+ patient have to be taken in account. The long-term control of the disease with ever less impact on patients' lives, the challenge of reducing the toxicity of the therapy, the necessity of research for new drugs and new mechanisms of action are all area to be discussed to choose the best research strategies for the benefit of the PLWHIV. This workshop aims to tell a long-term vision in HIV therapy, both from an epidemiological / virological point of view and also from clinical management, and to trace the next HIV challenges on which clinical research will have to concentrate, foreshadowing which new pharmaceutical paradigms will be needed to succeed.*

12.00-12.05	<b>Introduction to ViiV HC SE Symposium and rationale for the topic</b>	Paolo Rizzini (Verona)
12.05-12.20	<b>The virological vision</b>	Maurizio Zazzi (Siena)
12.20-12.35	<b>The clinical management vision</b>	Andrea Antinori (Roma)
12.35-12.45	<b>Discussion of Symposium issues and conclusions</b>	Antonella d'Arminio Monforte (Milano)



## SATELLITE SYMPOSIUM 12:00-12:45

## LEPTIS MAGNA

Unrestricted educational grant of Gilead Sciences

### Educate to Eradicate: from commitment to action

Chairs: M. Andreoni (Roma), C.F. Perno (Milano)

The WHO has set an ambitious goal to eliminate HCV as a major public health threat by 2030: reduce new HCV infections by 80%, the number of HCV deaths by 65%, increase HCV diagnoses to 90% and the number of eligible persons receiving HCV treatment to 80%.

The availability of simple and tolerable DAA therapies for HCV infection with cure rates >90% has brought considerable optimism to people working in HCV. However, the availability of open access to HCV cure is going to change progressively the HCV patients' demographics at point of care, bringing novel challenges in the care cascade.

The symposium will focus on addressing the challenges of achieving elimination of hepatitis C with the aim to go beyond the data and breaking down the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.

- |             |  |                           |
|-------------|--|---------------------------|
| 12.00-12.15 | <b>Beyond the liver: time for a new model for HCV patient management?</b>                    | Massimo Puoti (Milano)    |
| 12.15-12.30 | <b>The road toward HCV eradication: from the National plan to individual patient's needs</b> | Cristina Mussini (Modena) |
| 12.30-12.45 | <b>Discussion of Symposium issues</b>  |                           |

## SATELLITE SYMPOSIUM 12:50-13:35

## AUDITORIUM

Con il supporto incondizionato di Janssen

### The Protease Inhibitor in present and future

Chair: M. Galli (Milano)

PIs are an antiretroviral class whose efficacy and effectiveness are well known due to randomized clinical trials and real world experience. Nowadays it is required to offer new therapeutic options confirming the effectiveness and improving the patients' quality of life. The new PI-Single Tablet Regimen responds to these challenges and meets patients' needs, in terms of confirmed virological efficacy and high genetic barrier with improved tolerability and better adherence.

- |             |   |                             |
|-------------|---|-----------------------------|
| 12.50-12.55 | <b>Introduction</b>   | Massimo Galli (Milano)      |
| 12.55-13.10 | <b>PI evolution: randomized clinical trials in the modern HAART</b>           | Antonella Castagna (Milano) |
| 13.10-13.25 | <b>PI consolidated experience from clinical trials to real world evidence</b> | Andrea Antinori (Roma)      |
| 13.25-13.35 | <b>Discussion of Symposium issues and conclusions</b>                         | Massimo Galli (Milano)      |

## EXPERT MEETING 12:50-13:35

## ORANGE 1

Unrestricted educational grant of Gilead Sciences

### Towards HCV elimination program in PWID

PWIDs currently represent the major reservoir of the disease and the main source of infection. Injection drug use is responsible for 23% of the new infections and each PWID with HCV infection can infect at least 20 other consumers, within the first 3 years of the start of the infection. The availability of therapeutic tools capable of curing the HCV could allow to develop integrated models of patients' management with the aim to implement the screening, prevent reinfections through the increase of harm-reduction actions and improve the quality of life of patients. Despite access to care is now ensured to all persons with HCV, it is still difficult to reach high-risk behavior population as PWIDs who, in terms of public health, should be the primary target for the treatment of the disease.

The Expert Meeting will underline critical factors to shape a successful elimination program.

- |             |  |   |
|-------------|--|---|
| 12.50-13.35 | <b>Towards HCV elimination program in PWID</b> | Massimo Andreoni (Roma), Felice Alfonso Nava (Padova) |
|-------------|--|---|



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



**EXPERT MEETING** 13:40-14:40

**ORANGE 1**

## Long-acting antimicrobial therapy for Gram-positive infections: new patient management scenarios

Chair: M. Galli (Milano)

Acute bacterial skin and skin-structure infection (ABSSSI) is a frequent cause of morbidity in hospital settings. *Staphylococcus aureus* is the most frequent cause of these infections, and methicillin-resistant *S. aureus* (MRSA) represents the first resistant pathogen involved in complicated forms of skin and soft-tissue infections (cSSTI). Identification of early switch and early discharge opportunities for hospitalized patients with ABSSSI due to MRSA could lead to a significant reduction in length of stay, providing a mechanism for improving outcomes and increasing efficacy: the use of long-acting antibiotics seems to be the best strategy. This approach could profoundly modify the management of these infections by reducing or in some cases eliminating hospitalization costs and risks.

13.40-14.40 **Long-acting antimicrobial therapy for Gram-positive infections: new patient management scenarios**

Mario Venditti (Roma)

**EXPERT MEETING** 13:40-14:40

**SPALATO**

Unrestricted educational grant of AbbVie

## Elimination of Hepatitis C in a target population: a tailored strategy

In Italy, the incidence of HCV infections among the general population is approximately 1%, and there is a considerable burden of HCV infections among people with addictions, especially those who inject drugs (PWID). Direct-acting antiviral therapies (DAA) with HCV cure rates >95% provide an opportunity to reverse rising trends in HCV-related morbidity and mortality and reduce incidence. Aim of this Expert Meeting is to share the definition of a diagnostic therapeutic strategy to eradicate HCV infections in those special population.

13.40-14.40 **Elimination of Hepatitis C in a target population: a tailored strategy**

Massimo Andreoni (Roma),  
Stefano Regio (Roma)

**EXPERT MEETING** 13.40-14.40

**POLA**

Unrestricted educational grant of MSD Italy

## Focus Group "Shaping the future in HIV once-daily therapy"

Coordinators: A. Antinori (Roma), C.F. Perno (Milano)

Nowadays the effectiveness of HIV treatments is mainly due to the evolution ARV has undergone in the last years. The class of integrase inhibitors (INSTI) is today the most widely used as third antiretroviral combination drug and constitutes the present and the future of this therapeutic area. INSTI is widely used for its efficacy, tolerability, low rate of interactions with other drugs and peculiar and decisive mechanism of antiviral action.

A Focus Group composed by specialists and experts in the treatment of HIV infection will discuss the issues of the new anti-retroviral therapy (ARV) once daily therapeutic options.

Discussants: A. d'Arminio Monforte (Milano), A. Gori (Milano), A. Lazzarin (Milano), C. Mussini (Modena)

## EXPERT MEETING 13:40-14:40

**CESAREA**

Unrestricted educational grant of Gilead Sciences

### New perspectives in the management of HIV infected person clinical path: The App Co.HIV

The management of people with HIV infection in antiretroviral therapy, which have a prevalence and incidence of co-morbidity higher than the general population of equal sex and age, today requires an increase in the complexity of both the screening of vulnerabilities by co-morbidity and the management of frequent contemporary poly-pharmacy. The 15-20 minutes available to the clinic for the visit do not allow the normal follow-up of HIV / HAART infection and, at the same time, the search for vulnerability for all comorbidities (nephrology, endocrinology, bone, cardiovascular, neurological, dermatological, gynecological, metabolic, psychiatric).

Dedicated to the screening and management of co-morbidities in HIV, the new app allows a simple user interface to select the organ for screening or management of each single comorbidity, enter some specific parameters (sex, age, etc ...), complete a checklist to verify the patient's exact conditions, access the most appropriate online tools for the evaluation of each specific case with a guide to the reading of the results obtained, and also access the specific sections of the national guidelines and international recommendations.

Specific anamnesis and objective examination aimed at the screening of co-morbidities, predictive risk algorithms for co-morbidity, blood and urinary tests specific for single co-morbidity, request for first level instrumental exams, request for specialist advice and second level instrumental examinations: these are his areas of use.

- 13.40-14.40 **New technological tools for the management of co-morbidities. The App Co.HIV: rationale, structure and interactive practical tests** Marco Borderi (Bologna), Alessandro Porreca (Bologna)

## SYMPOSIUM 15:05-16:20

**AUDITORIUM**

### Designing strategies for combination prevention

Chairs: S. Mattioli (Bologna), V. Puro (Roma), G. Rezza (Roma)

Combination prevention for HIV/STIs integrates biomedical, behavioral and structural interventions, since no single HIV prevention approach alone can stop the epidemic. Achieving the 2020 and 2030 targets will require focused combination prevention efforts including condom provision, community based testing, immediate ART initiation, PrEP and Harm Reduction measures for people who inject drugs. The symposium will try to give a picture of the present situation in Italy and to identify the next steps.

- 15.05-15.20 **Planning an effective mix of prevention interventions** Enrico Girardi (Roma)
- 15.20-15.35 **Community based testing in Italy: from demonstration project to routine offer** Maria Luisa Cosmaro (Milano)
- 15.35-15.50 **Sexually transmitted infections as an indicator of at risk sexual behaviors in Italy** Barbara Suligoj (Roma)
- 15.50-16.05 **Transgenders: a hidden key population** Giuseppe Lapadula (Monza)
- 16.05-16.20 **Discussion of Symposium issues**

## ORAL COMMUNICATION 15.05-16.20

**LEPTIS MAGNA**

### Clinical Hepatitis I

Chairs: R. Bruno (Pavia), G. Carosi (Brescia), G. D'Offizi (Roma)

- 15.05-15.20 **HCV reinfection in high risk populations** Patrick Ingiliz, Berlin D

**OC 15 15.20-15.30 Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals?**

L.A. Kondili<sup>1</sup>, S. Robbins<sup>2</sup>, S. Blach<sup>2</sup>, I. Gamkrelidze<sup>2</sup>, A.L. Zignego<sup>3</sup>, M.R. Brunetto<sup>4</sup>, G. Raimondo<sup>5</sup>, G. Taliani<sup>6</sup>, A. Iannone<sup>7</sup>, F.P. Russo<sup>8</sup>, T.A. Santantonio<sup>9</sup>, M. Zuin<sup>10</sup>, L. Chessa<sup>11</sup>, P. Blanc<sup>12</sup>, M. Puoti<sup>13</sup>, M. Vinci<sup>14</sup>, E.M. Erne<sup>15</sup>, M. Strazzabosco<sup>16</sup>, M. Massari<sup>17</sup>, P. Lampertico<sup>18</sup>, M.G. Rumi<sup>19</sup>, A. Federico<sup>20</sup>, C. Ferrari<sup>21</sup>, A. Ciancio<sup>22</sup>, G. Borgia<sup>23</sup>, P. Andreone<sup>24</sup>, N. Caporaso<sup>25</sup>, M. Persico<sup>26</sup>, D. Ieluzzi<sup>27</sup>, S. Madonia<sup>28</sup>, A. Gori<sup>29</sup>, A. Gasbarrini<sup>30</sup>, C. Coppola<sup>31</sup>, G. Brancaccio<sup>32</sup>, A. Andriulli<sup>33</sup>, S. Montilla<sup>34</sup>, H. Razavi<sup>2</sup>, M. Melazzini<sup>34</sup>, S. Vella<sup>1</sup>, A. Craxi<sup>35</sup>, on behalf of PITER collaborating group\*

<sup>1</sup>Center for Global Health, Istituto Superiore di Sanità, Rome, <sup>2</sup>Center for Disease Analysis, CDA Foundation | Polaris Observatory, Lafayette, Colorado, <sup>3</sup>Department of Experimental and Clinical Medicine, Interdepartmental Centre MASVE, University of Florence, <sup>4</sup>Department of Hepatology, University Hospital of Pisa, <sup>5</sup>Department of Internal Medicine, University Hospital of Messina, <sup>6</sup>Infectious and Tropical Diseases Unit,



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



Umberto I Hospital, Sapienza University, Rome, <sup>7</sup>Department of Gastroenterology, University Hospital of Bari, <sup>8</sup>Department of Gastroenterology, University Hospital of Padua, <sup>9</sup>Department of Infectious Disease, Ospedali Riuniti, Foggia, <sup>10</sup>Liver and Gastroenterology Unit, ASST Santi Paolo e Carlo, Milan, <sup>11</sup>Liver Unit, University of Cagliari, <sup>12</sup>Department of Infectious Disease, S.M. Annunziata Hospital, Florence, <sup>13</sup>Department of Infectious Disease, Niguarda Hospital, Milan, <sup>14</sup>Hepatitis Center, Niguarda Hospital, Milan, <sup>15</sup>Department of Infectious Disease, University Hospital of Padua, <sup>16</sup>Department of Hepatology, San Gerardo Hospital, Monza, <sup>17</sup>Department of Infectious Disease, Arcispedale Santa Maria Nuova, Reggio Emilia, <sup>18</sup>Department of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, <sup>19</sup>Department of Gastroenterology and Hepatology, San Giuseppe Hospital, Milan, <sup>20</sup>Department of Hepatology and Gastroenterology, Università degli Studi della Campania Luigi Vanvitelli, Naples, <sup>21</sup>Department of Infectious Disease and Hepatology, University of Parma, <sup>22</sup>Gastroenterology Unit, Città della Salute e della Scienza-Ospedale Molinette, Turin, <sup>23</sup>Department of Infectious Disease, Federico II University, Naples, <sup>24</sup>Department of Hepatology, University of Bologna, <sup>25</sup>Gastroenterology Unit, Federico II University, Naples, <sup>26</sup>Department of Internal Medicine and Hepatology, University of Salerno, <sup>27</sup>Liver Unit, University Hospital of Verona, <sup>28</sup>Internal Medicine, Villa Sofia-Cervello Hospital, Palermo, <sup>29</sup>Department of Infectious Disease, San Gerardo Hospital, Monza, <sup>30</sup>Department of Internal Medicine and Gastroenterology, Catholic University of Rome, <sup>31</sup>Department of Hepatology, Gragnano Hospital, Naples, <sup>32</sup>Department of Infectious Disease, Second University of Naples, <sup>33</sup>Division of Gastroenterology, Casa Sollievo Sofferenza Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo, Foggia, <sup>34</sup>Italian Medicines Agency (AIFA), Rome, <sup>35</sup>Gastroenterology and Liver Unit, DiBiMIS, University of Palermo, Palermo, \*Available from: <https://progettopenet.it/rete.aspx>

**OC 16 15.32-15.42 Screening for HIV, HCV, HBV and syphilis and evaluation of serostatus for mandatory vaccinations in a juvenile jail in Milan**

F. Iannuzzi<sup>1</sup>, E. Frea<sup>1</sup>, F. Bai<sup>3</sup>, T. Sebastiani<sup>1</sup>, R. Giuliani<sup>1</sup>, R. Ranieri<sup>1</sup>, C. Lari<sup>2</sup>, A. Cospito<sup>2</sup>, A. d'Arminio Monforte<sup>3</sup>

<sup>1</sup>Penitentiary Infectious Diseases Unit Milan, <sup>2</sup>Penitentiary Health Service, Milan, <sup>3</sup>Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan

**OC 17 15.44-15.54 Real world adherence to Direct-Acting Antivirals in a cohort of people who use drugs in Rome, Italy**

E. Teti<sup>1</sup>, L. Foroghi<sup>1</sup>, V. Malagnino<sup>1</sup>, C. Stingone<sup>1</sup>, M. De Masi<sup>1</sup>, L. Campogiani<sup>1</sup>, L. Ferrari<sup>1</sup>, I. Spalliera<sup>1</sup>, M. Compagno<sup>1</sup>, R.A. Cavasio<sup>1</sup>, L. Coppola<sup>1</sup>, E. Rossi<sup>2</sup>, D. Masci<sup>2</sup>, B. Coladarcè<sup>2</sup>, G. Rodoquino<sup>2</sup>, M. Patti<sup>2</sup>, M. Pellegrino<sup>3</sup>, C. Sarrecchia<sup>1</sup>, M. Barra<sup>2</sup>, L. Sarmati<sup>1</sup>, M. Andreoni<sup>1</sup>

<sup>1</sup>Infectious Diseases Clinic, Tor Vergata University, Rome, Italy, <sup>2</sup>Villa Maraini Foundation ONLUS, Rome, Italy, <sup>3</sup>SeT Casilina 1368, Rome, Italy

**OC 18 15.56-16.06 Clinical, epidemiological and virological characteristics of patients with HCV infection experiencing a late failure to DAA therapy**

C. Minichini<sup>1</sup>, M. Starace<sup>1</sup>, M. Caroprese<sup>2</sup>, M. Macera<sup>2</sup>, G. Brancaccio<sup>2</sup>, S. De Pascalis<sup>2</sup>, M. Pisaturo<sup>1</sup>, A. Santonicola<sup>4</sup>, A. Galeota Lanza<sup>6</sup>, R. Zampino<sup>7</sup>, G. Cotticelli<sup>5</sup>, G.B. Gaeta<sup>2</sup>, N. Coppola<sup>1,3</sup>

<sup>1</sup>Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania, Napoli, Italy, <sup>2</sup>Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and preventive Medicine, University of Campania, Napoli, Italy, <sup>3</sup>Infectious Diseases Unit, AO Caserta, Caserta, Italy, <sup>4</sup>Gastroenterology Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno, Italy, <sup>5</sup>Internal Medicine and Hepatology Department of Clinical and Experimental Medicine, University of Campania "L. Vanvitelli", <sup>6</sup>Hepatology Unit, Cardarelli Hospital, Naples, Italy, <sup>7</sup>Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania "L. Vanvitelli"

**OC 19 16.08-16.18 Treatment-naïve and treatment-experienced HCV patients: what are the economic differences?**

E. Foglia<sup>1</sup>, L. Ferrario<sup>1</sup>, E. Garagiola<sup>1</sup>, B. Menzaghi<sup>2</sup>, A. Tebini<sup>2</sup>, G. Rizzardini<sup>3,4</sup>, M.V. Cossu<sup>3</sup>, S. Fagioli<sup>5</sup>, L. Pasulo<sup>5</sup>, M. Colombo<sup>6</sup>, S. De Nicola<sup>7</sup>, R. Bruno<sup>8</sup>, P. Sacchi<sup>9</sup>, M. Galli<sup>3</sup>, D. Croce<sup>1,9</sup>

<sup>1</sup>Liuc Business School, Centre for Research on Health Economics, Social and Health Care Management, LIUC - Università Cattaneo, Castellanza, Italy, <sup>2</sup>Infectious Diseases Department, ASST Valle Olona, Busto Arsizio, Italy, <sup>3</sup>Infectious Disease Department, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>4</sup>School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa, <sup>5</sup>Department of Gastroenterology, Papa Giovanni XXXIII Hospital Authority, Bergamo, Italy, <sup>6</sup>Clinical and Research Center Humanitas Rozzano, Italy, <sup>7</sup>Department of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, <sup>8</sup>Infectious Disease Department, Policlinico San Matteo, Pavia, Italy, <sup>9</sup>School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

**ORAL COMMUNICATION 15.05-16.20**

**ORANGE 1**

**Immunology**

Chairs: M. Clerici (Milano), A. De Maria (Genova), G. Poli (Milano)

**15.05-15.20 Current role of bone marrow transplantation in HIV-associated lymphoproliferative diseases**

Alessandra Bandera (Monza)

**OC 20 15.20-15.30 Different distribution of B regulatory cells (B regs) in untreated and treated HIV infection**

E. Merlini, C. Tincati, E.S. Cannizzo, A. d'Arminio Monforte, G. Marchetti

Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan

**OC 21 15.32-15.42 Myeloid derived suppressor cells increase after early cART treatment and may affect CD4 T cell recovery**

A. Sacchi<sup>1</sup>, N. Tumino<sup>1</sup>, V. Bordoni<sup>1</sup>, R. Casetti<sup>1</sup>, E. Cimini<sup>1</sup>, C. Pinnetti<sup>2</sup>, A. Mondì<sup>2</sup>, A. Ammassari<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>1</sup>

<sup>1</sup>Laboratory of Cellular Immunology and Pharmacology, INMI Lazzaro Spallanzani IRCCS, <sup>2</sup>Clinical Department, INMI Lazzaro Spallanzani IRCCS, Rome

**OC 22 15.44-15.54 Changes in immunological biomarkers of activation or senescence are not influenced by the onset of lung disorders in HIV patients**

M. Nasi<sup>1</sup>, S. Pecorini<sup>2</sup>, S. De Biasi<sup>3</sup>, S. Zona<sup>4</sup>, E. Bianchini<sup>1</sup>, M. Digaetano<sup>1,4</sup>, M. Pinti<sup>3</sup>, L. Gibellini<sup>5</sup>, R. Pullano<sup>5</sup>, C. Mussini<sup>1,4</sup>, G. Guaraldi<sup>4,5</sup>, A. Cossarizza<sup>5</sup>

<sup>1</sup>Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, <sup>5</sup>

Modena, Italy, <sup>3</sup>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy

**OC 23 16.56-16.06 Gut epithelial integrity, mucosal immunity and microbial translocation in primary, chronic untreated and treated HIV infection**

*E.S. Cannizzo<sup>1</sup>, C. Tincati<sup>1</sup>, D. Tosi<sup>2</sup>, F. Savi<sup>2</sup>, G. Ancona<sup>1</sup>, R. Adami<sup>3</sup>, C. Luigiano<sup>4</sup>, E. Merlini<sup>1</sup>, R. Cafaro<sup>1</sup>, G. Bulfamante<sup>2</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>*

<sup>1</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, <sup>2</sup>Unit of Pathology, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, <sup>3</sup>Department of Health Science, University of Milan, <sup>4</sup>Unit of Digestive Endoscopy, ASST Santi Paolo e Carlo, Milan, Italy

**OC 24 16.08-16.18 Sex-based differences of immune activation pattern in gut and blood compartments of HIV-1 positive patients**

*G. Corano Scheri<sup>1</sup>, C. Pinacchio<sup>1</sup>, G.P. Innocenti<sup>1</sup>, G. De Girolamo<sup>1</sup>, E.N. Cavallari<sup>1</sup>, L. Celani<sup>1</sup>, G. Fanello<sup>2</sup>, C. Scagnolari<sup>3</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastrocinanni<sup>1</sup>, G. d'Ettore<sup>1</sup>, V. Vullo<sup>1</sup>*

<sup>1</sup>Department of Public Health and Infectious diseases University of Rome Sapienza, Italy, <sup>2</sup>Department of Emergency Surgery-Emergency Endoscopic Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Istituto Pasteur Italia-Fondazione Cenci Bolognietti, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

**POSTER DISCUSSION 15.05-16.05**

**SPALATO**

**Clinical HIV**

*Chairs:* S. Babudieri (Sassari), T. Bini (Milano), M.A. Di Pietro (Pistoia)

**PD 1 15.05-15.10 Role of gender, age and indirect inflammation biomarkers as predictors of first-line cART discontinuation including integrase inhibitors: a longitudinal Cohort Study**

*E. Focà<sup>1</sup>, F. Donato<sup>2</sup>, C. Grumi<sup>3</sup>, M. Properzi<sup>1</sup>, A. Celotti<sup>1</sup>, F. Castelnuovo<sup>1</sup>, E. Festa<sup>3</sup>, M.C. Pezzoli<sup>1</sup>, G. Paraninfo<sup>1</sup>, I. Izzo<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelli<sup>1</sup>*

<sup>1</sup>Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili Hospital, Brescia, Italy, <sup>2</sup>Unit of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy, <sup>3</sup>Hospital Pharmacy, Spedali Civili Hospital, Brescia, Italy

**PD 2 15.12-15.17 A real-life analysis of dolutegravir adverse effects in a cohort of naïve and experienced HIV-infected patients**

*C. Monari<sup>1</sup>, C. Rogati<sup>2</sup>, M. Digaetano<sup>2</sup>, M. Menozzi<sup>2</sup>, A. Santoro<sup>2</sup>, A. Bonazza<sup>2</sup>, F. Carli<sup>2</sup>, V. Borghi<sup>2</sup>, C. Mussini<sup>2</sup>*

<sup>1</sup>Department of Mental Health and Public Medicine, University of Campania L. Vanvitelli, <sup>2</sup>Infectious Disease Clinic, AOU Policlinico di Modena, Modena, Italy

**PD 3 15.19-15.24 Efficacy and correlates of darunavir/cobicistat (DRV/c) based dual therapy: data from multicenter Italian cohort**

*M. Zaccarelli<sup>1</sup>, A. Vergori<sup>1</sup>, S. Di Giambenedetto<sup>3</sup>, P. Lorenzini<sup>1</sup>, G. Sterrantino<sup>2</sup>, R. Bellagamba<sup>1</sup>, E. Schiaroli<sup>4</sup>, A. Giannetti<sup>1</sup>, D. Francisci<sup>5</sup>, S. Cicalini<sup>1</sup>, A. Latini<sup>6</sup>, R. Maddaluno<sup>1</sup>, I. Mezzaroma<sup>7</sup>, M. Lichtner<sup>8</sup>, F. Di Sora<sup>9</sup>, G. D'Ettore<sup>7</sup>, G. Maffongelli<sup>10</sup>, A. Antinori<sup>1</sup>*

<sup>1</sup>Area Dipartimentale HIV/AIDS, Istituto Nazionale per le Malattie Infettive, IRCCS L. Spallanzani, Roma, <sup>2</sup>UO Malattie Infettive, Azienda Ospedaliera Universitaria Careggi, Firenze, <sup>3</sup>Istituto di Clinica Malattie Infettive, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Roma, <sup>4</sup>Divisione Malattie Infettive, Ospedale di Perugia, <sup>5</sup>Clinica Malattie infettive, Azienda Ospedaliera S. Maria, Terni, <sup>6</sup>Unità di Dermatologia infettiva, IFO-Istituto San Gallicano, Roma, <sup>7</sup>Clinica Malattie Infettive Università La Sapienza, Roma, <sup>8</sup>Università "La Sapienza di Roma", Polo Pontino, <sup>9</sup>Unità Operativa AIDS, Ospedale San Giovanni, Roma, <sup>10</sup>UOC Malattie Infettive, Policlinico Tor Vergata, Roma

**PD 4 15.26-15.31 Trend of incidence rates of AIDS-related and non AIDS-related tumours in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016**

*A. Borghetti<sup>1</sup>, S. Bellino<sup>2</sup>, F. Lombardi<sup>1</sup>, S. Belmonti<sup>1</sup>, S. La Monica<sup>1</sup>, I. Fanti<sup>1</sup>, A. Ciccullo<sup>1</sup>, G. Baldin<sup>1</sup>, A. Emiliozzi<sup>1</sup>, D. Moschese<sup>1</sup>, A. De Luca<sup>3</sup>, P. Pezzotti<sup>2</sup>, S. Di Giambenedetto<sup>1</sup>*

<sup>1</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy, <sup>3</sup>Division of Infectious Diseases, Siena University Hospital, Siena, Italy, Department of Medical Biotechnologies, University of Siena, Siena, Italy

**PD 5 15.33-15.38 Use of TAF with a HIV-RNA $\leq$ 50 copies/mL in clinical practice**

*A. Cozzi-Lepri<sup>1</sup>, M. Zaccarelli<sup>2</sup>, A. Capetti<sup>3</sup>, A. De Luca<sup>4</sup>, A. Castagna<sup>5</sup>, D. Bernacchia<sup>6</sup>, F. Bai<sup>7</sup>, A. Cingolani<sup>8</sup>, C. Mussini<sup>9</sup>, C.F. Perno<sup>6</sup>, A. d'Arminio Monforte<sup>7</sup>, A. Antinori<sup>2</sup> for the Icona Foundation Study*

<sup>1</sup>University College London, UK, <sup>2</sup>INMI Spallanzani, Roma, Italy, <sup>3</sup>Luigi Sacco Hospital, Milano, Italy, <sup>4</sup>University of Siena, Italy, <sup>5</sup>San Raffaele Hospital, Milano, Italy, <sup>6</sup>University of Milano, Italy, <sup>7</sup>San Paolo Hospital, Milano, Italy, <sup>8</sup>UCSC Roma, Italy, <sup>9</sup>University of Modena, Italy

**PD 6 15.40-15.45 Dual regimen with dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy**

*S. Rusconi<sup>1</sup>, R. Gulminetti<sup>2</sup>, S. Bonora<sup>3</sup>, A. Riva<sup>1</sup>, L. Pagnucco<sup>2</sup>, M. Ferrara<sup>3</sup>, G. Mazzola<sup>4</sup>, A. Cascio<sup>4</sup>, M.E. Quiros Roldan<sup>5</sup>, A. Ferraresi<sup>5</sup>, G. De Socio<sup>6</sup>, N. Ladisa<sup>7</sup>, S. Carosella<sup>8</sup>, A.M. Cattelan<sup>9</sup>, S. Cavinato<sup>9</sup>, S. Di Giambenedetto<sup>10</sup>, A. Ciccullo<sup>10</sup>, M. Mena<sup>11</sup>, C. Aizori<sup>12</sup>, M. Frigerio<sup>1</sup>, F.S. Falvella<sup>13</sup>, D. Cattaneo<sup>13</sup>, V. Spagnuolo<sup>14</sup>, A. Poli<sup>14</sup>, L. Galli<sup>14</sup>, A. Castagna<sup>14</sup> on behalf of DAU Study Group*

<sup>1</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>2</sup>Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>3</sup>Infectious Diseases Unit, Amedeo di Savoia Hospital, University of Turin, Turin, Italy, <sup>4</sup>Infectious Diseases Unit, Paolo Giaccone/Azienda Ospedaliera Universitaria Policlinico, Palermo, Italy, <sup>5</sup>Infectious Diseases Unit, Spedali Civili General Hospital, Brescia, Italy, <sup>6</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy, <sup>7</sup>Infectious Diseases Unit, Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy, <sup>8</sup>Division A of Infectious Diseases, Ospedale Amedeo di Savoia, Turin, Italy, <sup>9</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Padova, Padova, Italy, <sup>10</sup>Infectious Diseases Unit, Catholic University of Sacred Heart, Rome, Italy, <sup>11</sup>Infectious Diseases Unit, Azienda Ospedaliera di Legnano, ASST Ovest Milanese, Legnano, Italy, <sup>12</sup>First Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, Milan, Italy, <sup>13</sup>Unit of Clinical Pharmacology, Department of Laboratory Medicine, ASST Fatebenefratelli-Sacco, Milan, Italy, <sup>14</sup>Infectious Diseases Department, IRCCS San Raffaele Scientific Institute & Vita-Salute University, Milan, Italy





22-24  
MAGGIO  
2018 ERGIFE  
PALACE HOTEL,  
ROMA



**PD 7 15.47-15.52 Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort**

A. Cingolani<sup>1</sup>, J. Romaine<sup>2</sup>, A. Tavelli<sup>3</sup>, F. Maggiolo<sup>4</sup>, E. Girardi<sup>5</sup>, A. Antinori<sup>6</sup>, A. Cascio<sup>6</sup>, A.M. Cattelan<sup>7</sup>, A. De Luca<sup>8</sup>, M. Murray<sup>9</sup>, A. d'Armino Monforte<sup>10</sup>, A. Bradley<sup>2,11</sup> for ICONA Foundation study Group

<sup>1</sup>Catholic University, Roma, Italy, <sup>2</sup>Health Psychology Research Unit, University of London, London, UK, <sup>3</sup>Icona Foundation, Milano, Italy, <sup>4</sup>Azienda Ospedaliera S. Giovanni XXIII, Bergamo, Italy, <sup>5</sup>National Institute for Infectious Diseases "L. Spallanzani", Roma, Italy, <sup>6</sup>AOU Policlinico "P. Giaccone", Palermo, Italy, <sup>7</sup>Azienda Ospedaliera Padova, Padova, Italy, <sup>8</sup>University of Siena, Siena, Italy, <sup>9</sup>Viv Healthcare, London, United Kingdom, <sup>10</sup>University of Milano, Milano, Italy, <sup>11</sup>Health Psychology Research, Ltd, University of London, London, Italy

**SYMPOSIUM 16:25-18:00**

**AUDITORIUM**

**Tumors and chronic diseases in HIV infected patients: pathogenesis and clinical update**

Chairs: A. Cingolani (Roma), P. Cinque (Milano), A. De Luca (Siena)

*Tumors and chronic diseases represent a substantial cause of mortality and disability in the late-ART era. Although ART suppresses HIV replication in the great majority of treated people, residual persistent immune activation might favor the development of these conditions. This session will provide a clinical update and cover their pathogenesis, including the possible link with chronic inflammation.*

- |             |  |                                  |
|-------------|--|----------------------------------|
| 16.25-16.45 | <b>New insights in antimicrobial and antifungal therapy in immunocompromised setting</b> | Claudio Viscoli (Genova)         |
| 16.45-17.05 | <b>HIV-associated vasculopathy in stroke pathogenesis</b>                                | Laura A. Benjamin (Liverpool UK) |
| 17.05-17.25 | <b>HIV infection, gender and HPV risk of cancer</b>                                      | Silvia Franceschi (Aviano PN)    |
| 17.25-17.45 | <b>Lymphoma pathogenesis in the late cART era and possible role of HIV persistence</b>   | Ethel Cesarman (New York USA)    |
| 17.45-18.00 | <b>Discussion of Symposium issues</b>  |                                  |

**ORAL COMMUNICATION 16.25-17.40**

**LEPTIS MAGNA**

**Hepatitis: basic science and virology**

Chairs: N. Coppola (Napoli), G. Mazzola (Palermo), C. Torti (Catanzaro)

- |             |                       |   |
|-------------|-----------------------|---|
| 16.25-16.40 | <b>HCV resistance</b> | Francesca Ceccherini-Silberstein (Roma) |
|-------------|-----------------------|---|

**OC 25 16.40-16.50 Pattern of Resistance Associated Substitutions (RASs) in the HCV NS3 and NS5a domains of experienced or naïve HIV/HCV coinfecting patients with different HCV genotypes**

S. Bagaglio<sup>1</sup>, H. Hasson<sup>1</sup>, L. Galli<sup>1</sup>, A. Olgiate<sup>1</sup>, E. Messina<sup>1</sup>, S. Salpietro<sup>1</sup>, A. Lazzarin<sup>1</sup>, C. Uberti-Foppa<sup>2</sup>, G. Morsica<sup>1</sup>

<sup>1</sup>Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy, <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy

**OC 26 16.52-17.02 Direct acting antiviral failed HCV genotype 1 patients: a Southern Italy experience**

M. Starace<sup>1</sup>, C. Minichini<sup>1</sup>, S. De Pascalis<sup>2</sup>, M. Macera<sup>2</sup>, L. Occhiello<sup>1</sup>, M. Pisatura<sup>1</sup>, V. Messina<sup>3</sup>, V. Sangiovanni<sup>4</sup>, E. Claar<sup>5</sup>, D. Precone<sup>6</sup>, G. Stornaiuolo<sup>2</sup>, M. Stanzione<sup>2</sup>, I. Gentile<sup>8</sup>, G. Brancaccio<sup>2</sup>, S. Martini<sup>9</sup>, A. Masiello<sup>10</sup>, A. Salomone Megna<sup>11</sup>, C. Coppola<sup>12</sup>, A. Federico<sup>13</sup>, M. Persico<sup>14</sup>, A. Galeota Lanza<sup>15</sup>, A. Marrone<sup>16</sup>, G.B. Gaeta<sup>2</sup>, N. Coppola<sup>1,3</sup>

<sup>1</sup>Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania, Napoli, Italy, <sup>2</sup>Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania, Napoli, Italy, <sup>3</sup>Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, <sup>4</sup>Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, <sup>5</sup>Internal Medicine Unit, Evangelical Hospital Villa Betania Naples, Italy, <sup>6</sup>Internal Medicine unit A.O Sarno, Sarno (SA), Campania L. Vanvitelli, & Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi, Hospital, Naples, Italy, <sup>7</sup>Gastroenterology Unit, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno Italy, <sup>8</sup>Infectious Diseases Unit, University Federico II, Naples, Italy, <sup>9</sup>HIV Unit, University L. Vanvitelli, Naples, Italy, <sup>10</sup>Infectious Diseases Unit, A.O S.G. Moscati, Avellino Italy, <sup>11</sup>Infectious Diseases Unit, AO G.Rummo, Benevento, <sup>12</sup>Hepatology Unit, Gragnano Hospital, Gragnano, <sup>13</sup>Internal Medicine and Hepatology Department of Clinical and Experimental Medicine, University of Campania "L. Vanvitelli", <sup>14</sup>Internal Medicine and Hepatology Unit, PO G. Da Procida-AOU- San Giovanni e Ruggi D'Aragona, University of Salerno, <sup>15</sup>Hepatology Unit, Cardarelli Hospital, Naples, Italy, <sup>16</sup>Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, University of Campania "L. Vanvitelli"

**OC 27 17.04-17.14 Interleukine-6 decline after HCV cure is associated with VACS INDEX improvement in HIV-HCV patients**

L. Badia<sup>1,2</sup>, V. Guardigni<sup>1,2</sup>, G. Fornaro<sup>1</sup>, E. Francalanci<sup>1</sup>, M. Rinaldi<sup>1</sup>, F. Volpato<sup>1</sup>, P. Viale<sup>1</sup>, G. Verucchi<sup>1,2</sup>

<sup>1</sup>UO Malattie Infettive - Azienda Ospedaliero-Universitaria di Bologna, <sup>2</sup>Centro di Ricerca per lo studio delle Epatiti, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC) - Alma Mater Studiorum Università di Bologna

**OC 28 17.16-17.26 CD4-T cell and metabolic changes after DAAs: a multicenter case-control study**

L.A. Nicolini<sup>1</sup>, M.L. Borghesi<sup>1</sup>, E. Ricci<sup>2</sup>, B. Menzaghi<sup>3</sup>, P. Maggi<sup>4</sup>, N. Squillace<sup>5</sup>, S. Passerini<sup>6</sup>, B.M. Cesia<sup>7</sup>, C. Martinelli<sup>8</sup>, C. Grosso<sup>9</sup>, K. Falasca<sup>10</sup>, R. Gulminetti<sup>11</sup>, V. Colombo<sup>12</sup>, G.V. De Socio<sup>13</sup>, P. Bonfanti<sup>14</sup>, CISAI studygroup



<sup>1</sup>Malattie Infettive, Università degli Studi di Genova, AOU Policlinico San Martino-IST, IRCCS per la ricerca sul cancro, <sup>2</sup>Epi2004, Milano, <sup>3</sup>Divisione di Malattie Infettive, ASST della Valle Olona, Busto Arsizio, <sup>4</sup>Malattie Infettive, Università degli Studi di Bari, Ospedale Policlinico di Bari, Bari, <sup>5</sup>Malattie Infettive, Università Milano-Bicocca, Ospedale San Gerardo, Monza, <sup>6</sup>Malattie Infettive, Università degli Studi di Milano, Ospedale L. Sacco Milano, <sup>7</sup>Divisione di malattie Infettive, Università degli Studi di Catania, Dipartimento di Biomedicina Clinica e Molecolare, Catania, <sup>8</sup>SOD Malattie Infettive e Tropicali, AOU-Careggi, Firenze, <sup>9</sup>Malattie Infettive, Ospedale M. Bufalini, Cesena, <sup>10</sup>Malattie Infettive, Università "G. d'Annunzio" Chieti-Pescara, Dipartimento di Medicina e Scienze Dell'invecchiamento, Chieti, <sup>11</sup>Malattie Infettive, IRCCS Policlinico S. Matteo, Pavia, <sup>12</sup>Malattie Infettive, Università degli Studi di Milano, DIBIC "Luigi Sacco", Milano, <sup>13</sup>Malattie Infettive, Ospedale Santa Maria, Perugia, <sup>14</sup>Divisione di Malattie Infettive, Ospedale A. Manzoni, Lecco

**OC 29 17.28-17.38 The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocytes trajectories in HIV/HCV coinfecting patients: data from the Icona Foundation Cohort**

A. Bandera<sup>1</sup>, P. Lorenzini<sup>2</sup>, G. Lapadula<sup>1</sup>, C. Mussini<sup>3</sup>, A. Saracino<sup>4</sup>, F. Ceccherini-Silberstein<sup>5</sup>, M. Puoti<sup>6</sup>, E. Quiros-Roldan<sup>7</sup>, F. Montagnani<sup>8</sup>, A. Antinori<sup>2</sup>, A. Gori<sup>1</sup>, A. d'Arminio Monforte<sup>9</sup>, for the Icona Foundation Cohort

<sup>1</sup>Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, <sup>2</sup>HIV/AIDS Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy, <sup>3</sup>Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Institute of Infectious Disease, University of Bari, Bari, Italy, <sup>5</sup>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, <sup>6</sup>Department of Infectious Diseases, Grande Ospedale Metropolitano Niguarda, Milan, Italy, <sup>7</sup>Infectious Diseases, Spedali Civili Hospital, Brescia, Italy, <sup>8</sup>University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy, <sup>9</sup>Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy

**ORAL COMMUNICATION 16.25-17.40**

**ORANGE 1**

**Social Science, marginalized population**

Chairs: M.G. Di Benedetto (Catania), B. Marchini (Roma), S. Marcotullio (Roma)

16.25-16.40 **Chemsex recreational drug use and antiretroviral treatment**

Mauro Zaccarelli (Roma)

**OC 30 16.40-16.50 Educational and training initiatives decrease participants' misconception about people living with HIV**

L. Rancilio<sup>1,2</sup>, C. Neglia<sup>2</sup>, the AIDS network of Caritas Italiana<sup>2</sup>

<sup>1</sup>Caritas Ambrosiana, <sup>2</sup>Caritas Italiana

**OC 31 16.52-17.02 HRQoL estimate in Italian undetectable PLWH: how far we are in achieving the 4th 90 target in Italy? Results from an Italian Web Survey**

S. Marcotullio, D. Osorio, M. Martini, F. von Schloesser

Nadir Onlus, Rome, Italy

**OC 32 17.04-17.14 Social Marketing: strategies and tools to promote HIV prevention**

L. Milli<sup>1</sup>, S. Mattioli<sup>2</sup>, A.M. Pietrantonio<sup>1</sup>, G. Fattori<sup>3</sup>

<sup>1</sup>Marketing Sociale Onlus, <sup>2</sup>Plus Onlus, <sup>3</sup>Social Marketing Compass University of Bologna

**OC 33 17.16-17.26 A novel mobile application to improve fitness and metabolic outcomes in persons living with HIV: the SMARTAPP study**

F. Turrini<sup>1,2</sup>, M. Bonato<sup>3</sup>, L. Galli<sup>4</sup>, C. Vitobello<sup>1</sup>, A. Giordani<sup>1</sup>, L. Passeri<sup>1</sup>, A. Meloni<sup>3</sup>, G. Pavei<sup>5</sup>, A. La Torre<sup>3</sup>, A. Lazzarin<sup>4</sup>, G. Merati<sup>3,6</sup>, P. Cinque<sup>1,4</sup>

<sup>1</sup>Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San-Raffaele University, Milan, Italy, <sup>3</sup>Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy, <sup>4</sup>Department of Infectious Diseases, San Raffaele Hospital, Milan, Italy, <sup>5</sup>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, <sup>6</sup>Centre of Sport Medicine, Don Carlo Gnocchi Foundation, Milan, Italy

**OC 34 17.28-17.38 Women and HIV in prison setting: data from the Italian ROSE network**

E. Rastrelli<sup>1,2</sup>, R. Ranieri<sup>2,3</sup>, S. Marcellini<sup>2,4</sup>, E. Pontali<sup>2,5</sup>, N. Bobbio<sup>2,5</sup>, T. Prestileo<sup>2,6</sup>, G. Leo<sup>2,7</sup>, M. Giuliano<sup>2,7</sup>, O. Mollaretti<sup>2,7</sup>, R. Marocco<sup>8</sup>, F. Atzeni<sup>2,9</sup>, G. Barbarini<sup>2,10</sup>, D. Sacchini<sup>2,11</sup>, E. Fronti<sup>2,11</sup>, D. Racciatti<sup>2,12</sup>, F. Vignale<sup>12</sup>, A. Pomicino<sup>2,13</sup>, A. Lucarini<sup>14</sup>, E.C. Liguori<sup>1,2</sup>, S. Martuscelli<sup>2,15</sup>, G. Pugliese<sup>16</sup>, A.M. Ialungo<sup>1,2</sup>, S. Dell'Isola<sup>1,2</sup>, L. Lucania<sup>2,17</sup>, S. Babudieri<sup>2,18</sup>, G. Starnini<sup>1,2</sup>

<sup>1</sup>U.O.C. Medicina Protetta-Malattie Infettive, Ospedale Belcolle, Viterbo, <sup>2</sup>SIMSPE (Società Italiana di Medicina e Sanità Penitenziaria), <sup>3</sup>Azienda Ospedaliera Santi Paolo e Carlo Unità di Malattie Infettive, Università di Milano Unità di Malattie Infettive in Ambito Penitenziario, Milano, <sup>4</sup>Casa Circondariale Rebibbia Femminile, Roma, <sup>5</sup>Unità di Malattie Infettive, Ospedale Galliera, Genova, <sup>6</sup>ARNAS, Ospedale Civico-Benefratelli Palermo, Palermo, <sup>7</sup>Unità di Malattie Infettive, Ospedale Amedeo di Savoia, Torino, <sup>8</sup>Unità di Malattie Infettive, Università La Sapienza, Ospedale S. M., Latina, <sup>9</sup>Casa Circondariale E. Scaldas Uta ASL, Cagliari, <sup>10</sup>Casa Circondariale di Pavia, Voghera e Vigevano, <sup>11</sup>Azienda Ospedaliera di Piacenza - Malattie Infettive, Piacenza, <sup>12</sup>Clinica di Malattie Infettive, Dipartimento di Medicina ed Scienze dell'Invecchiamento, Università G. d'Annunzio, Chieti, <sup>13</sup>Casa di Reclusione Paliano, <sup>14</sup>Casa Circondariale di Perugia «Capanne», <sup>15</sup>Casa Circondariale e Reclusione Civitavecchia Casa Circondariale "G. Panzera", <sup>16</sup>Casa Circondariale Avellino, <sup>17</sup>Reggio Calabria ASP Reggio Calabria - Presidio I.P. RC "Panzera" e "Arghilla", <sup>18</sup>Unità di Malattie Infettive, Università di Sassari, Sassari



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



## ORAL COMMUNICATION 17.45-18.45

## LEPTIS MAGNA

### Comorbidities I

Chairs: M. Borderi (Bologna), A.M. Cattelan (Padova), G. Madeddu (Sassari)

#### OC 35 17.45-17.55 Impact of comorbidities on HIV associated neurocognitive disorder (HAND) in a large cohort of HIV infected (HIV+) patients (pts)

I. Mastrorosa, P. Lorenzini, C. Pinnetti, A. Vergori, G. Fabbri, R. Libertone, M.M. Plazzi, A.C. Brita, P. Balestra, R. Bellagamba, M. Zaccarelli, A. Ammassari, S. Cicalini, A. Antinori

HIV/AIDS Clinical Unit, National Institute for Infectious Disease "L. Spallanzani", Rome

#### OC 36 17.57-18.07 Role of fecal phenylalanine/tyrosine ratio in HIV infected subjects with neurocognitive impairment

E.N. Cavallari<sup>1</sup>, L. Laghi<sup>2</sup>, S. Turrone<sup>3</sup>, G. Corano Scheri<sup>1</sup>, C. Pinacchio<sup>1</sup>, M. Fratino<sup>4</sup>, L. Celani<sup>1</sup>, M. Ridolfi<sup>1</sup>, C. Scagnolari<sup>5</sup>, G. Ceccarelli<sup>6</sup>, V. Vullo<sup>1</sup>, G. d'Ettore<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases "Sapienza" University of Rome, <sup>2</sup>Department of Agro-Food Science and Technology University of Bologna, <sup>3</sup>Department of Pharmacy and Biotechnology University of Bologna, <sup>4</sup>Department of Neurology and Psychiatry "Sapienza" University of Rome, <sup>5</sup>Department of Molecular Medicine "Sapienza" University of Rome, <sup>6</sup>Department of Infectious Diseases Policlinico Umberto I of Rome

#### OC 37 18.09-18.19 Sexual dysfunction and generalized anxiety disorder in HIV positive women on stable antiretroviral therapy

R. Marocco, S. Maiolo, I. Pozzetto, T. Tieghi, B. Kertusha, L. Fondaco, S. Vita, M. D'Achille, V.S. Mercurio, C. Mastroianni, M. Lichtner

Infectious Disease Unit, Sapienza University, Latina, Italy

#### OC 38 18.21-18.31 HPV-related precancerosis screening in HIV infected MSM accessing the Infectious Diseases Clinic of Modena

C. Rogati<sup>1</sup>, M. Digaetano<sup>1</sup>, A. Bonazza<sup>1</sup>, M. Menozzi<sup>1</sup>, V. Borghi<sup>1</sup>, A. Farinetti<sup>2</sup>, R.P. Iachetta<sup>3</sup>, M. Pecorari<sup>4</sup>, F. Spatafora<sup>2</sup>, R.D. Villani<sup>3</sup>, C. Mussini<sup>1</sup>

<sup>1</sup>Infectious Diseases Clinic, AOU Policlinico di Modena, <sup>2</sup>Department of Surgery, Pathology and Radiology, University of Modena and Reggio Emilia, <sup>3</sup>Nuovo Ospedale Civile di Sassuolo (Modena), Pelvic Floor Center, Department of Proctology, <sup>4</sup>Struttura Complessa di Microbiologia e Virologia, AOU Policlinico di Modena

#### OC 39 18.33-18.43 In the era of modern cART bacterial infections are the main cause of admission to hospital in cART-treated HIV-positive patients: data from the SPID cohort, over 2010-2017

F. Bai, F. Parolo, A. Tavelli, E. Suardi, F. Crippa, T. Bini, G. Marchetti, A. d'Arminio Monforte

Clinic of Infectious Diseases, S. Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

## ORAL COMMUNICATION 17.45-18.45

## ORANGE 1

### HIV epidemiology and prevention

Chairs: B.M. Cesesia (Catania), S. Nozza (Milano), G. Parruti (Pescara)

#### OC 40 17.45-17.55 Reasons and outcomes of PEP use in a large urban center, the Outpatient Clinic of Turin: a year of observation

N. Forni, C. Alcantarini, C. Montrucchio, A. Trentalange, A. Barco, C. Costa, M. Milesi, M. Ferrara, A. Lazzaro, V. Pirriatore, L. Trentini, A. Calcagno, S. Bonora, G. Di Perri, M. Tettoni

Università di Torino, Unità di malattie infettive, Dipartimento Scienze Mediche

#### OC 41 17.57-18.07 Antiretroviral Pre-Exposure Prophylaxis for Conception (PrEP-C) in HIV-Serodiscordant Couples

G. De Carli<sup>1</sup>, A. Palummieri<sup>1</sup>, A. Ammassari<sup>1</sup>, R. Bellagamba<sup>1</sup>, S. Cicalini<sup>1</sup>, A. Cingolani<sup>2</sup>, R. Libertone<sup>1</sup>, G. Liuzzi<sup>1</sup>, G. Maffongelli<sup>3</sup>, S. Mosti<sup>1</sup>, C. Pinnetti<sup>1</sup>, A. Sampaolesi<sup>1</sup>, E. Savalli<sup>4</sup>, E. Tamburrini<sup>2</sup>, M. Zaccarelli<sup>1</sup>, V. Puro<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy, <sup>2</sup>Department of Infectious Diseases, Catholic University, Rome, Italy, <sup>3</sup>Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, <sup>4</sup>Infectious Diseases, AOU Pisana, Pisa, Italy

#### OC 42 18.09-18.19 Pre-exposure prophylaxis eligibility in a high-risk population

R. Rossotti, L. Chianura, M.C. Moiola, M. Merli, G. Travi, D. Motta, A. Pazzi, M. Puoti

Infectious Diseases Department, ASST Grande Ospedale Metropolitano Niguarda, Milan

#### OC 43 18.21-18.31 Missed opportunities to prevent HIV mother-to-child transmission in Italy

A. Di Biagio<sup>1</sup>, L. Taramasso<sup>2</sup>, G. Gustinetti<sup>2</sup>, G. Burastero<sup>2</sup>, V. Giacometti<sup>3</sup>, D. La Rovere<sup>4</sup>, O. Genovese<sup>5</sup>, C. Giaquinto<sup>6</sup>, I. Carloni<sup>7</sup>, S. Bernardi<sup>8</sup>, E. Bruzzese<sup>9</sup>, R. Badolato<sup>10</sup>, C. Gabiano<sup>11</sup>, L. Galli<sup>12</sup> on behalf of The Italian Register for HIV Infection in Children

<sup>1</sup>Clinica Malattie Infettive, Ospedale Policlinico San Martino, Genova, Italy, <sup>2</sup>Clinica Malattie Infettive, DISSAL, Università degli Studi di Genova, Italy, <sup>3</sup>Clinica Pediatrica, Ospedale Sacco, Milano, Italy, <sup>4</sup>Ospedale Pediatrico Giovanni XXIII, Bari, Italy, <sup>5</sup>Policlinico Gemelli, Roma, Italy, <sup>6</sup>Clinica Pediatrica, Università di Padova, Italy, <sup>7</sup>SOD Pediatrica, Ospedale Pediatrico Salesi, Ancona, Italy, <sup>8</sup>Immunoinfettivologia Pediatrica, Ospedale Bambin Gesù di Roma, Roma, Italy, <sup>9</sup>Clinica Pediatrica, Università Federico II, Napoli, Italy, <sup>10</sup>Clinica Pediatrica, Università degli Studi di Brescia, BS, <sup>11</sup>Clinica Pediatrica, Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Università degli Studi di Torino, Torino, <sup>12</sup>Clinica Pediatrica, Dipartimento di Scienze della Salute, Università degli Studi di Firenze, Ospedale Meyer, Firenze

**OC 44 18.33-18.43 Which is the current risk of tuberculosis in persons diagnosed with HIV in Italy?**

*E. Girardi<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, A. Gori<sup>3</sup>, A. Saracino<sup>4</sup>, A. Di Biagio<sup>5</sup>, G. Lapadula<sup>6</sup>, G. Orofino<sup>7</sup>, M. Lichtner<sup>8</sup>, S. Lo Caputo<sup>4</sup>, A. Antinori<sup>1</sup>, A. d'Arminio Monforte<sup>3</sup>, C. Mussini<sup>9</sup>, for the Icona Foundation Study Group*

<sup>1</sup>National Institute for Infectious Diseases L. Spallanzani - IRCCS, Rome, Italy, <sup>2</sup>University College London, London, UK, <sup>3</sup>University of Milan, Milan, Italy, <sup>4</sup>University of Bari, Bari, Italy, <sup>5</sup>University of Genoa, Genoa, Italy, <sup>6</sup>San Gerardo Hospital, Monza, Italy, <sup>7</sup>Amedeo di Savoia Hospital, Turin, Italy, <sup>8</sup>Sapienza University of Rome, Rome, Italy, <sup>9</sup>University of Modena and Reggio Emilia, Modena, Italy

**POSTER DISCUSSION 17.45-18.45**

**SPALATO**

**Social Science**

*Chairs: M. Oldrini (Como), L. Rancilio (Milano)*

**PD 8 17.45-17.50 HIV prevention project in Cagliari schools: EducAids survey**

*G. Dessì, B. Mocchi, A. Pontis, V. Mascia*  
 LILA, Cagliari

**PD 9 17.52-17.57 One year on the road to Meet, Test and Treat Sex Workers in Rome: a reparative psychological experience**

*L. Rosi<sup>1</sup>, E. Teti<sup>2</sup>, D. Masci<sup>1</sup>, G. Rodoquino<sup>1</sup>, B. Coladarce<sup>1</sup>, M. Patti<sup>1</sup>, E. Rossi<sup>1</sup>, M. Barra<sup>1</sup>*  
<sup>1</sup>Villa Maraini Foundation, Rome, Italy, <sup>2</sup>Infectious Disease Clinic, Tor Vergata University, Rome, Italy

**PD 10 17.59-18.04 Implementation of HIV infection Hospital-based active case finding: results from the SHOT project**

*M.S. Mameli<sup>1</sup>, P. Bagella<sup>1</sup>, F. Melis<sup>1</sup>, C. Fozza<sup>2</sup>, A. Murtas<sup>2</sup>, M.A. Montesu<sup>3</sup>, G. Deligia<sup>3</sup>, A.G. Fois<sup>4</sup>, S. Negri<sup>4</sup>, F. Filigheddu<sup>5</sup>, N. Manzoni<sup>6</sup>, S. Babudieri<sup>1</sup>, G. Madeddu<sup>1</sup>*

<sup>1</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Medicine, University of Sassari, <sup>2</sup>Unit of Hematology, Department of Medical, Surgical and Experimental Medicine, University of Sassari, <sup>3</sup>Unit of Dermatology, Department of Medical, Surgical and Experimental Medicine, University of Sassari, <sup>4</sup>Unit of Respiratory Diseases, Department of Medical, Surgical and Experimental Medicine, University of Sassari, <sup>5</sup>Unit of Internal Medicine, Department of Medical, Surgical and Experimental Medicine, University of Sassari, <sup>6</sup>Unit of Internal Medicine, University Hospital of Sassari, Italy

**PD 11 18.06-18.11 PrEP between desire and real needings**

*A. Bignardi<sup>1</sup>, D. Pavia<sup>2</sup>*  
<sup>1</sup>Arcigay, <sup>2</sup>Arcigay Modena

**PD 12 18.13-18.18 Health knows no boundaries**

*M. Errico<sup>1</sup>, A. Battistella<sup>1</sup>, S. Babudieri<sup>2</sup>, M. Cascio<sup>1,3</sup>, A. Borrelli<sup>1</sup>*  
<sup>1</sup>NPS Italia Onlus, <sup>2</sup>SIMSPE-Onlus, <sup>3</sup>European AIDS Treatment Group (EATG)

**PD 13 18.20-18.25 HIV test in an association: considerations on women's habits**

*A. Bianchi, F.M. Esposito, A. Antonino, G. Fracca, M. Lanza, V. Meneghin, F. Rossi, J.G. Scalisi, R. Repossi, D. Zagato, M. Cernuschi*  
 ASA, Associazione Solidarietà AIDS Onlus, Milan

**PD 14 18.27-18.32 Let's start talking about HIV again**

*A. Battistella<sup>1</sup>, R. Iardino<sup>1</sup>, L. Brogonzoli<sup>1</sup>, A. Toscano<sup>1</sup>, M. Errico<sup>2</sup>, S. Iardino<sup>1</sup>, G. Rizzardini<sup>3</sup>*  
<sup>1</sup>Fondazione The Bridge, <sup>2</sup>NPS Italia Onlus, <sup>3</sup>ASST Fatebenefratelli Sacco, Polo Universitario H. Sacco, Milano, Italy

**PD 15 18.34-18.39 On-line against HIV. Information and training service about HIV/AIDS/STD; Assistance and psychological support for people struggling with HIV and their families**

*R. Galipò, P. Ferri, J.D. Pamphilj, P. Narciso, M. Ghenzer*  
 Anlaids Lazio

**POSTER DISCUSSION 17.45-18.45**

**POLA**

**Immunology**

*Chairs: F. Baldelli (Perugia), L. Calza (Bologna), G. d'Ettore (Roma)*

**PD 16 17.45-17.50 Thymus is the barometer of aging in HIV patients, associated with metabolic syndrome and frailty**

*G. Guaraldi<sup>1</sup>, I. Franconi<sup>1</sup>, I. Pintassilgo<sup>2</sup>, J. Milic<sup>3</sup>, G. Besutti<sup>4</sup>, G. Ligabue<sup>4</sup>, N. Riva<sup>1</sup>, A. Raimondi<sup>1</sup>, A. Malagoli<sup>1</sup>, C. Mussini<sup>1</sup>*

<sup>1</sup>University of Modena and Reggio Emilia, Infectious Diseases Unit, <sup>2</sup>Hospital Garcia de Orta, Almada, Portugal, <sup>3</sup>University of Belgrade, Faculty of Medicine, <sup>4</sup>University of Modena and Reggio Emilia, Radiology Unit



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



**PD 17 17.52-17.57 B cell effector molecules modulation after ART interruption in chronically HIV-1 infected subjects with long-lasting virological suppression (APACHE study)**

L. Lopalco<sup>1</sup>, C. Pastori<sup>1</sup>, L. Galli<sup>2</sup>, A. Bigoloni<sup>2</sup>, A. Galli<sup>2</sup>, C. Muccini<sup>2</sup>, N. Galizzi<sup>2</sup>, A. Covizzi<sup>2</sup>, P. Cinque<sup>2</sup>, A. Lazzarin<sup>2</sup>, V. Spagnuolo<sup>2</sup>, A. Castagna<sup>2</sup>

<sup>1</sup>Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, <sup>2</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Milan

**PD 18 17.59-18.04 Modulation of gut microbiota improves zonulin level and integrity of enteric mucosa**

P. Vassalini<sup>1</sup>, G. Rossi<sup>2</sup>, G. Corano Scheri<sup>1</sup>, C. Pinacchio<sup>1</sup>, G. De Girolamo<sup>1</sup>, E.N. Cavallari<sup>1</sup>, G. Ceccarelli<sup>1</sup>, G. Fanello<sup>3</sup>, C. Scagnolari<sup>4</sup>, V. Vullo<sup>1</sup>, G. d'Etorre<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, <sup>2</sup>School of Biosciences, Veterinary Medicine University of Camerino, Matelica, Italy, <sup>3</sup>Department of Emergency Surgery-Emergency Endoscopic Unit, Sapienza University of Rome, <sup>4</sup>Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome

**PD 19 18.06-18.11 Plasma levels of bacterial 16S rRNA gene correlate with percentage of CD8+ T cells in HIV+ patients who underwent therapy interruption**

S. Pecorini<sup>1</sup>, E. Bianchini<sup>2</sup>, M. Digaetano<sup>3</sup>, S. De Biasi<sup>4</sup>, L. Gibellini<sup>5</sup>, D. Lo Tartaro<sup>5</sup>, M. Pinti<sup>4</sup>, G. Guaraldi<sup>5</sup>, C. Mussini<sup>2,3</sup>, A. Cossarizza<sup>5</sup>, M. Nasi<sup>2</sup>

<sup>1</sup>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>3</sup>Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, <sup>4</sup>Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, <sup>5</sup>Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy

**PD 20 18.13-18.18 Analysis of faecal microbiome during analytical treatment interruption in subjects with HIV chronic infection and long-lasting virological suppression (Apache Study)**

S. Nozza<sup>2</sup>, R. Ferrarese<sup>2</sup>, A. Poli<sup>2</sup>, L. Galli<sup>2</sup>, M. Sampaolo<sup>2</sup>, A. Bigoloni<sup>2</sup>, A. Galli<sup>2</sup>, C. Muccini<sup>3</sup>, V. Spagnuolo<sup>3</sup>, A. Lazzarin<sup>2</sup>, M. Clementi<sup>2,3</sup>, A. Castagna<sup>2,3</sup>, F. Canducci<sup>1,2</sup>

<sup>1</sup>University of Insubria, Varese, Italy, <sup>2</sup>San Raffaele Scientific Institute, Milano, Italy, <sup>3</sup>Vita-Salute San Raffaele University, Milan, Italy

**PD 21 18.20-18.25 Peripheral blood NK cells phenotype associate with evolution of HPV ano-genital lesions**

F. Bozzano<sup>1,2</sup>, F. Marras<sup>3</sup>, A. D'Arminio Monforte<sup>4</sup>, G. Marchetti<sup>4</sup>, L. Comi<sup>4</sup>, D. Bedognetti<sup>5</sup>, A. De Maria<sup>2,6</sup>

<sup>1</sup>Department of Experimental Medicine, University of Genoa, Italy, <sup>2</sup>Center of Excellence for Biomedical Research, University of Genoa, Italy, <sup>3</sup>G Gaslini Institute, Genoa, Italy, <sup>4</sup>University of Milan, San Paolo Hospital, Italy, <sup>5</sup>SIDRA Medical & Research Center, Doha, Qatar, <sup>6</sup>IRCCS AOU San Martino-IST Genova, Italy

**PD 22 18.27-18.32 Alteration of V 9 2 T Cells and dendritic cells in HIV/HCV co-infected patients after successful treatment with Directly Acting Antivirals**

E. Cimini<sup>1</sup>, A. Sacchi<sup>1</sup>, A. Romanelli<sup>1</sup>, N. Tumino<sup>1</sup>, R. Casetti<sup>1</sup>, V. Bordoni<sup>1</sup>, I. Mastroiosa<sup>2</sup>, O. Forini<sup>1</sup>, A. Vergori<sup>2</sup>, A. Ammassari<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>1</sup>

<sup>1</sup>Cellular Immunology and Pharmacology Laboratory; <sup>2</sup>Clinical Department, INM-HRCCS L. Spallanzani, Rome, Italy

09:00-10:00

**AUDITORIUM**

## KEYNOTE LECTURES

*Chairs:* A. Chirrianni (Napoli), G.M. Corbelli (Bologna), C. Mussini (Modena)

- 09.00-09.30 **The role of microbiome in HIV acquisition and progression and response to cART**
- 09.30-10.00 **Challenges with PrEP implementation: the French experience**

Giulia Marchetti (Milano)  
 Jean-Michel Molina (Paris F)

**SYMPOSIUM** 10:10-11:55

**AUDITORIUM**

## New Insights in viro-immunological pathogenesis in HIV

*Chairs:* G. Palù (Padova), M. Tavio (Ancona), M. Zazzi (Siena)

*The viro-immunological pathogenesis of HIV-infection is not fully understood, and results from a despite complex equilibrium between viral factors, host response, co-infections. Several approaches have been attempted to reach a cure, that include cART treatment in the earliest stages of the infection, as well as immune based approaches aimed at the containment of immune activation/inflammation, HIV-reservoir, and at the reconstitution of the immune competence to fully contain viral replication even in tissue (sanctuaries) once cART is stopped. The newest aspects of both HIV pathogenesis and cure will be discussed.*

- 10.10-10.25 **Host and viral factors in HIV and AIDS pathogenesis**
- 10.25-10.40 **Recent progress in anti-HIV broadly neutralizing antibodies**
- 10.40-10.55 **Immune and viral correlates of earliest HIV infection**
- 10.55-11.10 **Circulating and tissue reservoirs in HIV pathogenesis and cure**
- 11.10-11.25 **Role of viral coinfections in residual immune-activation**
- 11.25-11.55 **Discussion of Symposium issues**

Guido Silvestri (Atlanta USA)  
 Gabriella Scarlatti (Milano)  
 Giuseppe Tambussi (Milano)  
 Chiara Agrati (Roma)  
 Miriam Lichtner (Latina)

**ORAL COMMUNICATION** 10.10-11.55

**LEPTIS MAGNA**

## Clinical Hepatitis II

*Chairs:* O. Armignacco (Roma), F. Benanti (Catania), F. Mazzotta (Firenze)

- 10.10-10.25 **When is it safe to discontinue HBV prophylaxis in immunosuppressed patients?** Loredana Sarmati (Roma)

**OC 45 10.25-10.35 In patients with HBV-driven liver cancer, the levels of middle surface HBV antigen increase despite prolonged virological suppression: implications for a novel marker of HBV-driven hepatocarcinogenesis**

G. Brancaccio<sup>1</sup>, A. Battisti<sup>2</sup>, R. Salpini<sup>2</sup>, L. Colagrossi<sup>2</sup>, V. Fini<sup>2</sup>, M. Cantone<sup>1</sup>, L. Piermatteo<sup>2</sup>, Y. Oda<sup>3</sup>, C.F. Perno<sup>2,4</sup>, G.B. Gaeta<sup>1</sup>, V. Svicher<sup>2</sup>  
<sup>1</sup>University of Campania "Luigi Vanvitelli", Department of Mental Health and Public Medicine, Section of Infectious Diseases, Naples, Italy, <sup>2</sup>Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy, <sup>3</sup>Beacle Inc., Kyoto, Japan, <sup>4</sup>University of Milan, Department of Oncology and Haemato-Oncology, Milan, Italy

**OC 46 10.37-10.47 Acquisition of N-Glycosylation sites within HBV surface antigen promotes immunosuppression-driven HBV reactivation in vivo and alter HBsAg antigenicity in vitro**

R. Salpini<sup>1</sup>, L. Piermatteo<sup>1</sup>, A. Battisti<sup>1</sup>, L. Colagrossi<sup>1</sup>, M. Aragri<sup>1</sup>, L. Fabeni<sup>1</sup>, A. Bertoli<sup>1</sup>, C. Mastroianni<sup>2</sup>, M. Marignani<sup>3</sup>, S. Maylin<sup>4</sup>, C. Delaugerre<sup>4</sup>, F. Morisco<sup>5</sup>, N. Coppola<sup>6</sup>, A. Marrone<sup>7</sup>, N. Iapadre<sup>8</sup>, M. Angelico<sup>9</sup>, L. Sarmati<sup>10</sup>, M. Andreoni<sup>10</sup>, J. Verheyen<sup>11</sup>, F. Ceccherini-Silberstein<sup>1</sup>, M. Levrero<sup>12,13</sup>, C.F. Perno<sup>14</sup>, L. Belloni<sup>13</sup>, V. Svicher<sup>1</sup>  
<sup>1</sup>Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, <sup>2</sup>"Sapienza" University, Department of Public Health and Infectious Disease, Rome, Italy, <sup>3</sup>"S. Andrea Hospital", Department of Gastroenterology, Rome, Italy, <sup>4</sup>Laboratoire de Virologie, Hôpital Saint-Louis, AP-HP, Paris, France; Université Paris-Diderot, Paris, France; INSERM U941, Paris, France, <sup>5</sup>Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Naples "Federico II", via Sergio Pansini, Naples, Italy, <sup>6</sup>Department of Mental Health and Public Medicine, Second University of Naples, Naples, Italy, <sup>7</sup>Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, <sup>8</sup>"San Salvatore Hospital", L'Aquila, Italy, <sup>9</sup>Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, <sup>10</sup>Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, <sup>11</sup>Institute of Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany, <sup>12</sup>INSERM, U1052, Cancer Research Center of Lyon (CRCL), Université de Lyon (UCBL1), CNRS UMR\_5286, Centre Léon Bérard, Lyon, France, <sup>13</sup>Center for Life NanoScience@Sapienza, Istituto Italiano di Tecnologia, Italy, <sup>14</sup>University of Milan, Department of Oncology and Haemato-oncology, Milan, Italy

**OC 47 10.49-10.59 Effect of Direct-Acting Antivirals (DAA) on plasma levels of matrix metalloproteinase-2 and -9 and T-cell immune activation in HCV-monoinfected and HIV/HCV coinfecting patients**

P. Zuccalà<sup>1</sup>, T. Latronico<sup>2</sup>, M. Lichtner<sup>3</sup>, C. Mascia<sup>1</sup>, S. Vita<sup>3</sup>, R. Marocco<sup>3</sup>, F. Mengoni<sup>1</sup>, I. Pati<sup>2</sup>, T. Tieghi<sup>3</sup>, V. Vullo<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G.M. Liuzzi<sup>2</sup>





22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



<sup>1</sup>Department of Public Health and Infectious Diseases, "Sapienza", University of Rome, <sup>2</sup>Department of Biosciences, Biotechnologies and Biopharmaceutical, University of Bari, <sup>3</sup>Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Polo Pontino

**OC 48 11.01-11.11 Effect of interferon-free anti- HCV therapy on  $\gamma\delta$  T cells subset in cART-treated HIV/HCV coinfected patients**

*E.S. Cannizzo, E. Merlini, M. Chiamenti, A. De Bona, A. Magliano, C. Tincati, A. d'Arminio Monforte, G. Marchetti*  
I Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan

**OC 49 11.13-11.23 Hepatitis-related factors associated to cognitive impairment in HIV-HCV co-infected patients**

*M. Fabbiani<sup>1</sup>, N. Ciccarelli<sup>2</sup>, V. Castellì<sup>3</sup>, R. Gagliardini<sup>4</sup>, A. Soria<sup>3</sup>, A. Borghetti<sup>2</sup>, E. Colella<sup>3</sup>, D. Moschese<sup>2</sup>, M. Valsecchi<sup>3</sup>, A. Emiliozzi<sup>2</sup>, A. Gori<sup>3</sup>, A. De Luca<sup>4</sup>, A. Bandera<sup>3</sup>, S. Di Giambenedetto<sup>2</sup>*

<sup>1</sup>Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>2</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, <sup>3</sup>Infectious Diseases Unit, S. Gerardo Hospital, Monza, Italy, <sup>4</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy

**OC 50 11.25-11.35 Impact of HCV treatment with Direct-Acting Antivirals on glucose levels in diabetic HIV/HCV co-infected patients in the ICONA and HepalCONA cohorts**

*I. Mastroianni<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, M. Puoti<sup>3</sup>, R. Rossotti<sup>3</sup>, G. Marchetti<sup>4</sup>, G. Orofino<sup>5</sup>, L. Sighinolfi<sup>6</sup>, A. Raimondi<sup>7</sup>, A. d'Arminio Monforte<sup>4</sup>, A. Antinori<sup>1</sup>, A. De Luca<sup>8</sup> for the Icona/Hepalcona Foundation Study Group*

<sup>1</sup>Clinical Department, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, <sup>2</sup>Institute for Global Health, University College London, United Kingdom, <sup>3</sup>Unit of Infectious Diseases - ASST GOM Niguarda, Milan, Italy, <sup>4</sup>Clinic of Infectious and Tropical Diseases, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, <sup>5</sup>1st Division of Infectious Diseases, Amedeo di Savoia Hospital, Torino, Italy, <sup>6</sup>Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy, <sup>7</sup>Clinic of Infectious Diseases, AOU Policlinico di Modena, Modena, Italy, <sup>8</sup>Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

**OC 51 11.37-11.47 HCV clearance and pro-atherothrombotic shift in advanced liver disease**

*E. Biliotti<sup>1</sup>, D. Palazzo<sup>1</sup>, R. Cangemi<sup>2</sup>, R. Carnevale<sup>3</sup>, R. Esvan<sup>1</sup>, L. Fontanelli Sulekova<sup>1</sup>, C. Franchi<sup>1</sup>, P. Maida<sup>1</sup>, C. Nocella<sup>3</sup>, P. Perinelli<sup>1</sup>, M. Santori<sup>1</sup>, M. Spaziante<sup>1</sup>, F. Tamburini<sup>1</sup>, F. Violi<sup>2</sup>, G. Taliani<sup>1</sup>*

<sup>1</sup>Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Department of Internal Medicine and Medical Specialities, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

**ORAL COMMUNICATION 10.10-11.55**

**ORANGE 1**

**Virology and pharmacology**

*Chairs:* M. Clementi (Milano), L. Lopalco (Milano), G. Nunnari (Messina)

**10.10-10.25 Mitochondrial toxicity of NRTI: time to rethinking?**

Andrea Cossarizza (Modena)

**OC 52 10.25-10.35 Use of NRTIs in salvage therapy of treatment-experienced subjects with HIV-1 NRTI, NNRTI, PI and INSTI-drug resistance**

*M. Ferrara<sup>1</sup>, M. Zazzi<sup>2</sup>, L. Comi<sup>3</sup>, E. Focà<sup>4</sup>, G. Sterrantino<sup>5</sup>, A. Di Biagio<sup>6</sup>, M. Zaccarelli<sup>7</sup>, S. Rusconi<sup>8</sup>, G. Cenderello<sup>9</sup>, M. Gargiulo<sup>10</sup>, E. Schiaroli<sup>11</sup>, F. Fusco<sup>12</sup>, A.M. degli Antoni<sup>13</sup>, M. Tavio<sup>14</sup>, E. Garlassi<sup>15</sup>, B. Rossetti<sup>16</sup>, O. Bargiacchi<sup>17</sup>, G. Maffongelli<sup>18</sup>, M. Santoro<sup>19</sup>, C. della Casa<sup>20</sup>, N. Gianotti<sup>21</sup>, A. Poli<sup>21</sup>, F. Rinaldi<sup>22</sup>, L. Galli<sup>21</sup>, A. Castagna<sup>21,23</sup>, on behalf of the PRESTIGIO Study Group*

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Italy, <sup>2</sup>Department of Medical Biotechnology, University of Siena, Siena, Italy, <sup>3</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, <sup>4</sup>Università degli Studi di Brescia - Spedali Civili di Brescia, Italy, <sup>5</sup>Azienda Ospedaliera Universitaria Careggi, Firenze, Italy, <sup>6</sup>Infectious Diseases Unit, Hospital Policlinico San Martino, University of Genova, Genova, Italy, <sup>7</sup>Istituto Nazionale per le Malattie Infettive, Lazzaro Spallanzani, IRCCS, Rome, Italy, <sup>8</sup>Sacco Hospital, Infectious Diseases, University of Milan, Milano, Italy, <sup>9</sup>Infectious Diseases Department, Galliera Hospital, Genova, Italy, <sup>10</sup>AO Cotugno, Napoli, Italy, <sup>11</sup>Infectious Diseases, Perugia, Italy, <sup>12</sup>Ospedale S. Maria Annunziata, S.O.C. Malattie Infettive, USL Centro, Firenze, Italy, <sup>13</sup>UO Malattie Infettive ed Epatologia, Parma, Italy, <sup>14</sup>Azienda Ospedaliera Univ. Ospedali Riuniti, Ancona, Italy, <sup>15</sup>Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, <sup>16</sup>Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, <sup>17</sup>Ospedale Civile di Alessandria USL 70, Divisione di Malattie Infettive, Valmadonna, Alessandria, Italy, <sup>18</sup>Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, <sup>19</sup>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, <sup>20</sup>Healthcare Systems Department, CINECA, Casalecchio di Reno, Bologna, Italy, <sup>21</sup>Clinic of Infectious Diseases, Istituto Scientifico San Raffaele, Milano, Italy, <sup>22</sup>Dipartimento di Medicina Sperimentale e Clinica, University of Firenze, Firenze, Italy, <sup>23</sup>Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milano, Italy

**OC 53 10.37-10.47 Predicted activity of doravirine following exposure to NNRTI in a large observational cohort**

*G. Sterrantino<sup>1</sup>, V. Borghi<sup>2</sup>, A.P. Callegaro<sup>3</sup>, B. Bruzzone<sup>4</sup>, F. Saladini<sup>5</sup>, F. Maggiolo<sup>6</sup>, G. Maffongelli<sup>7</sup>, M. Andreoni<sup>8</sup>, M. De Gennaro<sup>9</sup>, N. Gianotti<sup>10</sup>, P. Bagnarelli<sup>11</sup>, A. Vergori<sup>12</sup>, A. Antinori<sup>12</sup>, M. Zazzi<sup>5</sup>, M. Zaccarelli<sup>12</sup> on behalf of the ARCA Study Group*

<sup>1</sup>Department of Tropical and Infectious Diseases, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, <sup>2</sup>Department of Infectious Diseases, Università di Modena, Modena, Italy, <sup>3</sup>Microbiology and Virology Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, <sup>4</sup>Igiene Unit, Azienda Ospedaliera-Universitaria San Martino, Genoa, Italy, <sup>5</sup>Department of Medical Biotechnologies, Università di Siena, Siena, Italy, <sup>6</sup>Department of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, <sup>7</sup>Virology Unit, Università di Tor Vergata, Rome, Italy, <sup>8</sup>Department of Infectious Diseases, Università di Tor Vergata, Rome, Italy, <sup>9</sup>Department of Infectious Diseases, Ospedale San Luca, Lucca, Italy, <sup>10</sup>Department of Infectious Diseases, Ospedale San Raffaele, Milan, Italy, <sup>11</sup>Virology Unit, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy, <sup>12</sup>Clinical Department, Istituto Nazionale per le Malattie infettive "Lazzaro Spallanzani", IRCCS, Rome, Italy

**OC 54 10.49-10.59 In vitro susceptibility of CRF02\_AG to fostemsavir**

*F. Saladini, A. Giannini, J. Dzemic, A. Boccuto, F. Dragoni, I. Vicenti, M. Zazzi*  
Department of Medical Biotechnologies, University of Siena

**OC 55 11.01-11.11 Gp120 substitutions at “hot” positions associated with resistance to fostemsavir in naïve HIV-positive individuals**

*L. Lepore<sup>1</sup>, C. Fabrizio<sup>1</sup>, E. Milano<sup>1</sup>, N. de Gennaro<sup>1</sup>, A. Lagioia<sup>1</sup>, A. Volpe<sup>1</sup>, L. Scudeller<sup>2</sup>, G. Angarano<sup>1</sup>, A. Saracino<sup>1</sup>, L. Monno<sup>1</sup>*

<sup>1</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>2</sup>Scientific Direction, Clinical Epidemiology Unit, IRCCS Policlinic San Matteo Foundation, Pavia, Italy

**OC 56 11.13-11.23 Multifaceted regulation of CD62L by HIV-1 accessory proteins**

*E. Giuliani, M.G. Desimio, M. Doria*

Laboratory of Immunoinfectivology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

**OC 57 11.25-11.35 SLC22A2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptoms in HIV-positive patients on dolutegravir**

*A. Borghetti<sup>1</sup>, A. Calcagno<sup>2</sup>, F. Lombardi<sup>1</sup>, J. Cusato<sup>2</sup>, S. Belmonti<sup>1</sup>, A. D’Avolio<sup>2</sup>, N. Ciccarelli<sup>3</sup>, S. La Monica<sup>1</sup>, M. Colafigli<sup>4</sup>, V. Delle Donne<sup>1</sup>, R. De Marco<sup>1</sup>, E. Tamburrini<sup>1</sup>, E. Visconti<sup>1</sup>, G. Di Perri<sup>2</sup>, A. De Luca<sup>5</sup>, S. Bonora<sup>2</sup>, S. Di Giambenedetto<sup>1</sup>*

<sup>1</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, <sup>2</sup>Unit of Infectious Diseases, Department of Infectious Diseases, University of Torino, <sup>3</sup>Department of Psychology, Catholic University of Sacred Heart, Milan, Italy, <sup>4</sup>Infectious Dermatology, IFO S. Galliciano, Rome, Italy, <sup>5</sup>Infectious Diseases Unit, Siena University Hospital, Siena

11.37-11.52 **Fundamentals of nanopharmacology applied to antiretrovirals**

Stefano Bonora (Torino)

**POSTER DISCUSSION 10.10-11.25**

**SPALATO**

**Comorbidities**

Chairs: D. Ripamonti (Bergamo), A. Saracino (Bari), G. Sterrantino (Firenze)

**PD 23 10.10-10.15 Fecal/plasma microbiota and cardio-metabolic risk factors in a cohort of HIV infected patients naïve to Antiretroviral Therapy (ART)**

*G. Ancona, E. Merlini, C. Tincati, V. Cogliandro, L. Gazzola, E.S. Cannizzo, A. d’Arminio Monforte, G. Marchetti*

Department of Health Sciences-University of Milan, Clinic of Infectious Diseases, San Paolo Hospital, Italy

**PD 24 10.17-10.22 The impact of HIV infection and antiretroviral therapy on aortic distensibility: meta-analysis of observational studies**

*G.J. Mulè<sup>2</sup>, M. Trizzino<sup>2</sup>, G. Mulè<sup>1</sup>, G. Geraci<sup>2</sup>, P. Colletti<sup>2</sup>, G. Mazzola<sup>2</sup>, C. Colomba<sup>2</sup>, S. Cottone<sup>1</sup>, A. Cascio<sup>2</sup>*

<sup>1</sup>Unit of Infectious Disease: Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo Italy, <sup>2</sup>Unit of Nephrology and Hypertension; ESH excellence centre; DIBIMIS; University of Palermo Italy

**PD 25 10.24-10.29 Longer Duration of HIV is associated with higher risk of Falls in an HIV ageing cohort**

*I. Franconi, N. Riva, A. Bianchi, A. Raimondi, M. Mancini, S. Zona, M. Menozzi, A. Malagoli, C. Mussini, G. Guaraldi*

University of Modena and Reggio Emilia, Infectious Diseases Unit

**PD 26 10.31-10.36 Declining prevalence over time and factors associated to HIV-associated neurocognitive disorder (HAND) in ART-treated HIVinfected individuals**

*I. Mastrorosa, C. Pinnetti, P. Lorenzini, A.C. Brita, R. Libertone, S. Menichetti, M.M. Plazzi, V. Mazzotta, A. Vergori, S. Cicalini,*

*R. Bellagamba, M. Zaccarelli, A. Antinori*

Clinical Department, National Institute for Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy

**PD 27 10.38-10.43 Pleocytosis and increased Cerebrospinal Fluid (CSF) neopterin level are associated with Blood Brain Barrier (BBB) damage in HIV positive patients**

*V. Mazzotta<sup>1</sup>, P. Lorenzini<sup>1</sup>, I. Mastrorosa<sup>1</sup>, S. Carta<sup>2</sup>, V. Fedele<sup>2</sup>, A. Giannetti<sup>1</sup>, R. Libertone<sup>1</sup>, A. Vergori<sup>1</sup>, F. Baldini<sup>1</sup>, S. Grisetti<sup>1</sup>, F. Forbic<sup>2</sup>,*

*C. Agrati<sup>3</sup>, C.F. Perno<sup>2</sup>, A. Antinori<sup>1</sup>, C. Pinnetti<sup>1</sup>*

<sup>1</sup>HIV/AIDS Clinical Unit, National Institute for Infectious Disease, <sup>2</sup>Cellular Immunology Laboratory, National Institute for Infectious Disease, <sup>3</sup>Antiviral Drug Monitoring Unit, National Institute for Infectious Disease

**PD 28 10.45-10.50 The prevalence of cerebrospinal fluid HIV escape varies according to different definitions and underlying comorbidities**

*M. Trunfio<sup>1</sup>, C. Pinnetti<sup>2</sup>, E. Focà<sup>3</sup>, F. Bai<sup>4</sup>, G. Maffongelli<sup>5</sup>, L. Celani<sup>6</sup>, P. Cinque<sup>7</sup>, A. Celotti<sup>3</sup>, M. Andreoni<sup>5</sup>, A. d’Arminio Monforte<sup>4</sup>,*

*G. d’Ettore<sup>6</sup>, A. Antinori<sup>2</sup>, A. Calcagno<sup>1</sup>*

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, <sup>2</sup>Clinical Department, National Institute for Infectious Diseases “Lazzaro Spallanzani,” Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, <sup>3</sup>Division of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and Spedali Civili General Hospital, Brescia, <sup>4</sup>Department of Health Sciences, Clinic of Infectious Diseases and Tropical Medicine, S.Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, <sup>5</sup>Department of Medicine of Systems, Infectious Diseases, University of Rome “Tor Vergata”, Rome, <sup>6</sup>Department of Public Health and Infectious Diseases, Azienda Policlinico Umberto I, Rome, <sup>7</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy

**PD 29 10.52-10.57 Liver transplantation from HIV+ donor to HIV+ recipient: a case report**

*G. Travi<sup>1</sup>, M. Merli<sup>1</sup>, M.C. Maioli<sup>1</sup>, A. Pazzi<sup>1</sup>, A. Lauterio<sup>2</sup>, R. De Carlis<sup>2</sup>, S. Di Sandro<sup>2</sup>, F. Ferla<sup>2</sup>, L. De Carlis<sup>2,4</sup>, A. De Gasperi<sup>3</sup>, M. Puoti<sup>1</sup>*

<sup>1</sup>SC Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>2</sup>SC Chirurgia Generale e dei Trapianti, Niguarda Transplant Centre, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>3</sup>III Servizio di Anestesia e Rianimazione, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>4</sup>Facoltà di Medicina e Chirurgia, Università degli Studi di Milano Bicocca



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



**PD 30 10.59-11.04 Oral HPV infection in HIV-positive MSM and its persistence**

A. Vergori<sup>1</sup>, A.R. Garbuglia<sup>2</sup>, M. Gentile<sup>1</sup>, F. Lupi<sup>1</sup>, C. Cimaglia<sup>3</sup>, D. Lapa<sup>2</sup>, C. Sias<sup>2</sup>, F. Del Nonno<sup>4</sup>, A. Baiocchini<sup>4</sup>, A. Brenna<sup>4</sup>, E. Girardi<sup>3</sup>, M.R. Capobianchi<sup>2</sup>, A. Ammassari<sup>1</sup>, A. Antinori<sup>1</sup>, P. Piselli<sup>3</sup>

<sup>1</sup>HIV/AIDS Unit, Clinical Department, <sup>2</sup>Laboratory of Virology, <sup>3</sup>Clinical Epidemiology Unit, <sup>4</sup>Laboratory of Pathology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy

**PD 31 11.06-11.11 Dolutegravir-related neuropsychiatric adverse events evaluated by patient reported outcomes: an ePROS project sub-study, final results**

C. Pallotta<sup>1</sup>, C. Papalini<sup>1</sup>, S. Cardaci<sup>1</sup>, A. Corsi<sup>2</sup>, M. Martini<sup>2</sup>, R. Bucciardini<sup>3</sup>, K. Pugliese<sup>3</sup>, S. Lucattini<sup>3</sup>, V. Bini<sup>4</sup>, S. Agolini<sup>2</sup>, F. Baldelli<sup>1</sup>, A. Costantini<sup>2</sup>, D. Francischi<sup>1</sup>

<sup>1</sup>Sezione di Malattie Infettive, Dipartimento di Medicina, Università di Perugia, <sup>2</sup>Servizio Regionale di Immunologia Clinica e Tipizzazione Tessutale, AOU Ospedali Riuniti di Ancona, <sup>3</sup>Istituto Superiore di Sanità, Roma, <sup>4</sup>Sezione di Medicina Interna e Scienze Endocrine e Metaboliche, Dipartimento di Medicina, Università di Perugia

**PD 32 11.13-11.18 Efficacy and safety of dolutegravir-based combination antiretroviral therapy in clinical practice in advanced HIV-infected naïves: results from a multicenter study**

B. Rossetti<sup>1</sup>, G. Baldin<sup>2</sup>, A. Capetti<sup>3</sup>, S. Rusconi<sup>4</sup>, G. Sterrantino<sup>5</sup>, M. Colafigli<sup>6</sup>, R. Gagliardini<sup>7</sup>, A. De Vito<sup>8</sup>, F. Lagi<sup>5</sup>, A. Ciccullo<sup>2</sup>, A. De Luca<sup>1</sup>, S. Di Giambenedetto<sup>2</sup>, G. Madeddu<sup>8</sup>

<sup>1</sup>Infectious Diseases Unit, Siena University Hospital, Siena, Italy, <sup>2</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, <sup>3</sup>Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, <sup>4</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>5</sup>Division of Tropical and Infectious Diseases, "Careggi" Hospital, Florence, Italy, <sup>6</sup>Infectious Dermatology and Allergology Unit, IFO S. Galliciano Institute (IRCCS), Rome, Italy, <sup>7</sup>Department of Medical Biotechnologies, University of Siena, Italy, <sup>8</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari

**SATELLITE SYMPOSIUM 12:00-12:45**

**AUDITORIUM**

Unrestricted educational grant of MSD Italy

**HIV & HCV: moving forward through tailored approaches**

Chairs: A. d'Arminio Monforte (Milano), M. Puoti (Milano)

*Innovation, as part of recent HIV and HCV therapeutic approaches, is essential to ensure and maximize treatment effectiveness. Versatility and therapy personalization are now crucial treatment imperatives which contribute to guarantee treatment durability, high efficacy and tolerability to ensure patients' every day high quality of life.*

- |             |   |                        |
|-------------|---|------------------------|
| 12.00-12.15 | <b>Patient centricity beyond HCV</b>  | Gloria Taliani (Roma)  |
| 12.15-12.30 | <b>Versatility: the key success factor in the management of HIV+ patients</b> | Andrea Antinori (Roma) |
| 12.30-12.45 | <b>Discussion of Symposium issues</b>   |                        |

**SATELLITE SYMPOSIUM 12:50-13:35**

**AUDITORIUM**

Con il supporto incondizionato di ViiV Healthcare

**Innovation in the treatment of HIV: definition and medical needs identification**

Chair: A. Antinori (Roma)

*The fight against HIV/AIDS is not yet won, and much remains to be done. The commitment of academic and pharmaceutical research must therefore be maintained, strengthened and directed towards the solution of identified and shared health needs. In this perspective, the challenge of pharmacological innovation is certainly fundamental, with objectives ranging from the long-term control of the disease with ever less impact on the lives of patients, the challenge of reducing the toxicity of therapy, the need for research into new molecules and mechanisms of action necessary to fight a virus that can hide in the reservoir of the organism and become resistant to the different classes of antiretrovirals. This workshop aims to address the issue of innovation in HIV therapy, its definition and evaluation, evaluating it according to the perspective of the various stakeholders able to express the needs that are still to be dealt with effectively through research: the scientific community and the people living with HIV.*

- |             |   |                                 |
|-------------|---|---------------------------------|
| 12.50-12.55 | <b>Introduction</b>                                   | Andrea Antinori (Roma)          |
| 12.55-13.10 | <b>The vision of scientific community</b>             | Massimo Andreoni (Roma)         |
| 13.10-13.25 | <b>The vision of PLWHIV community</b>                 | Giulio Maria Corbelli (Bologna) |
| 13.25-13.35 | <b>Discussion of Symposium issues and conclusions</b> | Andrea Antinori (Roma)          |

## ORAL COMMUNICATION 13.45-15.00

## AUDITORIUM

### Clinical HIV

Chairs: A. Di Biagio (Genova), S. Di Giambenedetto (Roma), R. Maserati (Pavia)

#### OC 58 13.45-13.55 HIV viral load kinetics during first-line antiretroviral treatment and risk of virological non-response or rebound among patient with high pre-treatment HIV-RNA

G. Lapadula<sup>1</sup>, A. d'Arminio Monforte<sup>2</sup>, A. Castagna<sup>3</sup>, S. Rusconi<sup>4</sup>, C. Mussini<sup>5</sup>, E. Colella<sup>1</sup>, A. Gori<sup>1</sup>, C. Fabrizio<sup>6</sup>, V. Spagnuolo<sup>3</sup>, E. Schiaroli<sup>7</sup>, A. Antinori<sup>8</sup>, A. Cozzi-Lepri<sup>9</sup> for the "ICONA Alte Viremie" collaboration

<sup>1</sup>Ospedale "San Gerardo", ASST Monza, <sup>2</sup>Ospedale "San Paolo", Università di Milano, Italy, <sup>3</sup>Ospedale San Raffaele, Università "Vita e Salute", Milan, Italy, <sup>4</sup>Ospedale "Luigi Sacco", Università di Milano, Italy, <sup>5</sup>Policlinico di Modena, Università di Modena e Reggio Emilia, Italy, <sup>6</sup>Clinic of Infectious Diseases, University of Bari, Bari, Italy, <sup>7</sup>Unit of Infectious Diseases, Department of Medicine, University of Perugia, Perugia, Italy, <sup>8</sup>Istituto Nazionale Malattie Infettive, Rome, Italy, <sup>9</sup>University College of London, UK

#### OC 59 13.57-14.07 Viral rebound after Thirteen-valent pneumococcal vaccination in HIV-1 infected subjects on stable virological suppression

R. Dell'Acqua<sup>1</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, A. Mastrangelo<sup>3</sup>, M. Albrecht<sup>2</sup>, P. Tadini<sup>2</sup>, D. Zandonà<sup>2</sup>, R. Melzi<sup>2</sup>, V. Gordo<sup>2</sup>, A. Lazzarin<sup>2</sup>, A. Castagna<sup>2,3</sup>, S. Nozza<sup>2</sup>

<sup>1</sup>University Hospital Policlinico, Bari, Italy, <sup>2</sup>San Raffaele Scientific Institute, Milano, Italy, <sup>3</sup>Vita-Salute San Raffaele University, Milan, Italy

#### OC 60 14.09-14.19 Non-AIDS related cancer risk is not affected by cART in ICONA cohort

P. Piselli<sup>1</sup>, D. Serraino<sup>2</sup>, A. Bandera<sup>3</sup>, A. Antinori<sup>1</sup>, E. Girardi<sup>1</sup>, C. Cimaglia<sup>1</sup>, A. Tavelli<sup>4</sup>, F. Bai<sup>4</sup>, G. Baldin<sup>5</sup>, A. Calcagno<sup>6</sup>, A. d'Arminio Monforte<sup>4</sup>, A. Cingolani<sup>5</sup>, for the ICONA Foundation Study Group

<sup>1</sup>National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, <sup>2</sup>CRO Aviano (PN), Italy, <sup>3</sup>San Gerardo Hospital, Monza, Italy, <sup>4</sup>University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, <sup>5</sup>Catholic University of the Sacred Heart, Rome, Italy, <sup>6</sup>University of Turin, Turin, Italy

#### OC 61 14.21-14.31 Effectiveness of an antiretroviral regimen based on cobicistat-boosted darunavir in an Italian prospective cohort: the TMC114FD1HTX4003 ("ST.O.RE.") study

A. Gori<sup>1</sup>, A. Vergori<sup>2</sup>, M.V. Cossu<sup>3</sup>, B. Menzaghi<sup>4</sup>, G. Sterrantino<sup>5</sup>, D. Ripamonti<sup>6</sup>, S. Marinello<sup>7</sup>, E. Focà<sup>8</sup>, V. Di Cristo<sup>9</sup>, A. Castagna<sup>10</sup>, M. Farenga<sup>11</sup>, S. La Monica<sup>12</sup>, S. Savinelli<sup>13</sup>, M. Gargiulo<sup>14</sup>, C. Gioè<sup>15</sup>, M.E. Locatelli<sup>16</sup>, P. Bagella<sup>17</sup>, S. Ferrara<sup>18</sup>, B. Rossetti<sup>19</sup>, P. Scerbo<sup>20</sup>, A. Venturini<sup>21</sup>, M. Annovazzi Lodi<sup>22</sup>, R. Curetti<sup>23</sup>, C. Stingone<sup>24</sup>, G. Di Perri<sup>25</sup>, A. Uglietti<sup>26</sup>, R. Termini<sup>26</sup>, D. Mancusi<sup>26</sup>

<sup>1</sup>San Gerardo Hospital, University of Milano-Bicocca, Department of Infectious Diseases, Monza - Italy, <sup>2</sup>National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, HIV/AIDS Department, Roma - Italy, <sup>3</sup>DIBIC Luigi Sacco, University of Milan, Infectious Diseases Unit, Milano - Italy, <sup>4</sup>Azienda Socio Sanitaria Territoriale della Valle Olona-Busto Arsizio, Unit of Infectious Diseases, Busto Arsizio (VA), <sup>5</sup>Azienda Ospedaliero-Universitaria Careggi, Division of Tropical and Infectious Diseases, Firenze, Italy, <sup>6</sup>ASST Papa Giovanni XXIII, Division of Infectious Diseases, Bergamo - Italy, <sup>7</sup>Azienda Ospedaliero-Universitaria di Padova, Division of Infectious and Tropical Diseases, Padova - Italy, <sup>8</sup>University of Brescia, Department of Infectious Diseases, Brescia - Italy, <sup>9</sup>ASST Fatebenefratelli-Sacco, 1st Division of Infectious Diseases, Milano - Italy, <sup>10</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy, <sup>11</sup>Amedeo di Savoia Hospital, Unit of Infectious Diseases, Torino - Italy, <sup>12</sup>Malattie Infettive, Fondazione Policlinico Universitario "A. Gemelli", Università Cattolica del Sacro Cuore, Roma - Italy, <sup>13</sup>Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Roma - Italy, <sup>14</sup>8th Department of Infectious Diseases, D. Cotugno Hospital, AORN dei Colli, Naples - Italy, <sup>15</sup>Infectious Diseases Division, Policlinico Universitario "P.Giaccone" - Palermo, Italy, <sup>16</sup>UOC Malattie Infettive - ARNAS "Garibaldi", Catania - Italy, <sup>17</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari - Sassari, Italy, <sup>18</sup>Clinic of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, <sup>19</sup>University Infectious Diseases Unit, AOU Senese, University of Siena, Siena, Italy, <sup>20</sup>Infectious Diseases Unit, Azienda Ospedaliera "Pugliese-Ciaccio", Catanzaro - Italy, <sup>21</sup>Infectious Diseases Department, Ente Ospedaliero Ospedali Galliera, Genova - Italy, <sup>22</sup>IRCCS Policlinico San Matteo Foundation, Infectious Diseases, Pavia, Italy, <sup>23</sup>Clinica Malattie Infettive e Tropicali, Dipartimento di Scienze della Salute, ASST Santi Paolo e Carlo, Milano - Italy, <sup>24</sup>Clinica delle Malattie Infettive, Dipartimento di Medicina dei Sistemi, Università Tor Vergata, Roma - Italy, <sup>25</sup>Unit of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Department of Medical Sciences, Torino - Italy, <sup>26</sup>Medical Affairs Department, Infectious Diseases, Janssen-Cilag SpA, Cologno Monzese (MI) - Italy

#### OC 62 14.33-14.43 From ETV to RPV-based cART, a hypothesis for effective intra-class de-escalation based on genotypic analysis of ARCA database

F. Del Puente<sup>1</sup>, N. Riccardi<sup>1</sup>, A. Borghetti<sup>2</sup>, A. D'Avino<sup>3</sup>, F. Lombardi<sup>4</sup>, D. Moschese<sup>5</sup>, M. Trezzi<sup>6</sup>, S.I. Bonelli<sup>6</sup>, A. Shallvari<sup>7</sup>, A. Bezenchek<sup>7</sup>, I. Vicenti<sup>8</sup>, V. Borghi<sup>9</sup>, M. Pecorari<sup>10</sup>, D. Francisci<sup>11</sup>, A. Di Biagio<sup>12</sup>

<sup>1</sup>Università di Genova, Policlinico San Martino, DISSAL Genoa, Italy, <sup>2</sup>Ospedale Policlinico A. Gemelli, Infectious disease unit, Roma, Italy, <sup>3</sup>Ospedale Cristo Re, Università Cattolica del Sacro cuore, Roma, Italy, <sup>4</sup>AUSL Bologna, Ospedale Maggiore, Bologna Italy, <sup>5</sup>Università Cattolica del Sacro Cuore, Istituto di Clinica delle Malattie Infettive - Roma, [2]Università Cattolica del Sacro Cuore, Istituto di Microbiologia - Roma, <sup>6</sup>AUSL Toscana Centro - Pistoia, Ospedale San Jacopo, Pistoia, Italy, <sup>7</sup>INFORMAPRO, Roma, Italy, <sup>8</sup>Università di Siena, Department of Medical Biotechnologies, <sup>9</sup>Università di Modena, Infectious disease unit, Modena, Italy, <sup>10</sup>Ospedale di Modena, Department of Diagnostic Medicine, Modena, Italy, <sup>11</sup>Azienda Ospedaliera S. Maria, Terni, Infectious disease unit Italy, <sup>12</sup>Ospedale Policlinico San Martino, Infectious disease unit, Genoa, Italy

#### OC 63 14.45-14.55 Switching away from tenofovir disoproxil fumarate (TDF): efficacy and durability of the different treatment strategies

G. Carosi<sup>1</sup>, N. Mazzini<sup>2</sup>, G. Parainfo<sup>1</sup>, F. Castelnovo<sup>1</sup>, S. Di Giambenedetto<sup>3</sup>, M. Di Pietro<sup>5</sup>, E. De Filippo<sup>2</sup>, L. Sighinolfi<sup>6</sup>, S. Lorenzotti<sup>8</sup>, N. Ladisa<sup>4</sup>, N. Squillace<sup>7</sup>, A. Soria<sup>7</sup>, G. Lapadula<sup>7</sup> and the MaSTER study group

<sup>1</sup>University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, <sup>2</sup>Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy, <sup>3</sup>Infectious Diseases, Policlinico A. Gemelli - Catholic University, Roma, Italy, <sup>4</sup>Infectious Diseases, Policlinico di Bari, Italy, <sup>5</sup>Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy, <sup>6</sup>Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy, <sup>7</sup>Infectious Diseases, San Gerardo Hospital, Monza, Italy, <sup>8</sup>Infectious Diseases, Istituti Ospitalieri, Cremona, Italy, <sup>9</sup>M.I.S.I. Foundation, Brescia, Italy



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



## ORAL COMMUNICATION 13.45-15.00

## LEPTIS MAGNA

### Comorbidities II

Chairs: P. Bonfanti (Lecco), C. Gervasoni (Milano), P. Maggi (Bari)

- OC 64 13.45-13.55 Homeostatic model assessment for insulin resistance (HOMA-IR) index trajectories in HIV-infected patients treated with firstline antiretroviral regimens based on non-nucleoside reverse transcriptase inhibitors (NNRTIs), ritonavir-boosted protease inhibitors (PIs/r) or on integrase strand transfer inhibitors (InSTIs)**  
C. Muccini<sup>1</sup>, N. Gianotti<sup>2</sup>, L. Galli<sup>2</sup>, A. Poli<sup>2</sup>, N. Galizzi<sup>1</sup>, R. Dell'Acqua<sup>3</sup>, A. Mastrangelo<sup>1</sup>, E. Messina<sup>2</sup>, P.M. Piatti<sup>4</sup>, A. Lazzarin<sup>2</sup>, A. Castagna<sup>1,2</sup>  
<sup>1</sup>Vita-Salute San Raffaele University, Milan, Italy, <sup>2</sup>San Raffaele Scientific Institute, Milano, Italy, <sup>3</sup>University Hospital Policlinico, Bari, Italy, <sup>4</sup>Cardiometabolic and Clinical Trials Unit, Internal Medicine Department, Metabolic and Cardiovascular Division, San Raffaele Scientific Institute, Milan, Italy
- OC 65 13.57-14.07 Changes in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted protease inhibitor to raltegravir or dolutegravir in non-diabetic HIV-infected patients**  
L. Calza<sup>1</sup>, M. Borderi<sup>1</sup>, V. Colangeli<sup>1</sup>, S. Coladonato<sup>1</sup>, B. Tazza<sup>1</sup>, G. Fornaro<sup>1</sup>, I. Bon<sup>2</sup>, M.C. Re<sup>2</sup>, P. Viale<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy, <sup>2</sup>Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- OC 66 14.09-14.19 Outcome after referral for solid organ transplantation in persons living with HIV**  
G. Travi<sup>1</sup>, M.C. Moio<sup>1</sup>, A. Pazzi<sup>1</sup>, M. Merli<sup>1</sup>, A. Panariello<sup>2</sup>, A. De Gasperi<sup>3</sup>, G. Colussi<sup>4</sup>, M. Frigerio<sup>5</sup>, E. De Juli<sup>6</sup>, L. Belli<sup>7</sup>, L. Santambrogio<sup>8</sup>, C. Russo<sup>9</sup>, S. Di Sandro<sup>10</sup>, F. Ferla<sup>10</sup>, L. De Carlis<sup>10</sup>, M. Puoti<sup>1</sup>  
<sup>1</sup>SC Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>2</sup>SC Psichiatria 2, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>3</sup>II Servizio Anestesia e Rianimazione, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>4</sup>SC Nefrologia e Trapianti di Rene, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>5</sup>SC Cardiologia 2 e dei Trapianti, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>6</sup>SC Pneumologia, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>7</sup>SC Epatologia e Gastroenterologia, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>8</sup>UOC Chirurgia Toracica, IRCCS Ospedale Maggiore Policlinico, Milano, <sup>9</sup>SC Cardiocirurgia, ASST Grande Ospedale Metropolitano Niguarda, Milano, <sup>10</sup>SC Chirurgia Generale e dei Trapianti, ASST Grande Ospedale Metropolitano Niguarda, Milano
- OC 67 14.21-14.31 Switching from Tenofovir disoproxil fumarate (TDF) to Tenofovir alafenamide (TAF) and hepatic safety: preliminary data from Surveillance Cohort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) project**  
N. Squillace<sup>1</sup>, E. Ricci<sup>2</sup>, B. Menzaghi<sup>3</sup>, A. Gori<sup>1,2</sup>, C. Gabrielli<sup>4</sup>, S. Passerini<sup>5</sup>, C. Martinelli<sup>6</sup>, M.S. Mameli<sup>7</sup>, P. Maggi<sup>8</sup>, K. Falasca<sup>9</sup>, L. Cordier<sup>10</sup>, B.M. Celesia<sup>11</sup>, F. Vichi<sup>12</sup>, A. Di Biagio<sup>13</sup>, G.F. Pellicanò<sup>14</sup>, P. Bonfanti<sup>15</sup> for the CISA Study Group  
<sup>1</sup>Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, <sup>2</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, <sup>3</sup>Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio (VA), <sup>4</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, <sup>5</sup>Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milano, <sup>6</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Florence, <sup>7</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, <sup>8</sup>Infectious Disease Clinic, University of Bari, Bari, <sup>9</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, <sup>10</sup>Infectious Disease Unit (II Divisione), ASST Fatebenefratelli Sacco, Milano, <sup>11</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, <sup>12</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, <sup>13</sup>Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, <sup>14</sup>Infectious Diseases, G. Martino Hospital - University of Messina, Messina, <sup>15</sup>Unit of Infectious Diseases, A. Manzoni Hospital, Lecco
- OC 68 14.33-14.43 Inflammation and anthropometric parameters in two different cohorts of patients with HIV infection**  
L. Taramasso<sup>1</sup>, C. Ammatuna<sup>1</sup>, F. Kall<sup>2</sup>, A. Parodi<sup>2</sup>, D. Fenoglio<sup>2,3</sup>, C. Dentone<sup>4</sup>, G. Filaci<sup>2,3</sup>, C. Viscoli<sup>1,5</sup>, A. Di Biagio<sup>5</sup>  
<sup>1</sup>Department of Health Science (DISSAL), University of Genova and Infectious Disease Clinic, Policlinico San Martino Hospital, Genova, Italy, <sup>2</sup>Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy, <sup>3</sup>Department of Internal Medicine; University of Genova, Policlinico San Martino Hospital, Genova, Italy, <sup>4</sup>Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, <sup>5</sup>Policlinico San Martino Hospital, Genova, Italy
- OC 69 14.45-14.55 Correlation between HIV-Index (HIVI), Protective Index (PI) and frailty in an HIV ageing population**  
I. Franconi<sup>1</sup>, O. Theou<sup>2</sup>, L. Wallace<sup>2</sup>, A. Malagoli<sup>1</sup>, R.J.A.H. Eendebak<sup>2</sup>, K. Rockwood<sup>2</sup>, C. Mussini<sup>1</sup>, G. Guaraldi<sup>1</sup>  
<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Dalhousie University, Halifax, Nova Scotia, Canada

## ORAL COMMUNICATION 13.45-15.00

## ORANGE 1

### Finding the undiagnosed and preventing new infections

Chairs: M. Breviglieri (Bologna), M. Farinella (Roma), M. Stagnitta (Firenze)

- OC 70 13.45-13.55 LILA Helplines' Data on HIV Self-testing**  
M. Oldrini<sup>1</sup>, D. Maggio<sup>1</sup>, P. Perone<sup>1</sup>, D. Savarino<sup>2</sup>, S. Penon<sup>2</sup>, L. Cosmaro<sup>2</sup>  
<sup>1</sup>LILA Nazionale Onlus - Lega Italiana per la Lotta contro l'AIDS, <sup>2</sup>Fondazione LILA Milano ONLUS
- OC 71 13.57-14.07 Impact of HIV self-test (HIVST) implementation on new HIV diagnoses in Italy**  
G. Chiaradia<sup>1</sup>, A. Navarra<sup>1</sup>, G. De Carli<sup>1</sup>, N. Orchi<sup>1</sup>, S. Pittalis<sup>1</sup>, V. Puro<sup>1</sup>, L. Badia<sup>2</sup>, F. Bai<sup>3</sup>, V. Borghi<sup>4</sup>, B.M. Celesia<sup>5</sup>, F. Lagi<sup>6</sup>, S. Nozza<sup>7</sup>, G. Orofino<sup>8</sup>, L. Taramasso<sup>9</sup>, A. Poli<sup>7</sup>, P. Viale<sup>2</sup>, A. Gori<sup>10</sup>, E. Girardi<sup>1</sup>  
<sup>1</sup>National Institute of Infectious Diseases "L. Spallanzani", IRCCS, Rome, <sup>2</sup>Policlinico S. Orsola-Malpighi, Bologna, <sup>3</sup>ASST Santi Paolo e Carlo Polo, Milano, <sup>4</sup>Azienda Ospedaliero Universitaria di Modena, <sup>5</sup>Università di Catania ARNAS Garibaldi, <sup>6</sup>AOU Careggi, Firenze, <sup>7</sup>IRCCS-Ospedale San Raffaele, Milano, <sup>8</sup>Ospedale Amedeo di Savoia, Torino, <sup>9</sup>Ospedale Policlinico San Martino, Genova, <sup>10</sup>Università Milano Bicocca - ASST Ospedale "San Gerardo", Monza, Italy



- OC 72** 14.09-14.19 **Preliminary analysis of a community based PrEP service**  
 A. Bianchi<sup>1</sup>, M. Lanza<sup>1</sup>, D. Delegn<sup>1</sup>, A. Antonino<sup>1</sup>, G. Fracca<sup>1</sup>, V. Frauneder<sup>1</sup>, P.L. Vinti<sup>1</sup>, S. Negri<sup>2</sup>, M. Bagnato<sup>2</sup>, G. Ancona<sup>3</sup>, A. De Bona<sup>3</sup>, A. Soria<sup>4</sup>, M. Cernuschi<sup>1</sup>  
<sup>1</sup>ASA Associazione Solidarietà AIDS Onlus, Milan, Italy, <sup>2</sup>Anlaids Sez. Lombarda, Milan, Italy, <sup>3</sup>Infective Disease Department, San Paolo Hospital, Milan, Italy, <sup>4</sup>Infective Disease Department, San Gerardo Hospital, Monza, Italy
- OC 73** 14.21-14.31 **Access to non-occupational post-exposure prophylaxis: clinical and management issues**  
 R. Rossotti, L. Chianura, M.C. Moiali, D. Motta, C. Orcese, C. Schiantarelli, G. Travi, B.P. Vigo, A. Volonterio, M. Puoti  
 Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- OC 74** 14.33-14.43 **Changing face of sexual behaviour, risk of STDs and chemsex in people attending out-patient unit and gay bars in Eastern Sicily**  
 M.E. Locatelli<sup>1</sup>, A. Pampaloni<sup>1</sup>, A. Ferrarotto<sup>2</sup>, G. Buongiorno<sup>1</sup>, A. Marino<sup>1</sup>, S. Accordino<sup>1</sup>, D. Scuderi<sup>1</sup>, M. Maresca<sup>1</sup>, R. Fontana del Vecchio<sup>1</sup>, M. Gussio<sup>1</sup>, B. Cocopardo<sup>1</sup>, B.M. Celesia<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi Catania, <sup>2</sup>ARCIGAY sez. Catania, Catania, Italy
- OC 75** 14.45-14.55 **High-risk sexual behavior in migrants: results from a dedicated health-care service in Sassari, Italy**  
 V. Fiore, P. Bagella, G. Madeddu, S. Babudieri  
 Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

## POSTER DISCUSSION 13.45-15.00

## SPALATO

### Hepatitis

Chairs: V. Cento (Milano), A. Giacometti (Ancona), G. Starnini (Viterbo)

- PD 33** 13.45-13.50 **HCV seroprevalence and associated risk factors in a cohort of people who use drugs screened with rapid tests in Rome: the hidden epidemic**  
 E. Teti<sup>2</sup>, V. Malagnino<sup>2</sup>, V. Cento<sup>3</sup>, M. De Masi<sup>2</sup>, L. Foroghi<sup>2</sup>, L. Coppola<sup>2</sup>, M. Compagno<sup>2</sup>, G. Malerba<sup>2</sup>, A. Gentile<sup>2</sup>, C. Stingone<sup>2</sup>, L. Campogiani<sup>2</sup>, D. Masci<sup>1</sup>, B. Coladarce<sup>1</sup>, G. Rodoquino<sup>1</sup>, D. Novarini<sup>1</sup>, T. Di Giovanni<sup>1</sup>, M. Patti<sup>1</sup>, E. Rossi<sup>1</sup>, L. Sarmati<sup>2</sup>, M. Andreoni<sup>2</sup>, M. Barra<sup>1</sup>  
<sup>1</sup>Villa Maraini Foundation ONLUS, Rome, Italy, <sup>2</sup>Infectious Diseases Clinic, Tor Vergata University, Rome, Italy, <sup>3</sup>Microbiology and Virology, Università degli studi di Milano, Italy
- PD 34** 13.52-13.57 **Preliminary results about HCV care cascade among PWID in Rome: "Una regione senza la C" project**  
 L. Campogiani<sup>1</sup>, L. Foroghi<sup>1</sup>, E. Teti<sup>1</sup>, M. De Masi<sup>1</sup>, C. Stingone<sup>1</sup>, L. Coppola<sup>1</sup>, M. Compagno<sup>1</sup>, A. Gentile<sup>1</sup>, G. Malerba<sup>1</sup>, M. Patti<sup>5</sup>, M. Barra<sup>5</sup>, S. Regio<sup>4</sup>, M. Bartoli<sup>3</sup>, I. Gardini<sup>3</sup>, M. Conforti<sup>3</sup>, T. Petrangolini<sup>2</sup>, L. Sarmati<sup>1</sup>, M. Andreoni<sup>1</sup>; Una regione senza la C group  
<sup>1</sup>Infectious Diseases Clinic, Tor Vergata University, Rome, <sup>2</sup>Regione Lazio, Rome, Italy, <sup>3</sup>Associazione EpaC Onlus, Italy, <sup>4</sup>CNCA – Coordinamento Nazionale Comunità di Accoglienza, Italy, <sup>5</sup>Villa Maraini Foundation ONLUS, Rome, Italy
- PD 35** 13.59-14.04 **Implementation of HCV oral testing in correctional facilities: experience from Minors and Adult detention centers in Milan**  
 R. Giuliani<sup>1</sup>, E. Freo<sup>1</sup>, F. Iannuzzi<sup>1</sup>, F. Bai<sup>2</sup>, T. Sebastiani<sup>1</sup>, F. Nigro<sup>3</sup>, L. Mannarini<sup>3</sup>, S. Negri<sup>4</sup>, D. Mainieri<sup>4</sup>, A. d'Arminio Monforte<sup>2</sup>, R. Ranieri<sup>1</sup>  
<sup>1</sup>Penitentiary Infectious Diseases Unit Milan, <sup>2</sup>Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, <sup>3</sup>Penitentiary Health Service, Milan, <sup>4</sup>ANLAIDS Section of Milan, Italy
- PD 36** 14.06-14.11 **Characterization of transmission clusters in DAA naïve HCV infected individuals in Rome**  
 L. Fabeni<sup>1</sup>, M. Aragri<sup>1</sup>, E. Teti<sup>2</sup>, C. Masetti<sup>3</sup>, V.C. Di Maio<sup>1</sup>, A. Bertoli<sup>1</sup>, V. Cento<sup>4</sup>, S. Barbaliscia<sup>1</sup>, I. Spalliera<sup>2</sup>, L. Ferrari<sup>2</sup>, I. Lenci<sup>3</sup>, G. Fiorentino<sup>5</sup>, P. Begini<sup>5</sup>, S. Mokake<sup>7</sup>, C. Stingone<sup>2</sup>, L. Foroghi<sup>2</sup>, R. Campoli<sup>1</sup>, K. Yu La Rosa<sup>1</sup>, C. Furlan<sup>8</sup>, A. Pellicelli<sup>9</sup>, M. Marignani<sup>6</sup>, G. Taliani<sup>10</sup>, L. Sarmati<sup>2</sup>, C. Pasquazzi<sup>2</sup>, C.F. Perno<sup>11</sup>, M. Angelico<sup>3</sup>, M. Andreoni<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>  
<sup>1</sup>Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, <sup>2</sup>Infectious Diseases Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, <sup>3</sup>Hepatology Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, <sup>4</sup>Residency program in Microbiology and Virology, Università degli Studi di Milano, Milan, Italy, <sup>5</sup>Infectious Diseases Unit, Sant'Andrea Hospital – "Sapienza" University, Rome, Italy, <sup>6</sup>Digestive and Liver Diseases Department, Sant'Andrea Hospital, Sapienza University, Rome, Italy, <sup>7</sup>Laboratory of Molecular Virology, University Hospital of Rome "Tor Vergata, Rome, Italy, <sup>8</sup>Department of Tropical and Infectious Diseases, Policlinico Umberto I, Rome, Italy, <sup>9</sup>Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, <sup>10</sup>Tropical Diseases, Umberto I Hospital – "Sapienza" University, Rome, Italy, <sup>11</sup>Department of Oncology and Oncohematology, Università degli Studi di Milano, Milan, Italy
- PD 37** 14.13-14.18 **Prevalence of Hepatitis B and C viruses and Human Immunodeficiency virusinfections in irregular and refugees migrants in southern Italy**  
 M. Macera<sup>1</sup>, L. Alessio<sup>2</sup>, L. Gualdieri<sup>3</sup>, M. Pisaturo<sup>2</sup>, M. Caroprese<sup>1</sup>, G. Di Caprio<sup>1</sup>, C. Sagnelli<sup>1</sup>, L. Onorato<sup>1</sup>, S. Curto<sup>1</sup>, C. Minichini<sup>1</sup>, M. Starace<sup>1</sup>, G. Scotto<sup>4</sup>, I.F. Angelillo<sup>5</sup>, E. Sagnelli<sup>1</sup>, N. Coppola<sup>2</sup>  
<sup>1</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, Università della Campania L. Vanvitelli, Napoli, <sup>2</sup>Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>3</sup>Centro per la Tutela della Salute degli Immigrati, Naples, Italy, <sup>4</sup>Infectious Diseases Unit, Foggia, <sup>5</sup>Department of Experimental Medicine, Università della Campania L. Vanvitelli, Naples, Italy
- PD 38** 14.20-14.25 **Treatment of hepatitis B virus-infected pregnant women for the prevention of mother-to-child transmission**  
 S. Lardo, G. Liuzzi, S. Meschi, S. Rosati, C. Minosse, F. Carletti, M.R. Capobianchi  
 National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



- PD 39** 14.27-14.32 **Treatment with PEG-IFN in a cohort of immigrant patients affected by chronic hepatitis delta: a longitudinal analysis**  
L. Boglione, G. Cariti, T. Lupia, S.M. Pinna, V. Ghisetti, G. Di Perri  
Unit of Infectious Diseases, Departement of Medical Sciences, University of Turin, Turin, Italy
- PD 40** 14.34-14.39 **The combined evaluation of HBV serological markers can predict intrahepatic HBV reservoir and the degree of liver fibrosis in HBeAg-negative Chronic Hepatitis B Infection**  
R. Salpini<sup>1</sup>, L. Colagrossi<sup>1,3</sup>, U.S. Gill<sup>2</sup>, A. Battisti<sup>1</sup>, L. Piermatteo<sup>1</sup>, N. Hansi<sup>2</sup>, C.F. Perno<sup>3</sup>, P.T.F. Kennedy<sup>1</sup>, V. Svicher<sup>1</sup>  
<sup>1</sup>University of Rome Tor Vergata, Department of Experimental Medicine and Surgery, Rome, Italy, <sup>2</sup>Hepatology, Centre for Immunobiology, Blizzard Institute, Barts and The London SMD, QMUL, London, United Kingdom, <sup>3</sup>University of Milan, Milan, Italy
- PD 41** 14.41-14.46 **Genotype I Hepatitis A virus introduction in Italy: Bayesian phylogenetic analysis to date different epidemics**  
E. Cella<sup>1</sup>, E. Riva<sup>2</sup>, S. Angeletti<sup>3</sup>, M. Fogolari<sup>3</sup>, A. Blasi, V. Scolamacchia<sup>3</sup>, S. Spoto<sup>4</sup>, R. Bazzardi<sup>5</sup>, A. Lai<sup>6</sup>, C. Sagnelli<sup>7</sup>, E. Sagnelli<sup>7</sup>, M. Ciccozzi<sup>1</sup>  
<sup>1</sup>Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Italy, <sup>2</sup>Unit of Virology, University Campus Bio-Medico of Rome, Italy, <sup>3</sup>Unit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Italy, <sup>4</sup>Internal Medicine Department, University Campus Bio-Medico of Rome, Italy, <sup>5</sup>Dipartimento di Igiene degli Alimenti, Istituto Zooprofilattico Sperimentale della Sardegna, Sassari, Italy, <sup>6</sup>Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, <sup>7</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples, Italy
- PD 42** 14.48-14.53 **Modification of cardiovascular risk and renal function in HIV/HCV co-infected patients treated with DAAs**  
A. Barco, L. Marinaro, V. Pirriatore, N. Forni, C. Montrucchio, C. Alcantarini, M. Tettoni, A. Trentalange, G. Palazzo, S. Scabini, C. Costa, A. Calcagno, G. Di Perri, S. Bonora  
Amedeo Di Savoia Hospital, University of Turin, Department of Medical Sciences, Torino, Italy

## POSTER DISCUSSION 13.45-15.00

**POLA**

### Basic science and virology

Chairs: P. Bagnarelli (Ancona), S. Parisi (Padova), M. Santoro (Roma)

- PD 43** 13.45-13.50 **Prevalence of polypharmacy and potential drug-drug interactions in PLWH: a cross sectional study from the Modena HIV Metabolic Clinic cohort**  
A. Raimondi<sup>1</sup>, S. Zona<sup>1</sup>, F. Carli<sup>1</sup>, M. Menozzi<sup>1</sup>, G. Nardini<sup>1</sup>, B. Beghetto<sup>1</sup>, M. Mancini<sup>1</sup>, V. Masi<sup>2</sup>, C. Mussini<sup>1</sup>, G. Guaraldi<sup>1</sup>  
<sup>1</sup>Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy, <sup>2</sup>Department of Immunology, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy
- PD 44** 13.52-13.57 **Loss of control of HIV viremia with OTC weight-loss drugs: a call for caution?**  
D. Cattaneo<sup>1,2</sup>, A. Giacomelli<sup>3</sup>, C. Gervasoni<sup>1,3</sup>  
<sup>1</sup>Gestione Ambulatoriale Politerapie (GAP) outpatient clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, <sup>2</sup>Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, <sup>3</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
- PD 45** 13.59-14.04 **Evaluation of the pharmacokinetics of psychotropic drugs in HIV-infected patients: implications for clinical practice**  
D. Cattaneo<sup>1,2</sup>, S. Baldelli<sup>1</sup>, C. Resnati<sup>3</sup>, A. Giacomelli<sup>3</sup>, P. Meraviglia<sup>3</sup>, D. Minisci<sup>3</sup>, N. Astuti<sup>3</sup>, A. Ridolfo<sup>3</sup>, G.V. De Socio<sup>4</sup>, C. Gervasoni<sup>2,3</sup>  
<sup>1</sup>Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>2</sup>Gestione Ambulatoriale Politerapie (GAP) outpatient clinic, ASST Fatebenefratelli Sacco, Milano, Italy, <sup>3</sup>Department of Infectious Disease, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>4</sup>Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy
- PD 46** 14.06-14.11 **Drug plasma trough concentrations during treatment with daclatasvir and sofosbuvir are associated respectively with liver impairment and with renal dysfunction in HIV/HCV co-infected patients**  
M. Tempestilli<sup>1</sup>, I. Mastroiosa<sup>2</sup>, S. Notari<sup>1</sup>, P. Lorenzini<sup>2</sup>, G. Fabbri<sup>2</sup>, F. Lupi<sup>2</sup>, R. Bellagamba<sup>2</sup>, A. Vergori<sup>2</sup>, M. Zaccarelli<sup>2</sup>, A. Ammassari<sup>2</sup>, C. Agrati<sup>1</sup>, A. Antinori<sup>2</sup>  
<sup>1</sup>Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy, <sup>2</sup>Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy
- PD 47** 14.13-14.18 **Characterization of treated acute HIV-1 infections with late or absent seroconversion**  
A. De Luca<sup>1,2</sup>, G. Marchetti<sup>3</sup>, M.B. Pasticcini<sup>4</sup>, G. Baldin<sup>5</sup>, E. Merlini<sup>3</sup>, I. Vicenti<sup>1</sup>, L. Mundo<sup>1</sup>, R. Ricci<sup>6</sup>, A. Borghetti<sup>5</sup>, F. Saladini<sup>1</sup>, R. Gagliardini<sup>1</sup>, S. Di Giambenedetto<sup>5</sup>, M. Zazzi<sup>1</sup>  
<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, <sup>2</sup>Infectious Diseases Unit, AOU Senese, Siena, <sup>3</sup>Department of Health Sciences - Clinic of Infectious Diseases, Univ of Milan, San Paolo Hospital, <sup>4</sup>Clinical Infectious Diseases, Dep. Of Medicine, University of Perugia, Perugia, <sup>5</sup>Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, <sup>6</sup>Istituto di Microbiologia, Policlinico Gemelli, Rome, Italy
- PD 48** 14.20-14.25 **Ultrasensitive p24 digital ELISA can lead to an overestimate of HIV reservoir size**  
F.R. Simonetti<sup>1</sup>, L.N. Bertagnoli<sup>1</sup>, S.A. Beg<sup>2</sup>, J. Lai<sup>2</sup>, P. Patel<sup>3</sup>, H Zhang<sup>4</sup>, G. Laird<sup>1</sup>, R.S. Siliciano<sup>1,2</sup>, J.D. Siliciano<sup>1</sup>  
<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, <sup>2</sup>Howard Hughes Medical Institute, Baltimore, Maryland, USA, <sup>3</sup>Quanterix Corporation, Lexington, Massachusetts, USA, <sup>4</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

- PD 49 14.27-14.32 Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors**  
 R. Scutari<sup>1</sup>, D. Di Carlo<sup>2,3</sup>, I. Vicenti<sup>4</sup>, C. Alteri<sup>1</sup>, V. Zuccaro<sup>5</sup>, A. Cascio<sup>6</sup>, F. Incardona<sup>7</sup>, V. Borghi<sup>8</sup>, A. Bezenchek<sup>7</sup>, M. Andreoni<sup>9</sup>, A. Antinori<sup>10</sup>, C.F. Perno<sup>10</sup>, A. De Luca<sup>4</sup>, M. Zazzi<sup>4</sup>, M.M. Santoro<sup>1</sup>  
<sup>1</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>2</sup>University of Milan, Paediatric Clinical Research Center "Romeo and Erica Invernizzi", Milan, Italy, <sup>3</sup>University of Pavia, Pavia, Italy, <sup>4</sup>University of Siena, Siena, Italy, <sup>5</sup>IRCCS "San Matteo", Pavia, Italy, <sup>6</sup>University of Palermo, Palermo, Italy, <sup>7</sup>IIPRO - InformaPRO S.r.l., Rome, Italy, <sup>8</sup>AOU Policlinico di Modena, Modena, Italy, <sup>9</sup>Polyclinic of Rome "Tor Vergata", Rome Italy, <sup>10</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy
- PD 50 14.34-14.39 Persistent low level viremia: the grey zone between virological success and risk of failure in clinical practice**  
 E. Balleto<sup>1</sup>, L. Taramasso<sup>1</sup>, C. Saffioli<sup>1</sup>, P. Tatarelli<sup>1</sup>, P. Caligiuri<sup>3,4</sup>, B. Bruzzone<sup>3</sup>, B. Giannini<sup>5</sup>, M. Giacomini<sup>5</sup>, C. Viscoli<sup>1,2</sup>, A. Di Biagio<sup>2</sup>  
<sup>1</sup>Clinic of Infectious Diseases, Department of Health Sciences (DiSSal), University of Genoa, Policlinico San Martino Hospital, Genoa, Italy, <sup>2</sup>Clinic of Infectious Diseases, Policlinico San Martino Hospital, Genoa, Italy, <sup>3</sup>Hygiene Unit, Policlinico San Martino Hospital, Genoa, Italy, <sup>4</sup>Department of Health Sciences (DiSSal), University of Genoa, Italy, <sup>5</sup>Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, Italy
- PD 51 14.41-14.46 HIV-DNA dynamics after ART interruption in chronically HIV-1 infected subjects with long-lasting virological suppression (APACHE study)**  
 C. Alteri<sup>1</sup>, L. Galli<sup>2</sup>, R. Scutari<sup>1</sup>, A. Bigoloni<sup>2</sup>, A. Poli<sup>2</sup>, A. Galli<sup>2</sup>, N. Gianotti<sup>2</sup>, S. Nozza<sup>2</sup>, C. Muccini<sup>3</sup>, A. Lazzarin<sup>2</sup>, V. Spagnuolo<sup>2,3</sup>, F. Ceccherini-Silberstein<sup>1</sup>, A. Castagna<sup>2,3</sup>  
<sup>1</sup>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, <sup>2</sup>Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, <sup>3</sup>Università Vito-Salute San Raffaele, Milan, Italy
- PD 52 14.48-14.53 Comparison of resistance mutation patterns between current proviral HIV DNA genotype and historical plasma HIV RNA genotype in multi-experienced HIV-positive patients**  
 M.A. Carleo<sup>1</sup>, N. Cuomo<sup>2</sup>, A. Raddi<sup>2</sup>, V. Rizzo<sup>1</sup>, A. Maddaloni<sup>1</sup>, P. Rosario<sup>1</sup>, R. Viglietti<sup>3</sup>, V. Sangiovanni<sup>3</sup>, M. D'Abbraccio<sup>1</sup>, V. Esposito<sup>1</sup>  
<sup>1</sup>UOC Immunodeficienze e Malattie Infettive di Genere - AO dei Colli - P.O. "D. Cotugno" - Napoli, <sup>2</sup>UOC Microbiologia e Virologia - AO dei Colli - P.O. "D. Cotugno" - Napoli, <sup>3</sup>UOC Infezioni Sistemiche e dell'Immunodepresso - AO dei Colli - P.O. "D. Cotugno" - Napoli, Italy

## SYMPOSIUM 15:00-16:15

## AUDITORIUM

### Management of HIV therapy in Special Populations

Chairs: S. Lo Caputo (Bari), F. Maggiolo (Bergamo), P. Magrini (Roma)

*cART is chronic therapy that requires adjustments according to the stage of infection. Treating a newly acquired acute infection is completely different from treating a multi-experienced patient harboring a virus with multiple resistance. The optimal management of cART, however must be modulated on the characteristics of patients, too. Only the comprehensive inclusion of these multiple variables leads to the optimal management of the chronic therapy.*

15.00-15.15	<b>Acute Infections</b>	Andrea Gori (Milano)
15.15-15.30	<b>Multi-failed</b>	Stefano Rusconi (Milano)
15.30-15.45	<b>Pregnancy</b>	Giuseppina Liuzzi (Roma)
15.45-16.00	<b>Elderly</b>	Giovanni Guaraldi (Modena)
16.00-16.15	<b>Discussion of Symposium issues</b>	

16:15-16:45

## ICAR 2018 SPECIAL AWARDS

## AUDITORIUM

Chair: M. Andreoni (Roma), A. Antinori (Roma), C.F. Perno (Milano) .

- **Best Poster Award** Massimo Andreoni (Roma), Andrea Antinori (Roma), Carlo Federico Perno (Milano)
- **SIMIT Awards to Best Oral Communications for Young Researchers** Massimo Galli (Milano)

16:45-17:00

## CLOSING REMARKS

## AUDITORIUM

M. Andreoni (Roma), A. Antinori (Roma), C.F. Perno (Milano)


10° CONGRESSO NAZIONALE



Italian Conference on  
AIDS and Antiviral Research



22-24  
MAGGIO  
2018  
PALACE HOTEL,  
ROMA



Indicates posters  
selected for  
"ICAR 2018 Best  
Poster Awards"  
see page 76

POSTER  
EXHIBITION



## ANTIRETROVIRAL THERAPY

### P 1 Liver enzyme elevations according to the first line cART regimen: real life data from the ICONA cohort

L. Taramasso<sup>1</sup>, P. Lorenzini<sup>2</sup>, A. Di Biagio<sup>3</sup>, M. Lichtner<sup>4</sup>, G. Marchetti<sup>5</sup>, R. Rossotti<sup>6</sup>, G. Lapadula<sup>7</sup>, D. Minisci<sup>8</sup>, F. Vichi<sup>9</sup>, A. Antinori<sup>2</sup>, S. Bonora<sup>10</sup>, A. d'Arminio Monforte<sup>5</sup> for ICONA Foundation Study Group

<sup>1</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, <sup>2</sup>HIV/AIDS Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy, <sup>3</sup>Infectious Diseases Clinic, Policlinico San Martino Hospital, Genoa, Italy, <sup>4</sup>Department of Infectious Diseases, Sapienza University, Polo Pontino, Latina, Italy, <sup>5</sup>Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy, <sup>6</sup>Infectious Diseases Department, ASST GOM Niguarda, Milan, Italy, <sup>7</sup>Infectious Diseases Unit, Ospedale San Gerardo, Monza, Italy, <sup>8</sup>Department of Infectious Disease, L. Sacco University Hospital, Milan, Italy, <sup>9</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, <sup>10</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy



### P 2 Therapy with darunavir/cobicistat impacts on total cholesterol and glomerular filtration rate

L. Taramasso<sup>1</sup>, E. Ricci<sup>2</sup>, A. Cascio<sup>3</sup>, B. Menzaghi<sup>4</sup>, L. Valsecchi<sup>5</sup>, N. Squillace<sup>6</sup>, G.V. De Socio<sup>7</sup>, C. Dentone<sup>8</sup>, P. Maggi<sup>9</sup>, C. Martinelli<sup>10</sup>, L. Calza<sup>11</sup>, M. Garau<sup>12</sup>, P. Bonfanti<sup>13</sup>, A. Di Biagio<sup>14</sup>, on Behalf of CISA study group

<sup>1</sup>Department of Health Science (DISSAL), Infectious Disease Clinic, University of Genova, Italy, <sup>2</sup>epi2004, Milano, Italy, <sup>3</sup>Infectious Disease Unit, Policlinico P. Giaccone Hospital, Palermo, Italy, <sup>4</sup>Infectious Disease Unit, ASST della Valle Olona, Busto Arsizio, Italy, <sup>5</sup>Infectious Disease Unit (II Divisione), ASST Fatebenefratelli Sacco, Milano, Italy, <sup>6</sup>Infectious Disease Unit, Milano-Bicocca University, San Gerardo Hospital, Monza, Italy, <sup>7</sup>Infectious Disease Unit, Santa Maria Hospital, Perugia, Italy, <sup>8</sup>Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, <sup>9</sup>Infectious Disease Unit, Policlinico Giovanni XXIII Hospital, Bari, Italy, <sup>10</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, <sup>11</sup>Infectious Disease Unit, S.Orsola Malpighi Hospital, Bologna, Italy, <sup>12</sup>Infectious Disease Unit, SS trinità Hospital, Cagliari, Italy, <sup>13</sup>Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, <sup>14</sup>Infectious Diseases Clinic, Policlinico Hospital San Martino, Genova, Italy

### P 3 Copy-years viremia in HIV-1 patients treated for a long time: risk of virological failure and association with inflammation markers

F. Falasca<sup>1</sup>, L. Mazzuti<sup>1</sup>, E. Cinquina<sup>1</sup>, G. d' Ettore<sup>3</sup>, I. Mezzaroma<sup>2</sup>, M. Falciano<sup>3</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup>

<sup>1</sup>Department of Molecular Medicine, <sup>2</sup>Department of Clinical Medicine, <sup>3</sup>Department of Public Health and Infectious Disease, Sapienza University, Rome, Italy

### P 4 Metabolic and renal impact of switching from boosted PIs to INI-containing regimens in a monocentric cohort of drug-experienced HIV-positive subjects

A. Giacomelli, A. Ranzani, E. Gervasi, L. Oreni, T. Formenti, V. Di Cristo, S. De Rose, M. Franzetti, A.L. Ridolfo, M. Galli, S. Rusconi  
 Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan, Italy

### P 5 Changes in lipids profile and eGFR after switching from darunavir/ritonavir (DRV/r) to darunavir/cobicistat (DRV/c)- based dual therapy: a multicenter analysis

A. Vergori<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Giannetti<sup>1</sup>, S. Di Giambenedetto<sup>2</sup>, R. Bellagamba<sup>1</sup>, G. Sterrantino<sup>3</sup>, E. Schiaroli<sup>4</sup>, D. Francisci<sup>5</sup>, S. Cicalini<sup>1</sup>, A. Latini<sup>6</sup>, I. Mezzaroma<sup>7</sup>, M. Lichtner<sup>8</sup>, F. Di Sora<sup>9</sup>, G. D'Ettore<sup>3</sup>, G. Maffongelli<sup>10</sup>, A. Antinori<sup>1</sup>, M. Zaccarelli<sup>1</sup>

<sup>1</sup>UOC Immunodeficienze Virali, Istituto Nazionale per le Malattie Infettive, IRCCS L. Spallanzani, Roma, <sup>2</sup>Istituto di Clinica Malattie Infettive, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Roma, <sup>3</sup>UO Malattie Infettive, Azienda Ospedaliera Universitaria Careggi, Firenze, <sup>4</sup>Divisione Malattie Infettive, Ospedale di Perugia, <sup>5</sup>Clinica Malattie infettive, Azienda Ospedaliera S. Maria, Terni, <sup>6</sup>Unità di Dermatologia infettiva, IFO-Istituto San Gallicano, Roma, <sup>7</sup>Clinica Malattie Infettive Università La Sapienza, Roma, <sup>8</sup>Università "La Sapienza di Roma", Polo Pontino, <sup>9</sup>Unità Operativa AIDS, Ospedale San Giovanni, Roma, <sup>10</sup>UOC Malattie Infettive, Policlinico Tor Vergata, Roma, Italy

### P 6 Reasons for choosing darunavir/ritonavir 600/100 mg twice daily vs. 800/100 mg once daily in treatment-naïve patients: 10 years data from the ICONA cohort

A. Tavelli<sup>1</sup>, M. Palma<sup>2</sup>, S. Lo Caputo<sup>3</sup>, G. Madeddu<sup>4</sup>, P. Bonfanti<sup>5</sup>, B. Menzaghi<sup>6</sup>, S. Nozza<sup>7</sup>, A. Antinori<sup>8</sup>, R. Termini<sup>2</sup>, A. d'Arminio Monforte<sup>9</sup>

<sup>1</sup>Icona Foundation, Milan, Italy, <sup>2</sup>Janssen-Cilag SpA, Cologno Monzese, Italy, <sup>3</sup>Policlinico di Bari, Bari, Italy, <sup>4</sup>University of Sassari, Sassari, Italy, <sup>5</sup>ASST di Lecco, A. Manzoni Hospital, Lecco, Italy, <sup>6</sup>ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, <sup>7</sup>San Raffaele Scientific Institute, Milan, Italy, <sup>8</sup>INMI "L.Spallanzani" IRCCS, Rome, Italy, <sup>9</sup>ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

### P 7 Dolutegravir plus rilpivirine versus dolutegravir plus lamivudine: a comparison between two dolutegravir-based 2-drug regimens from a multicenter cohort of treatment-experienced HIV-1 infected patients

A. Ciccullo<sup>1</sup>, G. Baldin<sup>1</sup>, A. Capetti<sup>2</sup>, S. Rusconi<sup>3</sup>, G. Sterrantino<sup>4</sup>, L. Celani<sup>5</sup>, S. Modica<sup>6</sup>, A. Latini<sup>7</sup>, A. Dusina<sup>1</sup>, M.V. Cossu<sup>2</sup>, S. Restelli<sup>2</sup>, A. De Luca<sup>6</sup>, S. Di Giambenedetto<sup>1</sup>

<sup>1</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, <sup>2</sup>Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, <sup>3</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, <sup>4</sup>Division of Tropical and Infectious Diseases, "Careggi" Hospital, Florence, Italy, <sup>5</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, <sup>6</sup>Infectious Diseases Unit, Siena University Hospital, Siena, Italy, <sup>7</sup>Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy

### P 8 Efficacy and safety of 2-drug combination antiretroviral therapy in clinical practice: results from a single center study

B. Rossetti<sup>1</sup>, G. Marri<sup>1</sup>, A. Gonnelli<sup>1</sup>, L. Toscano<sup>1</sup>, D. Marri<sup>1</sup>, P. Galluzzi<sup>1</sup>, F. Pippi<sup>1</sup>, N. Carnicelli<sup>1</sup>, C. Malcontenti<sup>1</sup>, C. Puttini<sup>1</sup>, R. Gagliardini<sup>2</sup>, F. Montagnani<sup>1,2</sup>, G. Zanelli<sup>1,2</sup>, M. Zazzi<sup>2</sup>, A. De Luca<sup>1,2</sup>

<sup>1</sup>Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, <sup>2</sup>Department of Medical Biotechnologies, University of Siena, Italy

### P 9 Lack of excess concentration-related side effects in patients on dolutegravir plus atazanavir dual therapy compared to other dual regimens

A.F. Capetti<sup>1</sup>, C. Atzori<sup>1</sup>, M.V. Cossu<sup>1</sup>, I. Gallazzi<sup>1</sup>, M. Piscaglia<sup>1</sup>, P. Meraviglia<sup>1</sup>, D. Cattaneo<sup>2</sup>, G. Rizzardini<sup>1</sup>

<sup>1</sup>1st Division of Infectious Diseases, <sup>2</sup>Clinical Pharmacology Unit, ASST Fatebenefratelli Sacco, Milano, Italy



- P 10 Characteristics and outcomes of naïve HIV-patients treated with Single Tablet Regimens. A single center experience**  
*M. De Masi, V. Malagnino, G. Maffongelli, L. Campogiani, T. Mulas, L. Coppola, M. Compagno, A. Gentile, P. Vitale, N. Cesta, L. Sarmati, M. Andreoni*  
 Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy
- P 11 Retrospective analysis on determinant factors of efficacy and safety of switch therapies to darunavir boosted with cobicistat (DRV/c) in different regimens**  
*A. Vergori<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Giannetti<sup>1</sup>, A. Antinori<sup>1</sup>, M. Palma<sup>2</sup>, R. Termini<sup>2</sup>, M. Zaccarelli<sup>1</sup>*  
<sup>1</sup>IRCCS L. Spallanzani, Roma, <sup>2</sup>Janssen-Cilag SpA, Cologno Monzese, Italy
- P 12 Evaluation of factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen**  
*D. Armenia<sup>1</sup>, C. Gori<sup>2</sup>, A. Bertoli<sup>3</sup>, V. Borghi<sup>3</sup>, M. Zaccarelli<sup>2</sup>, A. Di Biagio<sup>4</sup>, B. Bruzzone<sup>4</sup>, L. Fabeni<sup>1</sup>, W. Gennari<sup>3</sup>, D. Pizzi<sup>2</sup>, A. Giannetti<sup>2</sup>, A. Vergori<sup>2</sup>, I. Mastroianni<sup>2</sup>, A. Latini<sup>5</sup>, M. Colafigli<sup>5</sup>, C. Cerva<sup>6</sup>, R. Marocco<sup>7</sup>, M. Andreoni<sup>8</sup>, C. Mussini<sup>3</sup>, A. Antinori<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C.F. Perno<sup>2,8</sup>, M.M. Santoro<sup>1</sup>*  
<sup>1</sup>University of Rome "Tor Vergata", Rome, Italy, <sup>2</sup>National Institute for Infectious Diseases L. Spallanzani, IRCCS, <sup>3</sup>Polyclinic of Modena, Modena, Italy, <sup>4</sup>Hospital Policlinico San Martino, University of Genoa, Genoa, Italy, <sup>5</sup>San Gallicano Dermatological Institute, IRCCS, Rome, Italy, <sup>6</sup>Polyclinic of Rome "Tor Vergata", Rome, Italy, <sup>7</sup>La Sapienza University Polo Pontino, Latina, Italy, <sup>8</sup>University of Milan, Milan, Italy
- P 13 Dolutegravir-based dual therapy durability in clinical practice: results from the SCOLTA cohort**  
*G. Madeddu<sup>1</sup>, E. Ricci<sup>2</sup>, R. Gulminetti<sup>3</sup>, G. Orofino<sup>4</sup>, A. Di Biagio<sup>5</sup>, G. VL De Socio<sup>6</sup>, M.S. Mameli<sup>1</sup>, N. Squillace<sup>7</sup>, B.M. Celesia<sup>8</sup>, B. Menzaghi<sup>9</sup>, C. Martinelli<sup>10</sup>, S. Rusconi<sup>11</sup>, C. Bellacosa<sup>12</sup>, F. Vichi<sup>13</sup>, S. Passerini<sup>14</sup>, L. Valsecchi<sup>15</sup>, L. Calza<sup>16</sup>, C. Dentone<sup>17</sup>, G. Angioni<sup>18</sup>, K. Falasca<sup>19</sup>, G.F. Pellicano<sup>20</sup>, P. Bonfanti<sup>21</sup>, C.I.S.A.I. Group, Italy*  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, <sup>2</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, <sup>3</sup>Institute of Infectious Diseases, University of Pavia, Pavia, Italy, <sup>4</sup>Amedeo di Savoia Hospital Unit of Infectious Diseases Torino, Italy, <sup>5</sup>Unit of Infectious Diseases, IRCCS San Martino Hospital Genoa, University of Genoa, Italy, <sup>6</sup>Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, <sup>7</sup>Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy, <sup>8</sup>Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, <sup>9</sup>Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio, Italy, <sup>10</sup>SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, <sup>11</sup>Clinic of Infectious Diseases, ASST Fatebenefratelli Sacco, University of Milan, Italy, <sup>12</sup>Infectious Disease Clinic, University of Bari, Italy, <sup>13</sup>Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy, <sup>14</sup>Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, <sup>15</sup>Infectious Disease Unit (II Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, <sup>16</sup>University of Bologna, Department of Infectious Diseases, S. Orsola Malpighi Hospital, Bologna, Italy, <sup>17</sup>Unit of Infectious Diseases, Sanremo Hospital, Sanremo, Italy, <sup>18</sup>Unit of Infectious Diseases, Santissima Trinità Hospital, ATS Sardegna, Cagliari, Italy, <sup>19</sup>Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, <sup>20</sup>Unit of Infectious Diseases, G. Martino Hospital -University of Messina, Italy, <sup>21</sup>Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy
- P 14 The use of STR drugs in the management of HIV+ patients: analysis and comparison of the years 2016 and 2017**  
*F. Ferrara, M. Rizzica, A. Ascani, G. Zaccaro, B. Moreno, L. Chiroso, M. Carli, S. Murachelli, A. Antinori*  
 Istituto Nazionale Malattie Infettive "L.Spallanzani" IRCCS Rome, Italy
- P 15 Switch to Dolutegravir-based regimen in the setting of virologic suppression: study of virological and biological parameters**  
*D. Di Carlo<sup>1</sup>, I. Mezzaroma<sup>2</sup>, G. d'Ettore<sup>3</sup>, C. Fimiani<sup>2</sup>, M. Calabretto<sup>1</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup>*  
<sup>1</sup>Department of Molecular Medicine, <sup>2</sup>Department of Clinical Medicine, <sup>3</sup>Department of Public Health and Infectious Diseases, Rome, Italy
- P 16 Effect of simplification regimens on blood HIV-DNA reservoir compared to triple ART in patients with suppressed HIV-RNA**  
*C. Orlandi<sup>1</sup>, B. Canovari<sup>2</sup>, Z. Pasquini<sup>2,3</sup>, F. Barchiesi<sup>2,3</sup>, M. Magnani<sup>1</sup>, A. Casabianca<sup>1</sup>*  
<sup>1</sup>Dipartimento di Scienze Biomolecolari, Sezione di Biotecnologie, Università di Urbino "Carlo Bo", Italy, <sup>2</sup>Malattie Infettive, Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro, Italy, <sup>3</sup>Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Clinica Malattie Infettive Ospedali Riuniti di Ancona, Italy
- P 17 Can the new ART regimens influence adherence to guidelines in the clinical practice? Data from 2016-17 at S. Maria Annunziata Hospital, Florence, Tuscany**  
*F.M. Fusco<sup>1</sup>, F. Vichi<sup>1</sup>, L. Rabatti<sup>2</sup>, M.C. Burla<sup>3</sup>, M. Prato<sup>1</sup>, P. Blanc<sup>1</sup>*  
<sup>1</sup>SOC Malattie Infettive 1, Osp. S. Maria Annunziata, Bagno a Ripoli, FI, USL Toscana Centro, Italy, <sup>2</sup>Farmacia Ospedaliera, Osp. S. Maria Annunziata, Bagno a Ripoli, FI, USL Toscana Centro, Italy, <sup>3</sup>Farmacia Ospedaliera, Osp. S.S. Cosma e Damiano, Pesca, PT, USL Toscana Centro, Italy
- P 18 Abacavir/Lamivudine/Dolutegravir (Triumeq) associated to liver toxicity in antiretroviral treatment-naïve patient with HIV infection**  
*S. Martini, G. Di Caprio, L. Onorato, A. Cascone, N. Coppola*  
 University of Campania, L. Vanvitelli, Italy
- P 19 Protease Inhibitor-based dual regimens in real life**  
*O. Bargiacchi<sup>1</sup>, C. Bolla<sup>2</sup>, G. Orofino<sup>3</sup>, A. Parisini<sup>2</sup>, M. Farenga<sup>3</sup>, A. Rossati<sup>1</sup>*  
<sup>1</sup>Infectious Diseases Unit, AOU Maggiore della Carità, Novara, <sup>2</sup>Infectious Diseases Unit, AON SS Antonio e Biagio e Cesare Arrigo, Alessandria, <sup>3</sup>Infectious Diseases Unit, ASL Città di Torino, Italy



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



**P 20 Safety, efficacy and costs analysis of treatment simplification options in HIV-1 patients: real-world data analysis at Infectious Diseases Unit of University Hospital of Salerno**

*S. Madonia<sup>1</sup>, N. Boffa<sup>1</sup>, F.S. Mennini<sup>2</sup>, P. Sciattella<sup>2</sup>*

<sup>1</sup>Infectious Disease Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy, <sup>2</sup>Economic Evaluation and HTA (CEIS- EEHTA) - IGF Department, Faculty of Economics, Università di Roma "Tor Vergata", Italy

**BACTERIAL AND FUNGAL INFECTIONS IN IMMUNOCOMPROMISED HOST**

**P 21 Are Antifungal Stewardship Programs in Immunocompromised patients needed? An Italian teaching hospital experience**

*S. Lardo, D. Faliero, A. De Luca, L. Pavan*

<sup>1</sup>Infectious Diseases Department, Catholic University, Rome, <sup>2</sup>Pharmacy Department, Fondazione Policlinico Gemelli, Rome, Italy

**P 22 Antimicrobial Stewardship in Immunocompromised Hosts: a snapshot**

*D. Faliero, S. Lardo, A. De Luca, L. Pavan*

<sup>1</sup>Infectious Diseases Department, Catholic University, Rome, <sup>2</sup>Pharmacy Department, Fondazione Policlinico Gemelli, Rome, Italy

**P 23 Disseminated disease caused by Mycobacterium simiae in a patient with AIDS**

*S.B. Morella, S.R. Bruno, S. Sica, S.M. Ferrara, T.A. Santantonio*

UOC di Malattie Infettive Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Italy

**CLINICAL HIV**

**P 24 HIV infection, but not HAART, is independently associated with increased aortic stiffness and early vascular aging**

*M. Trizzino<sup>1</sup>, G.J. Mulè<sup>1</sup>, G. Mulè<sup>2</sup>, G. Geraci<sup>2</sup>, P. Colletti<sup>1</sup>, G. Mazzola<sup>1</sup>, C. Iaria<sup>3</sup>, C. Imburgia<sup>3</sup>, C. Colomba<sup>1</sup>, S. Cottone<sup>2</sup>, A. Cascio<sup>1</sup>*

<sup>1</sup>Unit of Infectious Disease: Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo Italy, <sup>2</sup>Unit of Nephrology and Hypertension; ESH excellence centre; DIBIMIS; University of Palermo Italy, <sup>3</sup>Infectious Diseases Unit-ARNAS Civico, Di Cristina, Benfratelli, Palermo, Italy



**P 25 Impact of integrase strand transfer inhibitor (INSTI) on body composition in a real-life setting**

*A. Bonazza<sup>1</sup>, S. Zona<sup>1</sup>, M. Menozzi<sup>1</sup>, A. Raimondi<sup>1</sup>, C. Monari<sup>2</sup>, M. Digaetano<sup>1</sup>, A. Santoro<sup>1</sup>, V. Borghi<sup>1</sup>, C. Mussini<sup>1</sup>, G. Guaraldi<sup>1</sup>*

<sup>1</sup>Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy, Infectious Disease Clinic, <sup>2</sup>Department of mental health and public medicine, University of Campania L. Vanvitelli, Infectious Disease Unit, Italy

**P 26 Changing face of HIV infection and ageing in two cohorts of older patients cross-sectionally observed in 2007 and in 2016**

*F. Alessi, A. Marino, M.E. Locatelli, A. Pampaloni, D. Scuderi, M. Maresca, L. Vinci, R. Fontana del Vecchio, R. Bruno, M. Gussio, F. Palermo, B. Cacopardo, B.M. Celesia*

Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi Catania, Italy

**P 27 Development of a Frailty Index, an HIV Index and a Protective Index from a clinical HIV database**

*G. Guaraldi<sup>1</sup>, I. Franconi<sup>1</sup>, O. Theou<sup>2</sup>, L. Wallace<sup>2</sup>, A. Malagoli<sup>1</sup>, R.J.A.H. Eendebak<sup>2</sup>, C. Mussini<sup>1</sup>, K. Rockwood<sup>2</sup>*

<sup>1</sup>Infectious Diseases Unit, University of Modena and Reggio Emilia, Modena, Italy, <sup>2</sup>Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

**P 28 Differences between infections sustained by different viral HIV subtypes in the management of antiretroviral therapy in a Roman hospital: a single experienced center**

*G. Maffongelli, M. De Masi, V. Malagnino, T. Mulas, L. Coppola, M. Compagno, L. Campogiani, A. Gentile, C. Cerva, L. Sarmati, M. Andreoni*

Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy

**P 29 HIV-RNA rebound during DAA treatment: influence of treatment complexity in HIV/HCV co-infected patients**

*A. Palazzo<sup>1</sup>, L. Marinaro<sup>1</sup>, A. Barco<sup>1</sup>, S. Scabini<sup>1</sup>, N. Forni<sup>1</sup>, C. Montrucchio<sup>1</sup>, C. Alcantarini<sup>1</sup>, V. Pirriatore<sup>1</sup>, M.C. Tettoni<sup>1</sup>, L. Trentini<sup>1</sup>, J. Cusato<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. Calcagno<sup>1</sup>, A. D'Avolio<sup>1,2</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup>*

<sup>1</sup>Department of Medical Sciences; University of Turin - ASL "Città di Torino", <sup>2</sup>Interdepartmental Center for Clinical and Experimental Pharmacology (CIFACS), University of Turin, Italy

**P 30 Immuno-virological response during antiretroviral therapy in HIV-1 infected patients according to subtype B and non-B**

*G. Ciusa, A. Bonazza, G. Cuomo, M. Menozzi, F. Carli, G. Guaraldi, V. Borghi, C. Mussini*

Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy, Infectious Disease Clinic, Italy

- P 31 Strongyloides stercoralis hyperinfection syndrome in a colombian HIV late presenter**  
 A. Ricciardi<sup>1</sup>, G. Picchi<sup>1</sup>, A. Cellini<sup>1</sup>, N. Iapadre<sup>1</sup>, M. Mariani<sup>1</sup>, A. Ciccone<sup>2</sup>, F. Marinangeli<sup>2</sup>, G. Bruno<sup>3</sup>, A. Santini<sup>3</sup>, A. Grimaldi<sup>1</sup>  
<sup>1</sup>San Salvatore Hospital, Infection Diseases Unit, <sup>2</sup>San Salvatore Hospital, Intensive Care Unit, <sup>3</sup>San Salvatore Hospital, Laboratory Medicine, Italy
- P 32 A nutraceutical combination targeting dyslipidemia and subclinical inflammation in HIV-infected patients on stable antiretroviral therapy**  
 E. Schiaroli<sup>1</sup>, S. Cardaci<sup>1</sup>, V. Bianconi<sup>2</sup>, C. Papalini<sup>1</sup>, M. Pirro<sup>2</sup>, F. Baldelli<sup>1</sup>, D. Francisci<sup>1</sup>  
<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, University of Perugia, Perugia, Italy, <sup>2</sup>Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, Italy
- P 33 Pneumocystosis as a complication of H1N1 Influenza A infection in an HIV positive patient under effective cART**  
 I. Franconi<sup>1</sup>, C. Monari<sup>2</sup>, M. Tutone<sup>1</sup>, G. Ciusa<sup>1</sup>, L. Corradi<sup>1</sup>, E. Franceschini<sup>1</sup>, M. Meschiarì<sup>1</sup>, C. Puzzolante<sup>1</sup>, G. Cuomo<sup>1</sup>, N. Riva<sup>1</sup>, A. Bianchi<sup>1</sup>, A. Raimondi<sup>1</sup>, W. Gennari<sup>3</sup>, M. Pecorari<sup>3</sup>, G. Guaraldi<sup>1</sup>, C. Mussini<sup>1</sup>  
<sup>1</sup>University of Modena and Reggio Emilia, Infectious Diseases Unit, <sup>2</sup>University of Naples Federico II, Infectious Diseases Unit, <sup>3</sup>University of Modena and Reggio Emilia, Microbiology and Virology Unit, Italy
- P 34 Cardiovascular risk in HIV-positive population: evaluation of the risk and serological markers**  
 A. Auricchio, C. Ucciferri, F. Vignale, K. Falasca, J. Vecchiet  
 Clinic of Infectious Diseases – Department of Medicine and Science of Aging, University “G. d’Annunzio”, Chieti, Italy
- P 35 Abnormal elevation of INR values in a patient during co-administration of E/C/F/TAF and warfarin: a case report**  
 V. Malagnino, G. Maffongelli, C. Stingone, G. Malerba, E. Teti, M. Capozzi, L. Sarmati, M. Andreoni  
 Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy
- P 36 Neurotoxoplasmosis in a sicilian HIV reference centre**  
 A. Cervo, A. De Luca, B. Romanin, F. Scarlata  
 UOC di Malattie infettive e Centro Regionale di Riferimento AIDS - Policlinico Palermo, Italy
- P 37 Immune reconstitution inflammatory syndrome and Cytomegalovirus encephalitis: a case report**  
 F. Trave, D.C. Cibelli, F. Sozio, A. Consorte, G. Parruti  
 Ospedale Spirito Santo Pescara, Italy

## HIV-ASSOCIATED AND NON HIV-ASSOCIATED CANCERS

- P 38 Lenalidomide as maintenance therapy for refractory HIV-associated plasmablastic lymphoma: feasible and effective?**  
 I. De Benedetto<sup>1</sup>, L. Verga<sup>2</sup>, F.A. Brioschi<sup>2</sup>, D. Dalu<sup>3</sup>, C. Gambacorti Passerini<sup>2</sup>, A. Gori<sup>1</sup>, A. Bandera<sup>1</sup> for the Musthal Study Group  
 \*Musthal Study Group: A. Bandera, L. Verga, I. De Benedetto, F. A. Brioschi, A. Gori, C. Gambacorti-Passerini, E. Doni, S. Bolis, G. Bozzi, E. Colella, M. Rossi, F. Pagni, B.E. Leone (San Gerardo Hospital, University of Milan Bicocca), Monza, F. Crippa, E. Suardi (San Paolo Hospital, University of Milan), D. Dalu, C. Fasola (Luigi Sacco Hospital Milan), M. Mena (Ospedale Civile of Legnano), O. Giglio, R. Epifani, D. Santoro (San’Anna Hospital Como), P. Vitiello, C. Zeroli, T. Quirino (Ospedale di Circolo of Busto Arsizio)  
<sup>1</sup>Infectious Diseases Unit, S. Gerardo Hospital, Monza, Italy and University of Milano-Bicocca, Milano, <sup>2</sup>Haematology Unit, S. Gerardo Hospital, Monza, Italy and University of Milano-Bicocca, <sup>3</sup>Department of Oncology, Luigi Sacco Hospital, Milan, Italy
- P 39 HCV-related hepatocellular carcinoma in people with or without HIV coinfection: a survival analysis of a single center cohort**  
 A. Soria<sup>1</sup>, V. Castelli<sup>1</sup>, E. Colella<sup>1</sup>, N. Squillace<sup>1</sup>, M. Rossi<sup>1</sup>, A. Ciaccio<sup>2</sup>, A. Gori<sup>1</sup>, G.M. Migliorino<sup>1</sup>, G. Lapadula<sup>1</sup>  
<sup>1</sup>Infectious Diseases Unit, San Gerardo Hospital, ASST Monza, <sup>2</sup>Gastroenterology and Liver Unit, San Gerardo Hospital, ASST Monza, Italy
- P 40 Sepsis from MDR gram-negative bacteria a lethal complication in a group of HIV positive patients during chemotherapy for hematological malignancies**  
 C. Cerva<sup>1</sup>, L. Campogiani<sup>1</sup>, G. Maffongelli<sup>1</sup>, G. De Simone<sup>1</sup>, I. Provenzano<sup>2</sup>, D. Nasso<sup>2</sup>, M. Cantonetti<sup>2</sup>, W. Arcese<sup>2</sup>, M. Andreoni<sup>1</sup>, L. Sarmati<sup>1</sup>  
<sup>1</sup>Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, <sup>2</sup>Department of Hematology, Tor Vergata University, Rome, Italy
- P 41 Oral plasmablastic lymphoma in HIV: a case report**  
 F. Trave, D.C. Cibelli, F. Sozio, A. Consorte, G. Parruti  
 Ospedale Spirito Santo Pescara, Italy
- P 42 Acute onset of fatal hematologic malignancy in HIV-1 infected patient: Report of a clinical case**  
 G. Caruana<sup>1</sup>, S. Grignolo<sup>2</sup>, R. Prinapori<sup>2</sup>, V. Cassano<sup>2</sup>, A. Realì<sup>2</sup>, M. Guerra<sup>2</sup>, S. Artioli<sup>2</sup>  
<sup>1</sup>Università degli Studi di Sassari, Dipartimento di Medicina Clinica e Sperimentale, U.O.C. di Malattie Infettive, Sassari, <sup>2</sup>Presidio Ospedaliero del Levante Ligure, S.C. di Malattie Infettive ed Epatologia, Ospedale Sant’Andrea, La Spezia, Italy



## HIV-ASSOCIATED TUBERCULOSIS

### P 43 Quantiferon-TB in HIV-positive patients: prognostic values and factors associated with indeterminate results

V. Pirriatore<sup>1</sup>, F. Grosso<sup>1</sup>, V. Ghisetti<sup>2</sup>, S. Raviolo<sup>1</sup>, S. Faraoni<sup>2</sup>, I. Motta<sup>1</sup>, M. Milesi<sup>1</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>2</sup>Laboratory of Microbiology, Ospedale Amedeo di Savoia, ASL Città della Salute, Torino, Italy

### P 44 Rapid development of unmasking disseminated tuberculosis-related immune reconstitution inflammatory (TB-IRIS) syndrome in a HIV-infected patient after starting combination antiretroviral therapy

N. Ronzoni<sup>1</sup>, G. Borghero<sup>2</sup>, F. Porcu<sup>2</sup>, A. Sannia<sup>2</sup>, M. Ligas<sup>1</sup>, V. Fiore<sup>1</sup>, G. Madeddu<sup>1</sup>, S. Babudieri<sup>1</sup>

<sup>1</sup>Department of Medical Surgical and Experimental Sciences, Unit of Infectious Diseases, University of Sassari, Sassari, Italy, <sup>2</sup>Unit of Infectious Diseases, Ospedale Santissima Trinità, Cagliari, Italy

### P 45 The diagnostic challenge of central nervous system (CNS) lesions in the HIV-infected patient

M. Caixeiro<sup>1</sup>, F. Peruzzo<sup>2</sup>, R. Jesus<sup>1</sup>, B. Flor de Lima<sup>1</sup>, D. Trigo<sup>1</sup>, M.J. Lopes<sup>1</sup>, J. Batista<sup>1</sup>, P. Pacheco<sup>1</sup>

<sup>1</sup>Hospital Prof. Doutor Fernando Fonseca, Infectious Diseases Department, Amadora, Portugal, <sup>2</sup>Università degli Studi di Sassari, U.O.C. Malattie Infettive, Sassari, Italy



## COINFECTIONS/SEXUALLY TRANSMITTED INFECTIONS

### P 46 Predictive score of Neurosyphilis (NS) in HIV infected persons: when to perform a lumbar puncture?

L. Celani<sup>1</sup>, C. Borrazzo<sup>1</sup>, A. Lazzaro<sup>1,2</sup>, S. Giuliano<sup>3</sup>, S. Savinelli<sup>1</sup>, E.N. Cavallari<sup>1</sup>, G. Corano-Scheri<sup>1</sup>, C. Pinacchio<sup>1</sup>, A. Vullo<sup>4</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>

<sup>1</sup>Department of Public Health and Infectious diseases University of Rome Sapienza, Italy, <sup>2</sup>Department of Medical Sciences, University of Torino, Italy, <sup>3</sup>Infectious Disease Unit, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy, <sup>4</sup>Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy

### P 47 Chemsex and risk of Sexually Transmitted Infections (STI): a pilot survey

M. Colafigli<sup>1</sup>, F. Roscini<sup>1</sup>, C. Ancona<sup>1</sup>, S. Foracappa<sup>1</sup>, A.E. Levi<sup>1</sup>, M. Frasca<sup>1</sup>, D. Orsini<sup>1</sup>, L. Alei<sup>1</sup>, M.G. Donà<sup>1</sup>, M. Giuliani<sup>1</sup>, A. Cristaudo<sup>1</sup>, A. Latini<sup>1</sup>

UOSD Dermatologia MST, ambientale, Tropicale e Immigrazione, IRCCS IFO-San Gallicano, Roma, Italy

### P 48 Scaling up Hepatitis A vaccination through a community-based intervention among MSM population during 2016-2017 epidemic outbreak

S. Coladonato<sup>1</sup>, L. Badia<sup>1</sup>, V. Guardigni<sup>1</sup>, A. Gianninoni<sup>2</sup>, M.C. Risi<sup>2</sup>, P. Viale<sup>1</sup>, G. Verucchi<sup>1</sup>, S. Mattioli<sup>3</sup>

<sup>1</sup>UO Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum - Università degli Studi di Bologna, <sup>2</sup>UO Profilassi Malattie Infettive - AUSL di Bologna, <sup>3</sup>PLUS ONLUS - Bologna, Italy

### P 49 The impact of multiple HPV-types on the clinical outcome of HPV infection

L. Ronga<sup>2</sup>, G. Addati<sup>1</sup>, R. Magrone<sup>1</sup>, A. Abbasciano<sup>1</sup>, D. Di Carlo<sup>3,4</sup>, G. Miragliotta<sup>1,2</sup>, R. Del Prete<sup>1,2</sup>

<sup>1</sup>Section of Microbiology, Interdisciplinary Department of Medicine (DIM), School of Medicine, University of Bari "Aldo Moro", Bari, <sup>2</sup>UOC Microbiology and Virology, Azienda Ospedaliero-Universitaria Policlinico of Bari, Bari, <sup>3</sup>Pediatric Clinical Research Center "Romeo and Erico Invernizzi", University of Milan, Milan, <sup>4</sup>Department of Biology and Biotechnology, University of Pavia, Pavia, Italy

### P 50 Cerebrospinal fluid/plasma biomarkers in patients with suspected neurosyphilis

M. Scarvaglieri<sup>1</sup>, L. Di Girolamo<sup>2</sup>, S. Audagnotto<sup>2</sup>, A. Lucchini<sup>2</sup>, C. Costa<sup>2</sup>, L. Mighetto<sup>3</sup>, G. Di Perri<sup>2</sup>, I. Dal Conte<sup>1</sup>, A. Calcagno<sup>2</sup>

<sup>1</sup>STI Clinic, Amedeo di Savoia Hospital, ASL Città di Torino, <sup>2</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, <sup>3</sup>Laboratory of Biochemistry and Immunology, Maria Vittoria Hospital, ASL Città di Torino, Italy

### P 51 An unusual case of hepatic syphilis mimicking a hepatocellular carcinoma

L. Bianchi<sup>1</sup>, V. Bellelli<sup>1</sup>, G. Russo<sup>1</sup>, G. d'Ettore<sup>1</sup>, C. D'Agostino<sup>1</sup>, A. Ciardi<sup>1</sup>, M.R. Ciardi<sup>1</sup>, V. Vullo<sup>1</sup>

Sapienza University of Rome, Italy

### P 52 Improvement in quantitative detection of Human Herpesvirus 6 with a ready-to-use PCR-based Real Time PCR assay

D. Rigamonti<sup>1</sup>, M. Gramegna<sup>1</sup>, M. Ballarini<sup>1</sup>, M.L. Incandela<sup>1</sup>, L.J. Turner<sup>1</sup>, G. Ferri<sup>1</sup>, L. Bavagnoli<sup>1</sup>, L. Spinelli<sup>1</sup>

Sentinel CH. SpA, Milano, Italy

## COMORBIDITIES HIV AND HCV

### P 53 Prevalence of thyroid diseases in a cohort of HIV-infected people of Northern Italy

E. Quiros-Roldan<sup>1</sup>, A. Ferraresi<sup>1</sup>, T. Della Giustina<sup>1</sup>, I. Izzo<sup>1</sup>, M. Properzi<sup>1</sup>, A. Bonito<sup>1</sup>, A. Celotti<sup>1</sup>, M.C. Pezzoli<sup>1</sup>, R. Allegri<sup>1</sup>, F. Castelnuovo<sup>1</sup>, E. Focà<sup>1</sup>, F. Castelli<sup>1</sup>

University Department of Infectious and Tropical Diseases, ASST Spedali Civili and University of Brescia, Brescia, Italy



- P 54 Longitudinal evaluation of neurocognitive performances in antiretroviral-treated HIV/HCV co-infected patients receiving Directly-Acting Antivirals**  
*I. Mastrorosa, P. Lorenzini, C. Pinnetti, A.C. Brita, G. Fabbri, A. Vergori, M. Zaccarelli, A. Ammassari, A. Antinori*  
 Clinical Department, National Institute for Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy
- P 55 Which factors delay the HCV treatment in patients with HIV/HCV co-infection? The HCV Cascade of Care among HIV+ patients at S. Maria Annunziata Hospital, Florence**  
*F.M. Fusco<sup>1</sup>, E. Salomoni<sup>1</sup>, A. Paggi<sup>1</sup>, F. Vichi<sup>1</sup>, A. Degli Esposti<sup>1</sup>, P. Pierotti<sup>1</sup>, F. Baragli<sup>1</sup>, F. Esperti<sup>2</sup>, M. Di Pietro<sup>3</sup>, P. Blanc<sup>1</sup>*  
<sup>1</sup>SOC Malattie Infettive 1, Osp. S. Maria Annunziata, Bagno a Ripoli, FI, USL Toscana Centro, <sup>2</sup>SOS Malattie Infettive, Osp. S. Giuseppe, Empoli, USL Toscana Centro, <sup>3</sup>SOC Malattie Infettive 2, Osp. S. Jacopo, Pistoia, USL Toscana Centro, Italy
- P 56 Markers of cumulative exposure to HIV viremia predict hepatocellular carcinoma occurrence in HIV patients treated with DAAs for Hepatitis C**  
*V. Guardigni<sup>1,2</sup>, A. Casabianca<sup>1</sup>, S. Coladonato<sup>1</sup>, L. Badia<sup>1,2</sup>, P. Viale<sup>1</sup>, G. Verucchi<sup>1,2</sup>*  
<sup>1</sup>Department of Medical and Surgical Sciences, University of Bologna, Italy, <sup>2</sup>Research Centre for the Study of Hepatitis, University of Bologna, Bologna, Italy
- P 57 Clinical experience with dolutegravir in HIV-HCV co-infected patients treated with Direct-acting Antivirals**  
*S.T. Kiros<sup>1</sup>, F. Lagi<sup>1</sup>, I. Campolmi<sup>1</sup>, S. Giachè<sup>1</sup>, D. Bartolozzi<sup>2</sup>, A. Bartoloni<sup>1,2</sup>, G. Sterrantino<sup>2</sup>*  
<sup>1</sup>Infectious Disease Unit, Department of Experimental and Clinical Medicine, University of Florence Italy, <sup>2</sup>Tropical and Infectious Disease, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
- P 58 Evaluation of transient detectable HIV-RNA (blips) in HIV/HCV coinfecting patients during therapy with direct acting antivirals: the experience of Infectious Disease Unit of Verona**  
*D. Piacentini, S. Chiesi, S. Rizzardo, G. Carolo, E. Lattuada, E. Concia, E. Tacconelli, M. Lanzafame*  
 Unità Operativa Complessa di Malattie Infettive - Dipartimento di diagnostica e sanità pubblica - AOUI Verona, Italy
- P 59 Impact of HCV eradication on lipidic, glycemic and renal parameters in HIV+ co-infected patients**  
*E. Milano<sup>1</sup>, C. Fabrizio<sup>1</sup>, L. Scudeller<sup>2</sup>, N. de Gennaro<sup>1</sup>, N. Ladisa<sup>1</sup>, L. Monno<sup>1</sup>, A. Saracino<sup>1</sup>, G. Angarano<sup>1</sup>*  
<sup>1</sup>Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy, <sup>2</sup>Scientific Direction, Clinical Epidemiology Unit, IRCCS San Matteo Foundation, Pavia, Italy
- P 60 Significant improvement in liver steatosis after switching from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with nonalcoholic fatty liver disease (NAFLD)**  
*L. Calza, M. Borderi, V. Colangeli, S. Coladonato, B. Tazza, G. Fornaro, L. Badia, V. Guardigni, G. Verucchi, P. Viale*  
 Clinic of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- P 61 HBV/HCV/HDV coinfection HIV positive patient: analysis of reciprocal viral dynamics in plasma, PBMC and liver tissue**  
*G. Di Caprio, S. Martini, C. Monari, A. Cascone, N. Coppola*  
 Università degli studi della Campania, L. Vanvitelli, Italy
- P 62 Alexithymia in a group of HIV/HCV infected patients. Preliminary data**  
*M. Vitale, A. Cappabianca, S. Madonia, N. Boffa*  
 A.O.U. San Giovanni di Dio e Ruggi d'Aragona, U.O.C. Malattie Infettive, Salerno, Italy

## CLINICAL HEPATITIS

- P 63 Does baseline liver stiffness value influence fibrosis outcome after direct-acting antiviral treatment in HIV-HCV coinfecting patients?**  
*G. Fornaro<sup>1</sup>, V. Guardigni<sup>1</sup>, F. Ravaiole<sup>2</sup>, L. Badia<sup>1</sup>, P.L. Viale<sup>1</sup>, D. Festi<sup>2</sup>, G. Verucchi<sup>1</sup>*  
<sup>1</sup>University of Bologna, S. Orsola - Malpighi Hospital, Department of Medical and Surgical Sciences, Infectious Diseases Unit, Bologna, Italy, <sup>2</sup>University of Bologna, S. Orsola - Malpighi Hospital, Department of Medical and Surgical Sciences, Gastroenterology Unit, Bologna, Italy
- P 64 Vitamin D deficiency and health-related quality of life in chronic Hepatitis C**  
*D. Palazzo<sup>1</sup>, E. Biliotti<sup>1</sup>, R. Esvan<sup>1</sup>, F. Severini<sup>1</sup>, L. Volpicelli<sup>1</sup>, P. Perinelli<sup>1</sup>, P. Maida<sup>1</sup>, M. Spaziante<sup>1</sup>, L. Fontanelli Sulekova<sup>1</sup>, C. Franchi<sup>1</sup>, M. De Angelis<sup>1</sup>, G. Iaiani<sup>1</sup>, P. Rucci<sup>2</sup>, G. Taliani<sup>1</sup>*  
<sup>1</sup>Department of Clinical Medicine, Sapienza University of Rome, Italy, <sup>2</sup>Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna, Italy
- P 65 HCV and hepatic steatosis measured by Transient Elastography (CAP): the impact of HCV eradication in a population of patients treated with DAAs**  
*E. Salomoni<sup>1</sup>, A. Degli Esposti<sup>1</sup>, A. Gabbuti<sup>1</sup>, P. Pierotti<sup>1</sup>, F. Vichi<sup>1</sup>, F. Baragli<sup>1</sup>, C. Blè<sup>1,2</sup>, F. Esperti<sup>1,2</sup>, L. Mecocci<sup>1</sup>, P. Blanc<sup>1</sup>*  
<sup>1</sup>Azienda USL Toscana Centro, SOC Malattie Infettive 1, Ospedale Santa Maria Annunziata, Bagno a Ripoli (FI), <sup>2</sup>Azienda USL Toscana Centro, SOS Malattie Infettive, Ospedale S. Giuseppe, Empoli (FI), Italy
- P 66 Immune Thrombocytopenic Purpura associated with Hepatitis A infection in a 39-year old man**  
*G. Parrella, V. Iodice, N. Capoluongo, G. Di Flumeri, R. Viglietti, V. Sangiovanni, A. Chirianni*  
 U.O.C. Infezioni Sistemiche e dell'Immunodepresso, Azienda Ospedaliera dei Colli Monaldi - Cotugno - C.T.O., Ospedale "D. Cotugno" Napoli, Italy





- P 67 Hepatitis B virus reactivation sustained by an HBsAg immune-escape mutant isolate in an anti-HBc positive patient in course of Sofosbuvir/Velpatasvir treatment of HCV infection: a case report**  
*L. Foroghi<sup>1</sup>, V. Malagnino<sup>1</sup>, E. Teti<sup>1</sup>, M. Araghi<sup>2</sup>, C. Cerva<sup>1</sup>, M. De Masi<sup>1</sup>, A. Gentile<sup>1</sup>, R. Salpini<sup>2</sup>, V.C. Di Maio<sup>2</sup>, C. Sarrecchia<sup>1</sup>, M. Andreoni<sup>1</sup>, V. Svicher<sup>2</sup>, F. Ceccherini-Silberstein<sup>2</sup>, L. Sarmati<sup>1</sup>*  
<sup>1</sup>Infectious Diseases Clinic, University of Rome Tor Vergata, Rome, <sup>2</sup>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome

## DAAS THERAPY IN HCV

- P 68 Viral dynamics in HCV infected patients with different genotypes during old and new direct-acting antiviral agents combination**  
*S. Paolucci<sup>1</sup>, F. Novazzi, R. Gulminetti<sup>2</sup>, S. Novati<sup>2</sup>, R. Maserati<sup>2</sup>, G. Barbarini<sup>3</sup>, P. Sacchi<sup>3</sup>, A. Piralla<sup>1</sup>, F. Baldanti<sup>1,4</sup>*  
<sup>1</sup>Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>2</sup>Institute of Infectious Diseases, University of Pavia, Pavia, Italy, <sup>3</sup>Division of Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, <sup>4</sup>Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
- P 69 NS5A inhibitor natural resistance associated substitutions (RASs) in a cohort of genotype (GT) 1a and 1b Hepatitis C (HCV) chronically infected patients**  
*P. Canepa<sup>1,2</sup>, L. Nicolini<sup>3</sup>, S. Marengo<sup>4</sup>, B. D'Ambrosio<sup>1,2</sup>, C. Arcuri<sup>1,2</sup>, G. Guarona<sup>1,2</sup>, G. Pieri<sup>4</sup>, A. Picciotto<sup>4</sup>, G. Icardi<sup>1,2</sup>, B. Bruzzone<sup>2</sup>*  
<sup>1</sup>Department of Health Sciences (DiSSal), University of Genoa, Italy, <sup>2</sup>Hygiene Unit, Polyclinic Hospital San Martino, Genoa, Italy, <sup>3</sup>Infectious Diseases, Polyclinic Hospital San Martino, Genoa, Italy, <sup>4</sup>Hepatology and Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Polyclinic Hospital San Martino, Genoa, Italy
- P 70 Response to DAA among HIV-HCV co-infected people who inject drugs (PWID) in clinical practice**  
*A. Tavelli<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, C. Mussini<sup>3</sup>, A. Castagna<sup>4</sup>, A. Saracino<sup>5</sup>, A. Cingolani<sup>6</sup>, B. Menzaghi<sup>7</sup>, G. Lapadula<sup>8</sup>, S. Savinelli<sup>9</sup>, A. Antinori<sup>10</sup>, A. d'Arminio Monforte<sup>1</sup>, M. Puoti<sup>12</sup> for Icona Foundation Study Group*  
<sup>1</sup>Icona Foundation, Milan, Italy, <sup>2</sup>Institute for Global Health, University College London, London, UK, <sup>3</sup>Clinic of Infectious Diseases, AOU Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, <sup>4</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy, <sup>5</sup>Clinic of Infectious Diseases, Polyclinic of Bari, University of Bari, Bari, Italy, <sup>6</sup>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, <sup>7</sup>Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy, <sup>8</sup>Infectious Diseases Unit, ASST di Monza, San Gerardo Hospital, Monza, Italy, <sup>9</sup>Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, <sup>10</sup>HIV/AIDS Department, INMI "L. Spallanzani" IRCCS, Rome, Italy, <sup>11</sup>ASST Santi Paolo e Carlo, University of Milan, Clinic of Infectious and Tropical Diseases, Milan, Italy, <sup>12</sup>Unit of Infectious Diseases - ASST GOM Niguarda, Milan Italy
- P 71 Changes in serum lipid profiles in the HIV-HCV co-infected patients treated with direct acting antivirals (DAAs)**  
*M. Schiavini<sup>1</sup>, F. Niero<sup>1</sup>, A.L. Croci<sup>1</sup>, M. Passerini<sup>1</sup>, S. Landonio<sup>1</sup>, C. Magni<sup>1</sup>, V. Scalzi<sup>2</sup>, S. Vimercati<sup>2</sup>, L. Valsecchi<sup>1</sup>, M. Bolis<sup>1</sup>, S. Passerini<sup>1</sup>, N. Astuti<sup>1</sup>, P. Meraviglia<sup>1</sup>, G. Gubertini<sup>1</sup>, G. Rizzardini<sup>1</sup>*  
<sup>1</sup>Department of Infectious Diseases, ASST-FBF-Sacco, Milan, Italy, <sup>2</sup>Pharmacy Unit, ASST-FBF-Sacco, Milan, Italy
- P 72 HCV patients and economic resources optimisation: the role of the DAA**  
*E. Garagiola<sup>1</sup>, L. Ferrario<sup>1</sup>, B. Menzaghi<sup>2</sup>, A. Tebini<sup>2</sup>, G. Rizzardini<sup>3,4</sup>, M.V. Cossu<sup>3</sup>, E. Foglia<sup>1</sup>, D. Croce<sup>1,5</sup>*  
<sup>1</sup>Liuc Business School, Centre for Research on Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy, <sup>2</sup>Infectious Diseases Department, ASST Valle Olona, Busto Arsizio, Italy, <sup>3</sup>Infectious Disease Department, ASST Fatebenefratelli Sacco, Milan, Italy, <sup>4</sup>School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa, <sup>5</sup>School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- P 73 HIV-HCV coinfecting patients' fibrosis improves less after Direct-Acting Antiviral treatment: analysis of a single centre cohort**  
*S. Oldrini<sup>1</sup>, D. Tomasoni<sup>1</sup>, V. Cappa<sup>2,3</sup>, S. Zaltron<sup>1</sup>, A. Spinetti<sup>1</sup>, P. Nasta<sup>1</sup>, C. Chirico<sup>1</sup>, C. Carriero<sup>1</sup>, G. Zuglian<sup>1</sup>, F. Castelnuovo<sup>1</sup>, L. Biasi<sup>1</sup>, E. Festa<sup>1</sup>, F. Castelli<sup>1</sup>*  
<sup>1</sup>University Department of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, <sup>2</sup>Unit of Biostatistics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>3</sup>Big&Open Data Innovation Laboratory (BODa-Lab), University of Brescia, Brescia, Italy
- P 74 Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) during Direct-Acting Antiviral treatment. Is PLR a predictor of sustained virological response?**  
*S. Odolini<sup>1</sup>, D. Tomasoni<sup>1</sup>, V. Cappa<sup>2,3</sup>, S. Zaltron<sup>1</sup>, A. Spinetti<sup>1</sup>, P. Nasta<sup>1</sup>, C. Chirico<sup>1</sup>, C. Carriero<sup>1</sup>, G. Zuglian<sup>1</sup>, F. Castelnuovo<sup>1</sup>, L. Biasi<sup>1</sup>, E. Festa<sup>1</sup>, F. Castelli<sup>1</sup>*  
<sup>1</sup>University Department of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, <sup>2</sup>Unit of Biostatistics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, <sup>3</sup>Big&Open Data Innovation Laboratory (BODa-Lab), University of Brescia, Brescia, Italy

**P 75 Integrated efficacy and safety analysis of Italian population treated with Glecaprevir/Pibrentasvir in phase 3 clinical trials**

A. Aghemo<sup>1</sup>, P. Andreone<sup>2</sup>, G. D'Offizi<sup>3</sup>, S. Fagioli<sup>4</sup>, M. Galli<sup>5</sup>, A. Gasbarrini<sup>6</sup>, P. Lampertico<sup>7</sup>, M. Persico<sup>8</sup>, M. Puoti<sup>9</sup>, G. Rizzardini<sup>10</sup>, G. Taliani<sup>11</sup>, E. Villa<sup>12</sup>, M. Vinci<sup>13</sup>, A.L. Zignego<sup>14</sup>, M. Zuin<sup>15</sup>, A. Perretti<sup>16</sup>, S. Petta<sup>17</sup>

<sup>1</sup>Department of Biomedical Sciences, Humanitas University and Humanitas Research Hospital, Rozzano, Italy, <sup>2</sup>Dipartimento di Scienze Mediche e Chirurgiche e Centro Studi e Ricerche sulle Epatiti, Università di Bologna, Bologna, Italy, <sup>3</sup>Infectious Diseases-Hepatology Unit, POIT Department, National Institute for Infectious Diseases, "Lazzaro Spallanzani" I.R.C.C.S., Roma, Italy, <sup>4</sup>U.S.C. Gastroenterologia Epatologia e Trapiantologia, Dipartimento di Medicina Specialistica e dei Trapianti, Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy, <sup>5</sup>Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Cattedra di Malattie Infettive, Milano, Italy, <sup>6</sup>Gastroenterologia, Policlinico Gemelli-Università Cattolica, Roma, Italy, <sup>7</sup>Gastroenterology and Hepatology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università di Milano, Italy, <sup>8</sup>Medicina Interna, Ospedale San Giovanni da Procida, Università degli Studi di Salerno, Italy, <sup>9</sup>SC Malattie Infettive, Dept of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, <sup>10</sup>Infectious Diseases Department ASST-FBF-Sacco, Milano, Italy and School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa, <sup>11</sup>Chronic Infectious Diseases Unit, School of Tropical Medicine, Sapienza University of Rome, Roma, Italy, <sup>12</sup>Department of Internal Medicine, Gastroenterology Unit, University of Modena & Reggio Emilia, Modena, Italy, <sup>13</sup>SC di Epatologia e Gastroenterologia ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, <sup>14</sup>Interdepartmental Hepatology Center MaSVE, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy, <sup>15</sup>Gastroenterology and Liver Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milano, Italy, <sup>16</sup>AbbVie srl, Rome, Italy, <sup>17</sup>Section of Gastroenterology and Hepatology, Biomedical Department of Internal and Specialized Medicine (DiBiMIS), University of Palermo, Italy

**P 76 Anti-HCV therapy in HIV/HVC co-infected patients**

H. Ernandes<sup>1</sup>, L. Ammari<sup>1</sup>, R. Abdelmalek<sup>1</sup>, A. Berriche<sup>1</sup>, S. Aissa<sup>1</sup>, F. Kanoun<sup>1</sup>, H. Harrabi<sup>1</sup>, B. Kilani<sup>1</sup>, O. Bahri<sup>2</sup>, H.T. Benaissa<sup>1</sup>

<sup>1</sup>Infectious disease department, La Rabta hospital, Tunis, Tunisia, <sup>2</sup>Virology department, Aziza Othmana hospital, Tunis, Tunisia

**HCV ERADICATION AND MODEL TO ACCESS TO CARE**

**P 77 Hepatitis C micro-elimination Project - ASL Roma 1**

P. Casella<sup>1</sup>, A. Torreggiani<sup>2</sup>, E. Dorigo<sup>2</sup>, A. Lupi<sup>1</sup>, S. Sereno<sup>3</sup>, T. Girolami<sup>1</sup>, E. Biliotti<sup>3</sup>, D. Palazzo<sup>3</sup>, A. Rugova<sup>3</sup>, M. Santori<sup>3</sup>, T. Petrangolini<sup>4</sup>, G. Taliani<sup>3</sup>

<sup>1</sup>UOC Dipendenza ASL RMT1, <sup>2</sup>T e C srl, <sup>3</sup>Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy, <sup>4</sup>Councilor of the Lazio Region, Italy

**P 78 Clinical and virological characteristics of two paediatric patients on treatment with DAA**

M. Mazzitelli<sup>1</sup>, N. Marascio<sup>2</sup>, G. Pavia<sup>2</sup>, C. Costa<sup>1</sup>, G. Giuseppe<sup>1</sup>, M.C. Pastorino<sup>1</sup>, G.S. Barreca<sup>2</sup>, V. Pisani<sup>1</sup>, M.C. Liberto<sup>2</sup>, A. Focà<sup>2</sup>, C. Torti<sup>1</sup>

<sup>1</sup>Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy, <sup>2</sup>Institute of Microbiology, Department of Health Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy

**P 79 A model of care of HCV elimination in prison: an epidemiological Survey in the the remand Center of Padua**

D. Lageder, V. Grigolin, L. Marcolongo, E. Conti, S. Lobello, F.A. Nava

Penitentiary Medicine and Drug Abuse Unit Padua, Italy

**P 80 A model of Harm reduction program in an attenuate custody section for drug users: results and findings from the pilot experience of Padua prison**

M. Rampazzo<sup>1</sup>, V. Minutella<sup>1</sup>, P. Vinti<sup>2</sup>, M. Galdiolo<sup>2</sup>, M. Costacurta<sup>2</sup>, G.B. Padovan<sup>1</sup>, F.A. Nava<sup>1</sup>

<sup>1</sup>Penitentiary Medicine and Drug Abuse Unit Padua, <sup>2</sup>Arci Gay Padua, Italy

**HEPATITIS CLINICAL DIAGNOSTICS**

**P 81 Low performance of the OraQuick Hepatitis C Virus rapid antibody test in HIV/HCV infected individuals**

S. Vita<sup>1</sup>, I. Pozzetto<sup>1</sup>, I. Mastrini<sup>1</sup>, R. Marocco<sup>1</sup>, L. Fondaco<sup>1</sup>, B. Kertusha<sup>1</sup>, V. Rossi<sup>1</sup>, T. Tieghi<sup>1</sup>, M. Lichner<sup>1,2</sup>, C.M. Mastroianni<sup>2</sup>

<sup>1</sup>Santa Maria Goretti Hospital, Latina, <sup>2</sup>Sapienza University, Rome, Italy

**P 82 HBV molecular epidemiology and clinical condition of immigrants living in Italy**

C. Sagnelli<sup>1,2,3</sup>, M. Ciccozzi<sup>4</sup>, L. Alessio<sup>2</sup>, E. Cella<sup>4</sup>, L. Gualdieri<sup>5</sup>, M. Pisaturo<sup>2,6</sup>, C. Minichini<sup>1</sup>, G. Di Caprio<sup>2</sup>, M. Starace<sup>1</sup>, L. Onorato<sup>2</sup>, M. Capoprese<sup>2</sup>, L. Occhiello<sup>2</sup>, S. Angeletti<sup>4</sup>, G. Scotto<sup>7</sup>, M. Macera<sup>1,2</sup>, E. Sagnelli<sup>1</sup>, N. Coppola<sup>1</sup>

<sup>1</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy, <sup>2</sup>Medical Center, Centro Sociale ex Canapificio, Caserta; Medical Center, Centro di Accoglienza "La tenda di Abramo", Caserta, Italy, <sup>3</sup>Medical center, Centro Suore Missionarie della Carità, Naples, Italy, <sup>4</sup>Unit of Clinical Pathology and Microbiology, University Campus Bio-Medico of Rome, Rome, Italy, <sup>5</sup>Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, <sup>6</sup>Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, <sup>7</sup>Infectious Diseases Unit, Foggia, Italy

**P 83 HCV genetic variability in patients with HCV-genotype 1-related hepatocellular carcinoma**

M. Pisaturo<sup>1</sup>, C. Minichini<sup>1</sup>, M. Starace<sup>1</sup>, L. Occhiello<sup>1</sup>, A. Di Fraia<sup>1</sup>, N. Farella<sup>2</sup>, G. De Stefano<sup>2</sup>, V. Iodice<sup>2</sup>, N. Coppola<sup>1,3</sup>

<sup>1</sup>Department of Mental Health and Public Medicine, Division of Infectious Diseases, University of Campania, Luigi Vanvitelli, Naples, Italy, <sup>2</sup>AORN dei Colli, Cotugno Hospital, Naples, Italy, <sup>3</sup>AORN S. Anna S. Sebastiano, Caserta, Italy

**P 84 HEV antibodies detection: comparison between two different commercially available assays**

P. Caligiuri<sup>1,2</sup>, E. Furfaro<sup>1,3</sup>, L.A. Nicolini<sup>3</sup>, M. Mikulska<sup>3</sup>, G. Barisione<sup>1,2</sup>, R. Cerruti<sup>2</sup>, M. Ferraris<sup>2</sup>, G. Icardi<sup>1,2</sup>, B. Bruzzone<sup>2</sup>

<sup>1</sup>Department of Health Sciences (DiSSal), University of Genoa, Italy, <sup>2</sup>Hygiene Unit, Polyclinic Hospital San Martino, Genoa, Italy, <sup>3</sup>Infectious Diseases, Polyclinic Hospital San Martino, Genoa, Italy



22-24  
MAGGIO  
2018 ERGIFE  
PALACE HOTEL,  
ROMA



## HEPATITIS EPIDEMIOLOGY

- P 85 Molecular epidemiology of HAV infection in Liguria: genetic analysis of HAV strains collected from December 2016 to February 2018**  
*P. Canepa<sup>1</sup>, B. D'Ambrosio<sup>1</sup>, C. Arcuri<sup>1</sup>, L. Santin<sup>2</sup>, C. Dentone<sup>3</sup>, M. Mela<sup>3</sup>, F. Briano<sup>4</sup>, A. Orsi<sup>1,2</sup>, F. Butera<sup>1</sup>, A. Schenone<sup>1</sup>, G. Icardi<sup>1,2</sup>, B. Bruzzone<sup>2</sup>*  
<sup>1</sup>Department of Health Sciences (DiSSal), University of Genoa, Italy, <sup>2</sup>Hygiene Unit, Polyclinic Hospital San Martino, Genoa, Italy, <sup>3</sup>Infectious Diseases, Giovanni Borea Hospital, Sanremo, Italy, <sup>4</sup>Infectious Diseases, Polyclinic Hospital San Martino, Genoa, Italy
- P 86 Epidemiology and risk factors for HCV infection among Italian intravenous drug users**  
*A. Boschini<sup>1</sup>, M. Begnini<sup>1</sup>, R. Poletti<sup>1</sup>, C. Smacchia<sup>1</sup>, C. Sala<sup>2</sup>, G. Castellani<sup>2</sup>, M. Colombo<sup>3</sup>*  
<sup>1</sup>San Patrignano Medical Center, Italy, <sup>2</sup>Physic and Biostatistics Department, University of Bologna, Italy, <sup>3</sup>Humanitas Research Hospital, Italy
- P 87 Epidemiology and risk factors for HCV infection among Italian non-injection drug users**  
*A. Boschini<sup>1</sup>, M. Begnini<sup>1</sup>, R. Poletti<sup>1</sup>, C. Smacchia<sup>1</sup>, C. Sala<sup>2</sup>, G. Castellani<sup>2</sup>, M. Colombo<sup>3</sup>*  
<sup>1</sup>San Patrignano Medical Center, <sup>2</sup>Physic and Biostatistics Department, University of Bologna, <sup>3</sup>Humanitas Research Hospital, Italy

## HEPATITIS PATHOGENESIS

- P 88 Correlation between the hepatic concentrations of miR-125a-5p and the progression of liver damage in patients with overt and occult HBV infection**  
*L. Onorato<sup>1</sup>, A. Russo<sup>2</sup>, G. de Stefano<sup>2</sup>, C. Minichini<sup>1</sup>, M. Panella<sup>3</sup>, V. Messina<sup>4</sup>, M. Starace<sup>1</sup>, P. Filippini<sup>4</sup>, N. Mosca<sup>3</sup>, L. Alessio<sup>4</sup>, L. Desiato<sup>3</sup>, N. Farella<sup>2</sup>, N. Potenza<sup>3</sup>, E. Sagnelli<sup>1</sup>, N. Coppola<sup>1</sup>*  
<sup>1</sup>Department of Mental Health and Public Medicine, Università della Campania L. Vanvitelli, Naples, <sup>2</sup>IX Interventional Ultrasound Unit for Infectious Diseases, AORN dei Colli, P.O. Cotugno, Naples, <sup>3</sup>Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università della Campania L. Vanvitelli, Caserta, <sup>4</sup>Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy

## HEPATITIS TREATMENT

- P 89 Combination therapy with pegylated interferon and tenofovir in HBV/HDV-infected patients**  
*A. Maccaro, L. Badia, V. Guardigni, P. Viale, G. Verucchi*  
 Infectious Diseases Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Italy
- P 90 Off label retreatment of a patient failed to NS5A based DAAs regimen with advanced liver failure: a case report**  
*E. Ciraci<sup>1</sup>, S. Semeraro<sup>1</sup>, G. Angarano<sup>2</sup>, L. Monno<sup>2</sup>, L. Lepore<sup>2</sup>, P. Gatti<sup>1</sup>*  
<sup>1</sup>Ospedale di Ostuni, ASL BRINDISI, <sup>2</sup>Clinica di Malattie Infettive, Università degli Studi di Bari, Italy
- P 91 Treatment with IFN-free regimen in a cohort of patients affected by chronic hepatitis C and psychiatric disorders: a retrospective analysis**  
*T. Lupia, L. Boglione, G. Cariti, S. Mornese Pinna, G. Di Perri*  
 Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy

## HIV EPIDEMIOLOGY

- P 92 HIV infection among transgender patients: our experience**  
*C. Papalini, S. Cardaci, S. Bastianelli, S. Pierucci, C. Sfara, F. Baldelli, D. Francisci*  
 Infectious Diseases Unit, Department of Medicine, University of Perugia, Italy
- P 93 Acceptability of HIV rapid test: comparison of capillary whole blood test and oral fluid test in outpatient service for migrants in Italy**  
*G. Chiaradia<sup>1</sup>, P. Scognamiglio<sup>1</sup>, P. Piselli<sup>1</sup>, C. Angeletti<sup>1</sup>, M. Oldrini<sup>2</sup>, E. Albertini<sup>3</sup>, A. Camposeragna<sup>4</sup>, M. Farinella<sup>5</sup>, D. Lorenzetti<sup>6</sup>, L. Rancilio<sup>7</sup>, G. Ippolito<sup>1</sup>, E. Girardi<sup>1</sup>*  
<sup>1</sup>Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, Roma, <sup>2</sup>Lila, <sup>3</sup>Arcigay, <sup>4</sup>CNCA, <sup>5</sup>Circolo Mario Mieli, <sup>6</sup>ANLAIDS, <sup>7</sup>Caritas, Italy
- P 94 Significant spread to the native Italian population of HIV-1 non-B subtypes and worse virological response at week 48 to first-line cART: a single cohort experience in a region with a high migration rate**  
*I. Izzo<sup>1</sup>, M.A. De Francesco<sup>2</sup>, F. Gargiulo<sup>2</sup>, E. Quiros-Roldan<sup>1</sup>, F. Invernici<sup>1</sup>, F. Castelnuovo<sup>1</sup>, E. Focà<sup>1</sup>, A. Bonito<sup>1</sup>, A. Caruso<sup>2</sup>, F. Castelli<sup>1</sup>*  
<sup>1</sup>University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, <sup>2</sup>Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia and Spedali Civili General Hospital, Brescia, Italy



- P 95 Low prevalence of HTLV1/2 infection in a population of sub-Saharan immigrants living in Southern Italy**  
*L. Occhiello<sup>2</sup>, L. Alessio<sup>1,3,4</sup>, C. Minichini<sup>2</sup>, M. Starace<sup>2</sup>, M. Caroprese<sup>3,4</sup>, G. Di Caprio<sup>2,3,4</sup>, C. Sagnelli<sup>2,3,5</sup>, L. Gualdieri<sup>6</sup>, M. Pisaturo<sup>2,3,4</sup>, L. Onorato<sup>2,3,4</sup>, G. Scotta<sup>7</sup>, M. Macera<sup>2,3,4</sup>, S. De Pascalis<sup>2</sup>, E. Sagnelli<sup>2</sup>, N. Coppola<sup>1,2</sup>*  
<sup>1</sup>Infectious Diseases Unit, AORN Sant'Anna and San Sebastiano, Caserta, Italy, <sup>2</sup>Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples, Italy, <sup>3</sup>Medical Center, Centro Sociale ex Canapificio, Caserta, <sup>4</sup>Medical Center, Centro di Accoglienza "La tenda di Abramo", Caserta, Italy, <sup>5</sup>Medical center, Centro Suore Missionarie della Carità, Naples, Italy, <sup>6</sup>Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, <sup>7</sup>Infectious Diseases Unit, Foggia, Italy
- P 96 Prevalence of drug resistance and circulating viral subtypes in a real-life cohort of ART naïve HIV positive patients from 2005-2017**  
*L. Mazzuti<sup>1</sup>, T. Melengu<sup>1</sup>, I. Mezzaroma<sup>2</sup>, G. d'Ettore<sup>3</sup>, E. Cella<sup>4</sup>, C. Fimiani<sup>3</sup>, G. Iaiani<sup>5</sup>, M. Falciano<sup>3</sup>, M. Ciccozzi<sup>4</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup>*  
<sup>1</sup>Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Department of public health and infectious diseases, Sapienza University of Rome, Rome, Italy, <sup>4</sup>Unit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Rome, Italy, <sup>5</sup>Department of Infectious and Tropical Disease, Sapienza University of Rome, Rome, Italy
- P 97 Impact of tuberculosis and HIV infection on healthcare activities of infectious disease units in the Calabria region**  
*M. Mazzitelli<sup>1</sup>, E. Raffetti<sup>2</sup>, L. Cosco<sup>3</sup>, R. Marino<sup>4</sup>, A. Mastroianni<sup>5</sup>, N. Serrao<sup>6</sup>, G. Apuzzo<sup>5</sup>, G. Berardelli<sup>7</sup>, J. Carioti<sup>6</sup>, D. Teti<sup>4</sup>, S. Nisticò<sup>7</sup>, L. Surace<sup>8</sup>, G. Foti<sup>9</sup>, C. Torti<sup>1</sup>*  
<sup>1</sup>Infectious and Tropical Diseases Unit, Magna Graecia University, Catanzaro, Italy, <sup>2</sup>Unit of Hygiene, Epidemiology and Public Health, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Brescia, Italy, <sup>3</sup>Infectious and Tropical Disease Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy, <sup>4</sup>Infectious and Tropical Disease Unit, "G. Jazzolino" Hospital, Vibo Valentia, Italy, <sup>5</sup>Infectious and Tropical Disease Unit, "Annunziata" Hospital, Cosenza, Italy, <sup>6</sup>Infectious and Tropical Disease Unit, "San Giovanni di Dio" Hospital, Crotona, Italy, <sup>7</sup>Microbiology and Virology Unit, "Giovanni Paolo II" Hospital, Lamezia Terme, Italy, <sup>8</sup>Travelers and Migration Medical Center, "Giovanni Paolo II" Hospital, Lamezia Terme, Italy, <sup>9</sup>Infectious and Tropical Disease Unit, "Bianchi Melacrino Morelli" Hospital, Reggio Calabria, Italy
- P 98 Late presentation and six months survival in a cohort of HIV+ subjects diagnosed across the last years in Catania**  
*A. Pampaloni, M.E. Locatelli, A. Marino, D. Scuderi, M. Maresca, L. Vinci, R. Fontana del Vecchio, R. Bruno, M. Gussio, F. Palermo, B. Caccopardo, B.M. Celesia*  
 Unit of Infectious Diseases. University of Catania. ARNAS Garibaldi Catania, Italy
- P 99 Therapy switch in an HIV-infected female cohort: the therapy adherence issue and the ADR risk**  
*G. Piazza<sup>1</sup>, L. Appolloni<sup>1</sup>, S. Vitale<sup>1</sup>, I. Martens<sup>1</sup>, J. Baldi<sup>1</sup>, M. Morotti<sup>1</sup>, L. Calza<sup>2</sup>, C. Puggioli<sup>1</sup>*  
<sup>1</sup>Clinical Pharmacy, S. Orsola-Malpighi Polyclinic, Bologna, <sup>2</sup>Infectious Disease S. Orsola-Malpighi Polyclinic, Bologna, Italy
- P 100 Molecular epidemiology of HIV-2 infected migrant in asylum seeker centre**  
*E. Cella<sup>1</sup>, S. Vita<sup>2</sup>, G. Ceccarelli<sup>2</sup>, M. Fogolari<sup>3</sup>, V. Scolamacchia<sup>1</sup>, G. d'Ettore<sup>2</sup>, V. Vullo<sup>2</sup>, S. Angeletti<sup>3</sup>, M. Ciccozzi<sup>1</sup>*  
<sup>1</sup>Medical statistic and molecular epidemiology, University Campus Bio-Medico of Rome, <sup>2</sup>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy, <sup>3</sup>Unit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Italy
- P 101 HIV-1 Subtypes and Circulating Recombinant Forms (CRFs) and blood donation NAT screening test: experience of LIGURIA Region**  
*G. Ubezio<sup>1</sup>, A. Di Biagio<sup>2</sup>, M. Setti<sup>3</sup>, N. Nigro<sup>4</sup>, A. Marghero<sup>1</sup>, G. Barisione<sup>4,5</sup>, M.C. De Luigi<sup>1</sup>, P. Strada<sup>1</sup>, B. Bruzzone<sup>4</sup>*  
<sup>1</sup>Transfusional Service, Polyclinic Hospital San Martino, Genoa, Italy, <sup>2</sup>Infectious Diseases, Department of Internal Medicine, University of Genoa, Polyclinic Hospital San Martino, Genoa, Italy, <sup>3</sup>Internal Medicine and Clinical Immunology Unit, Polyclinic Hospital San Martino, Genoa, Italy, <sup>4</sup>Hygiene Unit, Polyclinic Hospital San Martino, Genoa, Italy, <sup>5</sup>Department of Health Sciences (DiSSal), University of Genoa, Italy
- P 102 Foreign women under 49 years: a high risk group for HIV infection. A single center study in Brescia, Northern Italy**  
*I. Izzo, A. Celotti, B. Saccani, M. Properzi, E. Quiros-Roldan, A. Ferraresi, M.C. Pezzoli, R. Allegri, F. Castelnuovo, F. Castelli*  
 University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
- P 103 Direct distribution anti-HIV drugs through the Edotto system: appropriateness, traceability and innovation**  
*F. Digioseppe, L. D'Aprile*  
 Dipartimento Gestione del Farmaco ASL BARI, Italy
- P 104 Epidemiological and clinical characteristics of newly diagnosed HIV infected patients: a single center study in Northern Italy**  
*I. Izzo, M. Properzi, A. Celotti, B. Saccani, E. Focà, E. Van Hauwermeiren, M.A. Forleo, I. El-Hamad, F. Castelnuovo, F. Castelli*  
 University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy

## HIV CASCADE AND RETENTION IN CARE

- P 105 Epidemiological and clinical characteristics of HIV-infected patients lost to follow up (LTFU) and re-engaged in care: a singlecohort observational study in Northern Italy**  
*A. Comelli, I. Izzo, E. Quiros-Roldan, F. Castelnuovo, G. Parainfo, A. Ferraresi, F. Invernici, G. Zambolin, F. Castelli*  
 University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy





22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



**P 106 Retention in care of HIV-positive patients from 2005 to 2014: comparison between Italian and non Italian patients**

*C. Gabrielli, E. Schiaroli, G. De Socio, C. Papalini, M. B. Pasticci, F. Baldelli, D. Francisci*  
Clinica delle Malattie Infettive, Ospedale S. M. della Misericordia, Perugia, Italy



## HIV PREVENTION

**P 107 Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis: a safe option**

*A. Franco<sup>1</sup>, L. Aprea<sup>2</sup>, N. Papa<sup>3</sup>, T. Pizzella<sup>2</sup>, F. Simioli<sup>2</sup>, E. Manzillo<sup>2</sup>*

<sup>1</sup>UOSD di Sorveglianza e Profilassi Post-esposizione - AORN "Ospedali dei Colli" - Napoli, <sup>2</sup>UOC di Immunodeficienze e Malattie dell'Emigrazione - AORN "Ospedali dei Colli" - Napoli,

<sup>3</sup>UOSD di Farmacovigilanza - AORN "Ospedali dei Colli" - Napoli, Italy

**P 108 Project Schools, "Anlaidi Lazio meets the students": an in/formative school prevention campaign on HIV/AIDS/STI, in cooperation with the National Institute for infectious diseases Spallanzani, to promote safe behaviors and a mindful sexuality in the Lazio Region**

*R. Galipò<sup>1</sup>, E. Farinola<sup>1</sup>, A. Ferraroni<sup>1</sup>, P. Ferri<sup>1</sup>, F. Maroso<sup>1</sup>, S. Ondedei<sup>1</sup>, N. Orchi<sup>2</sup>, A. Palummieri<sup>1</sup>, A. Pulimeno<sup>3</sup>*

<sup>1</sup>Anlaidi Lazio Onlus, <sup>2</sup>Epidemiology Unit - AIDS Reference Centre, National Institute for Infectious Disease "L. Spallanzani" - INMI, <sup>3</sup>OPI of Rome, Italy

**P 109 PrEP awareness and willingness in Italy, a one-month cross sectional study in a free access outpatient clinic**

*A. Santoro, G. Guaraldi, G. Campagna, A. Bianchi, N. Riva, I. Franconi, A. Bonazza, A. Raimondi, C. Rogati, C. Ciusa, M. Tutone, C. Mussini*  
AOU Policlinico di Modena, Dipartimento di Malattie Infettive, Italy

**P 110 HIV seroconversion after stopping TDF-based treatment for HBV**

*B. Tazza, L. Badia, V. Guardigni, G. Verucchi, P. Viale*

Infectious Diseases Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna

**P 111 Unconsistent use of condom in heterosexual HIV-serodiscordant couples from Southeastern Italy as revealed by the detection of Y chromosomal DNA in vaginal swabs**

*F. Zoboli<sup>1</sup>, M. Di Stefano<sup>1</sup>, M. Fasano<sup>1</sup>, S.R. Bruno<sup>1</sup>, T.A. Santantonio<sup>1</sup>, J.R. Fiore<sup>1,2</sup>*

<sup>1</sup>Clinic of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, <sup>2</sup>Imam Abdulrahman Bin Faisal University, College of Medicine, Saudi Arabia

## HIV CLINICAL DIAGNOSTICS

**P 112 Going towards undetectable: preliminary results**

*B. Bruzzone<sup>1</sup>, M. Setti<sup>2</sup>, A. Di Biagio<sup>3</sup>, R. Barresi<sup>1</sup>, N. Nigro<sup>1</sup>, A. Torretta<sup>4</sup>, G. Guarona<sup>1,5</sup>, P. Strada<sup>4</sup>, G. Ubezio<sup>4</sup>*

<sup>1</sup>Hygiene Unit, Polyclinic Hospital San Martino, Genoa, Italy, <sup>2</sup>Internal Medicine and Clinical Immunology Unit, Polyclinic Hospital San Martino, Genoa, Italy, <sup>3</sup>Infectious Diseases, Polyclinic Hospital San Martino, Genoa, Italy, <sup>4</sup>Transfusional Service, Polyclinic Hospital San Martino, Genoa, Italy, <sup>5</sup>Department of Health Sciences (DiSSal), University of Genoa, Italy

**P 113 Evaluation of the rapid HIV-1 RNA quantification Xpert HIV-1 Viral load assay: comparison with the COBAS AmpliPrep/COBAS TaqMan HIV test**

*T. Alice, M.G. Milia, E. Burdino, G. Gregori, T. Ruggiero, M. Malta, E. Scuccimarra, P. Tremante, V. Ghisetti*

Laboratory of Microbiology and Virology, ASL Città di Torino, Torino, Italy

## HIV IMMUNOLOGY

**P 114 APOBEC3G/3A expression in HIV-1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz**

*D.A. Covino<sup>1</sup>, C. Purificato<sup>1</sup>, L. Catapano<sup>1</sup>, C.M. Galluzzo<sup>1</sup>, M.C. Gauzzi<sup>1</sup>, S. Vella<sup>1</sup>, E. Lefebvre<sup>2</sup>, M. Andreotti<sup>1</sup>, L. Fantuzzi<sup>1</sup>*

<sup>1</sup>National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, <sup>2</sup>Allergan plc, South San Francisco, CA, USA

**P 115 Modulation of the Natural Killer Cell compartment during DAAs treatment in Interferon-naïve HCV patients: the impact of the type of DAA**

*L.A. Nicolini<sup>1,2</sup>, S. Dettori<sup>1</sup>, F. Bozzano<sup>3,4</sup>, A. Di Biagio<sup>2</sup>, A. De Maria<sup>1,2,3,4</sup>*

<sup>1</sup>U.O. Clinica Malattie Infettive, Department of Health Sciences (DISSAL), University of Genoa/Genoa, Italy, <sup>2</sup>Ospedale Policlinico San Martino-IRCCS for Oncology, Genoa, Italy, <sup>3</sup>Center for Excellence in Biomedical Research, University of Genoa, Genoa, Italy, <sup>4</sup>Department of Experimental Medicine, University of Genova, Genoa, Italy



- P 116 Peripheral loss of regulatory T cells and polyautoimmunity in a HIV-infected patient**  
*E. Quiros-Roldan, A. Ferraresi, M. Properzi, A. Bonito, A. Celotti, M.C. Pezzoli, R. Allegri, F. Castelnovo, E. Focà, I. Izzo, F. Castelli*  
 University Department of Infectious and Tropical Diseases, ASST Spedali Civili and University of Brescia, Brescia, Italy
- P 117 In HIV primary infection, early cART reduced gd T cell activation but failed to restore their polyfunctionality**  
*R. Casetti<sup>1</sup>, A. Sacchi<sup>1</sup>, V. Bordonì<sup>1</sup>, E. Cimini<sup>1</sup>, C. Pinnetti<sup>2</sup>, R. Libertone<sup>2</sup>, A. Ammassari<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>1</sup>*  
<sup>1</sup>Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., <sup>2</sup>Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy
- P 118 Evaluation of myeloid cells, classical, intermediate and non-classical monocytes, T-cell activation markers in virologically suppressed treated patients with DRV-based regimen**  
*S. Savinelli, S. Vita, C. Mascia, L. Celani, L. Bianchi, M. Lichtner, G. d'Ettore, V. Vullo, C.M. Mastroianni*  
 Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
- P 119 Association of inflammation and coagulation markers with clinical, virological or immunological progression of HIV-1 Infection in adult patients naïve to antiretroviral therapy and with a CD4+ T lymphocyte count above 500 cells/MCL**  
*L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, M. Borderi<sup>1</sup>, R. Manfredi<sup>1</sup>, S. Coladonato<sup>1</sup>, B. Tazza<sup>1</sup>, I. Bon<sup>2</sup>, M.C. Re<sup>2</sup>, P. Viale<sup>1</sup>*  
<sup>1</sup>Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna, <sup>2</sup>Department of Medical and Surgical Sciences, Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna, Italy
- P 120 HIV-1 and host restriction factors: relationship between viral reservoir and RFs expression levels**  
*V. D'Urbano<sup>1</sup>, S. Longo<sup>1</sup>, E. De Crignis<sup>1</sup>, A. Bertoldi<sup>1</sup>, G. Musumeci<sup>1</sup>, I. Bon<sup>1</sup>, L. Calza<sup>2</sup>, G. Gallinella<sup>3</sup>, M.C. Re<sup>1</sup>*  
<sup>1</sup>Microbiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Italy, <sup>2</sup>Clinic of Infectious Diseases, Department of Medical and Surgical Sciences, St. Orsola-Malpighi Hospital, University of Bologna, Italy, <sup>3</sup>Department of Pharmacy and Biotechnology, University of Bologna, Italy

## VACCINES AND IMMUNE-BASED THERAPIES

- P 121 Vaccine usage extent in people living with HIV: a snapshot from a single center cohort**  
*N. de Gennaro, A. Procopio, C. Santoro, C. Fabrizio, D.F. Bavaro, N. Ladisa, S. Lo Caputo, L. Monno, A. Saracino, G. Angarano*  
 Clinic of Infectious Diseases, University of Bari Aldo Moro, Bari, Italy

## HIV PATHOGENESIS

- P 122 Impact of ART on dynamics of growth factors and cytokines in primary HIV infection**  
*V. Bordonì<sup>1</sup>, A. Sacchi<sup>1</sup>, R. Casetti<sup>1</sup>, E. Cimini<sup>1</sup>, C. Pinnetti<sup>2</sup>, A. Mondì<sup>2</sup>, A. Ammassari<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>1</sup>*  
<sup>1</sup>Cellular Immunology and Pharmacology Laboratory, <sup>2</sup>Clinical Department, INMI-IRCCS L. Spallanzani, Rome, Italy
- P 123 MicroRNA profile and CD4/CD8 ratio recovery after antiretroviral therapy**  
*A. Gabrieli<sup>1</sup>, L. Dioni<sup>2</sup>, C. Favero<sup>2</sup>, M. Tarkowski<sup>1</sup>, E. Gervasi<sup>1</sup>, S. Limonta<sup>1</sup>, M. Galli<sup>1</sup>, V. Bollati<sup>2</sup>, A. Riva<sup>3</sup>*  
<sup>1</sup>Infectious Diseases Unit, Department of Biomedical and Clinical Sciences, University of Milan, Italy, <sup>2</sup>EPIGET LAB, Department of Clinical Sciences and Community Health, University of Milan, <sup>3</sup>III Divisione di Malattie Infettive ASST Fatebenefratelli-Sacco, Milan, Italy

## HIV VIROLOGY

- P 124 No impact of minor accessory mutations to Integrase strand transfer inhibitors (InSTI) on cART effectiveness after 24 weeks of follow-up: a longitudinal single-cohort study**  
*A. Celotti<sup>1</sup>, M. Properzi<sup>1</sup>, M. De Francesco<sup>2</sup>, F. Gargiulo<sup>2</sup>, I. Izzo<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelnovo<sup>1</sup>, A. Bonito<sup>1</sup>, A. Ferraresi<sup>1</sup>, M.C. Pezzoli<sup>1</sup>, A. Caruso<sup>2</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>*  
<sup>1</sup>Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, <sup>2</sup>Institute of Microbiology, Department of Molecular and translational Medicine, University of Brescia, Italy





22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



**P 125 Epidemiological analysis of primary resistance to Integrase strand –transfer inhibitors in real life setting from January 2016 to December 2017 in “D. Cotugno” Hospital, Naples (Italy)**

S. Mascolo<sup>1</sup>, A. Raddi<sup>2</sup>, M. Sardo<sup>1</sup>, V. Sangiovanni<sup>1</sup>, L. Atripaldi<sup>2</sup>, N. Cuomo<sup>2</sup>

<sup>1</sup>U.O.C. Infezioni sistemiche e dell’immunodepresso - PO “D. Cotugno”, <sup>2</sup>U.O.C. Microbiologia e Virologia - PO “D. Cotugno”, Naples, Italy

**P 126 NK cell-mediated lysis of CD4+ T lymphocytes harboring reactivated HIV-1**

M.G. Desimio, E. Giuliani, M. Doria

Laboratory of Immunoinfectivology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

**P 127 Role of low-level viremia during chemotherapy for non-hodgkin lymphoma**

G. Bozzi<sup>1</sup>, I. De Benedetto<sup>1</sup>, L. Verga<sup>1</sup>, S. Malandrini<sup>1</sup>, V. Micheli<sup>2</sup>, M. Mena<sup>3</sup>, E. Doni<sup>1</sup>, D. Dalu<sup>2</sup>, C. Fasola<sup>2</sup>, E. Colella<sup>1</sup>, A. Muscatello<sup>1</sup>, C. Gambacorti-Passerini<sup>1</sup>, A. Gori<sup>1</sup>, A. Bandera<sup>1</sup> for the Musthal study group

<sup>1</sup>San Gerardo Hospital, ASST Monza, Monza, <sup>2</sup>L. Sacco Hospital, ASST FBF-Sacco, Milano, <sup>3</sup>Legnano Hospital, ASST Ovest Milanese, Legnano, Italy

**P 128 Apoptotic effects in macrophages infected by CXCR4- but not by CCR5-viruses, caused by the involvement of HIV-1 coreceptors**

A. Borrajo<sup>1,3</sup>, A. Ranazzi<sup>1</sup>, M.C. Bellocchi<sup>1</sup>, M. Pollicita<sup>1</sup>, V. Svicher<sup>1</sup>, C.F. Perno<sup>1</sup>, S. Aquaro<sup>1,2</sup>

<sup>1</sup>Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Roma, Italy, <sup>2</sup>Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italia, <sup>3</sup>Clinical Virology group, Institute of Biomedical Research of A Coruña (INIBIC)-University hospital of A Coruña (CHUAC), Sergas, University of A coruña, (UDC), A Coruña, Spain

## NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS

**P 129 Mini-Addenbrooke’s Cognitive Examination test for HIV-Associated Neurocognitive Disorders**

M. Trunfio<sup>1</sup>, M. Milesi<sup>1</sup>, D. Vai<sup>2</sup>, C. Montrucchio<sup>1</sup>, C. Alcantarini<sup>1</sup>, M.C. Tettoni<sup>1</sup>, G. Orofino<sup>3</sup>, S. Audagnotto<sup>1</sup>, D. Imperiale<sup>2</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>

<sup>1</sup>Unit of Infectious Diseases, Amedeo di Savoia hospital, Department of Medical Sciences, University of Torino, Torino, Italy, <sup>2</sup>Unit of Neurology, Maria Vittoria hospital, ASL Città di Torino, Torino, Italy, <sup>3</sup>Unit of infectious Diseases, Amedeo di Savoia hospital, Divisione A, Torino, Italy

## PEDIATRIC, ADOLESCENT, MATERNAL, FETAL ASPECTS

**P 130 Viral and Immunological Profile of HIV-1 chronically infected children under cART with or without persistent suppression of HIV-1 plasmaviremia**

A. Dalzini<sup>1</sup>, G. Ballin<sup>1</sup>, F. Carmona<sup>2</sup>, R. Freguja<sup>1</sup>, M.R. Petrara<sup>1</sup>, M. Zanchetta<sup>2</sup>, O. Rampon<sup>3</sup>, C. Giaquinto<sup>3</sup>, A. de Rossi<sup>1,2</sup>

<sup>1</sup>Department of Oncology, AIDS Reference Center, University of Padova, Italy, <sup>2</sup>Istituto Oncologico Veneto - IRCCS, Padova, Italy, <sup>3</sup>Department of Women’s and Children’s Health, University of Padova, Italy

**P 131 Rilpivirine during pregnancy: is it associated with preterm delivery?**

F. Peruzzu<sup>1</sup>, M.J. Lopes<sup>2</sup>, M. Caixeiro<sup>2</sup>, D. Trigo<sup>2</sup>, J. Batista<sup>2</sup>, B.F. de Lima<sup>2</sup>, G. Madeddu<sup>1</sup>, S. Babudieri<sup>1</sup>, P. Pacheco<sup>2</sup>

<sup>1</sup>Università degli Studi di Sassari, U.O.C. Malattie Infettive, Sassari, Italy, <sup>2</sup>Hospital Professor Doutor Fernando Fonseca, Infectious Diseases Department, Amadora, Portugal

**P 132 Adherence to antiretroviral therapy in HIV+ Adolescents: an open issue for multidisciplinary team**

G. Orofino<sup>1</sup>, M. Guastavigna<sup>1</sup>, M. Farenga<sup>1</sup>, D. Penoncelli<sup>1</sup>, S. Carosella<sup>1</sup>, S. Lupo<sup>2</sup>, G. Cinnirella<sup>3</sup>, C. Gabiano<sup>4</sup>, P. Caramello<sup>1</sup>

<sup>1</sup>Amedeo di Savoia Hospital, Division A of Infectious Diseases, Torino, Italy, <sup>2</sup>Amedeo di Savoia Hospital, Psychiatric and Psychological Clinical Liaison Department, Torino, Italy, <sup>3</sup>Amedeo di Savoia Hospital, Pharmacy Department, Torino, Italy, <sup>4</sup>Città della Salute e della Scienza- Regina Margherita Hospital, Pediatric Infectious Diseases, Torino, Italy

**P 133 Effects of universal access to ART on MTC transmission and maternal health in West Cameroon**

A.M. Doro Altan<sup>1</sup>, L. Palombi<sup>2</sup>, F. Ciccacci<sup>2</sup>, F. Tafo<sup>3</sup>, J. Castro Forns<sup>1</sup>, S. Orlando<sup>2</sup>, S. Mancinelli<sup>2</sup>, C. Marazzi<sup>4</sup>

<sup>1</sup>Community of S.Egidio, DREAM Programme, Rome, Italy, <sup>2</sup>University of Tor Vergata, Department of Biomedicine and Prevention, Rome, Italy, <sup>3</sup>DREAM Centre, Hospital of St Vincent de Paul, Dschang, Cameroon, <sup>4</sup>University IUMSA, Rome, Italy

## PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

**P 134 How relevant are drug-drug interactions between boosted antiretroviral -based regimens and calcium channel blockers in real life?**

D. Cattaneo<sup>1,2</sup>, T. Formenti<sup>3</sup>, N. Astuti<sup>3</sup>, P. Meraviglia<sup>3</sup>, A. Ridolfo<sup>3</sup>, C. Gervasoni<sup>1,3</sup>

<sup>1</sup>Gestione Ambulatoriale Politerapie (GAP) outpatient clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, <sup>2</sup>Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, <sup>3</sup>Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

**P 135 A pharmacogenetic study in ritonavir treated patients: hematological and cardiovascular disease risk analysis**

J. Cusato, A. Calcagno, S. Allegra, M. Antonucci, L. Marinaro, A. De Nicolo’, S. Bonora, G. Di Perri, A. D’Avolio

Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy

- P 136 Factors influencing sofosbuvir intracellular concentrations at one month of therapy**  
*J. Cusato, A. De Nicolò, L. Boglione, G. Caviglia, M. Sciandra, S. Mornese Pinna, A. Ciancio, G. Troshina, A. Smedile, C. Carcieri, G. Cariti, G. Saracco, G. Di Perri, A. D'Avolio*  
 Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
- P 137 Use of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in a HIV-positive woman during pregnancy**  
*C. Alcantarini<sup>1</sup>, M. Tettoni<sup>1</sup>, L. Trentini<sup>1</sup>, C. Costa<sup>1</sup>, C. Montrucchio<sup>1</sup>, A. Trentalange<sup>1</sup>, N. Forni<sup>1</sup>, A. Barco<sup>1</sup>, G. Masuelli<sup>2</sup>, C. Scalfaro<sup>3</sup>, V. Avataneo<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. D'Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>*  
<sup>1</sup>Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, <sup>2</sup>Department of Obstetrics and Neonatology, Città della Salute e della Scienza Hospital, and University of Turin, Italy, <sup>3</sup>Department of Paediatrics, Infectious Diseases Unit, University of Turin, Turin, Italy
- P 138 Myocardial infarction and other adverse drug reaction among antiretroviral treatment in HIV positive patients**  
*M. De Fina*  
 Farmacista Dirigente, Azienda Sanitaria Provinciale Reggio Calabria, Italy

## PROGRAMMATIC ISSUES, IMPLEMENTATION OF DIAGNOSIS AND CARE

- P 139 Access to anti-HCV treatment with DAAs in the migrant population in Italy: data from the Piter cohort**  
*A. Saracino<sup>1</sup>, D.F. Bavaro<sup>1</sup>, S. Rosato<sup>2</sup>, A. Giorgini<sup>3</sup>, R. Corsini<sup>4</sup>, E. Castelli<sup>5</sup>, M. Vinci<sup>6</sup>, F. Baragli<sup>7</sup>, E. Biliotti<sup>8</sup>, A. Orlandini<sup>9</sup>, M. Monti<sup>10</sup>, A. Zanetto<sup>11</sup>, C. Baiguera<sup>6</sup>, G. Morsica<sup>12</sup>, A. Soria<sup>13</sup>, S. Bruno<sup>14</sup>, A. Ciancio<sup>15</sup>, V. Donati<sup>16</sup>, V. Calvaruso<sup>17</sup>, M.G. Quaranta<sup>2</sup> on behalf of PITER collaborating group*  
<sup>1</sup>University of Bari, <sup>2</sup>Istituto Superiore di Sanità, Rome, <sup>3</sup>San Paolo Hospital, University Milan, <sup>4</sup>Arcispedale Santa Maria Nuova, Reggio Emilia, <sup>5</sup>University Hospital of Padua, <sup>6</sup>Niguarda Hospital, Milan, <sup>7</sup>S.M. Annunziata Hospital, Florence, <sup>8</sup>Umberto I Hospital, "Sapienza" University, Rome, <sup>9</sup>University of Parma, <sup>10</sup>University of Florence, <sup>11</sup>University Hospital of Padua, <sup>12</sup>San Raffaele Hospital, Milan, <sup>13</sup>San Gerardo Hospital, Monza, <sup>14</sup>Ospedali Riuniti, Foggia, <sup>15</sup>University Hospital "Città della Salute e della Scienza-Molinette", Turin, <sup>16</sup>University Hospital "S. Orsola Malpighi", Bologna, <sup>17</sup>University of Palermo, Italy
- P 140 The motivation analysis of the HIV-infected patients to spontaneous access to the hospital psychotherapy service in San Raffaele Hospital**  
*M.M. Ratti, E. Sangiovanni, G.B. Delli Zotti, L. Sarno*  
 Health and Clinical Psychology Service, IRCCS San Raffaele Hospital, Milan, Italy
- P 141 Free to live well with HIV in prison**  
*A. Battistella<sup>1</sup>, S. Dell'Isola<sup>2</sup>, S. Babudieri<sup>3</sup>, G. Starnini<sup>4</sup>, M. Errico<sup>5</sup>, C. Frontini<sup>4</sup>, A. Borrelli<sup>5</sup>, F. Perocco<sup>1</sup>, M. Cascio<sup>5,6</sup>, M. Formisano<sup>5</sup>, FLEW group\**  
 \*Collaborators: E. Rastrelli, A. Ialungo, S. Marcellini, M. Scuderi, M. Merlino, S. Carbonara, L. D'Argenio, T. Prestileo, F. Di Lorenzo, E. Pontali, L. Butini, G. Korb  
<sup>1</sup>University Ca' Foscari, Department of Philosophy and Cultural Heritage, Venice, Italy, <sup>2</sup>SIMSPE - Italian society of Penitential Medicine - Viterbo, Italy, <sup>3</sup>Infectious Diseases Unit, University of Sassari, Sassari, Italy, <sup>4</sup>Medicina Protetta-Malattie Infettive Unit- Belcolle Hospital, Viterbo, Italy, <sup>5</sup>NPS Italy Onlus - Network of people living with HIV, Milan, Italy, <sup>6</sup>European AIDS Treatment Group (EATG)
- P 142 Doctor Apollo: a digital health tool to improve management and wellbeing of people living with HIV**  
*S. Vita<sup>1</sup>, R. Marocco<sup>1</sup>, I. Pozzetto<sup>1</sup>, G. Morlino<sup>2</sup>, E. Vigilante<sup>2</sup>, L. Fondaco<sup>1</sup>, B. Kertusha<sup>1</sup>, G. Colazingari<sup>1</sup>, V. Mercurio<sup>1</sup>, V. Vullo<sup>2</sup>, C.M. Mastroianni<sup>3</sup>, M. Lichtner<sup>1,3</sup>*  
<sup>1</sup>Santa Maria Goretti Hospital, Latina, <sup>2</sup>SnapBack, <sup>3</sup>Sapienza University Rome, Italy
- P 143 Capillary free HIV testing at voluntary and counseling PEG Checkpoint: report of tests performed in 2016-2017**  
*S. Cardaci<sup>1</sup>, E. Albertini<sup>2</sup>, C. Sfara<sup>1</sup>, C. Papalini<sup>1</sup>, V. Scaglione<sup>1</sup>, E. Riguccini<sup>1</sup>, M. Nofri<sup>1</sup>, F. Paciosi<sup>1</sup>, A. Gidari<sup>1</sup>, C. Gabrielli<sup>1</sup>, G. Angeli<sup>1</sup>, D. Rosignoli<sup>1</sup>, P. Diana<sup>2</sup>, L. Ciaccarini<sup>2</sup>, M.G. Gaggini<sup>2</sup>, F. Baldelli<sup>1</sup>*  
<sup>1</sup>Unit of Infectious Diseases, Department of Medicine, University of Perugia, <sup>2</sup>Omphalos LGBTI Perugia, Italy
- P 144 BLQ Checkpoint: characteristics of users in the first 30 months of activity**  
*S. Mattioli, M. Bonanni, C. Degli Esposti, C. Franchini, P. Gorgoni, P. Pieralli, P. Tomasi, G.M. Corbelli*  
 Plus onlus, Italy
- P 145 Financial costs related to antiretroviral treatment switch (Studio Costi attribuibili alla modifica di una terapia antiretrovirale-SCUDI). Preliminary analysis**  
*G. Cenderello<sup>1</sup>, B. Giannini<sup>2</sup>, M. Giacomini<sup>2</sup>, R. Ungaro<sup>3</sup>, N. Riccardi<sup>3</sup>, D. Fiorellino<sup>1</sup>, G. Cassola<sup>1</sup>, A. Di Biagio<sup>3</sup>*  
<sup>1</sup>SC Malattie Infettive, EO Ospedali Galliera, Genova, <sup>2</sup>Dipartimento di Informatica, Bioingegneria, Robotica e Ingegneria dei Sistemi (DIBRIS) - Università di Genova, <sup>3</sup>Clinica Malattie Infettive, Ospedale Policlinico San Martino, Genova, Italy
- P 146 Psychological assessment of HIV-infected patients in need of a psychotherapeutic treatment: psychopathological related characteristics**  
*G.B. Delli Zotti, M.M. Ratti, E. Sangiovanni, L. Sarno*  
 Health and Clinical Psychology Service, IRCCS San Raffaele Hospital, Milan, Italy





## SOCIAL AND BEHAVIOURAL SCIENCE, MARGINALIZED GROUPS, COMMUNITY ASPECTS AND COMMUNITY SURVEYS

### P 147 Educational and training initiatives increase participants' competence about HIV

L. Rancilio<sup>1,2</sup>, C. Neglia<sup>2</sup> and the AIDS network of Caritas Italiana

<sup>1</sup>Caritas Ambrosiana, <sup>2</sup>Caritas Italiana, Italy

### P 148 Alcohol use disorder in HIV infected people

M. Scarzella<sup>1</sup>, G. Mozzone<sup>2</sup>, S. Rusconi<sup>3</sup>

<sup>1</sup>ASL AL, Dipartimento Patologia delle Dipendenze, S.S. Alcologia, <sup>2</sup>Medico, libero professionista, <sup>3</sup>Ospedale Luigi Sacco Milan, Italy

### P 149 Alice & frames - Alice e Cornici

A. Infante

Infection Disease Tor Vergata University Rome, Italy

### P 150 "What about AIDS?" Health education targeted at student population

S. Antonelli, P. Roselli, P. Mancino, M.P. Sciotti, M.R. Ferrone, M. Marra, M. Grasso, S. Del Borrello, C. Di Giambattista

U.O. Infectious Diseases Hospital Vasto - ASL 2 Lanciano-Vasto-Chieti-Regione Abruzzo, Italy

### P 151 Should we improve student's knowledge about STIs? Preliminary results from a pilot project in a Secondary High School in Sassari, Italy

N. Ronzoni, V. Fiore, P. Bagella, G. Caruana, F. Peruzzu, F. Mori Ubaldini, G. Flore, V. Nardi, A.G. Pintus, S. Babudieri, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

### P 152 Testing MSM in cruising venues: perception of the risk of infection

D. Zagato, A. Bianchi, A. Costantino, F.M. Esposito, G. Fissore, S. Lollì, M. Manfredini, V. Nicotera, D. Pennisi, A. Pezzotti, M. Pierini, F. Rossi, R. Rossotti, J. G. Scalisi, P. Testoni, P. Vinti, M. Zoia, M. Cernuschi

Associazione Solidarietà AIDS, Italy

### P 153 Serodiscordant partner: exception or normality?

M. Zetti, A. Bianchi, M. Cernuschi

ASA-Associazione Solidarietà Aids Onlus, Italy

### P 154 Behaviors and knowledge on HIV and sexually transmitted infections (STIs) among blood donors and people sensitive to donation

V. Regine<sup>1</sup>, L. Pugliese<sup>1</sup>, A. Argentoni<sup>2</sup>, V. Saturni<sup>2</sup>, F. Marchionni<sup>2</sup>, A. Simonetti<sup>2</sup>, B. Suligo<sup>1</sup>

<sup>1</sup>Centro Operativo AIDS, Istituto Superiore di Sanità, Roma, <sup>2</sup>Associazione Volontari Italiani del Sangue (AVIS), Italy

### P 155 The self-help group as a resource in better dealing with HIV infection: 10 years of experience in Arcobaleno AIDS

S. Patrucco<sup>1</sup>, A. Siliato<sup>2</sup>, P. Gusmeroli<sup>3</sup>, P. Altini<sup>4</sup>, G. Orofino<sup>5</sup>

Associazione Arcobaleno Aids, Italy

### P 156 #SalutediGruppo: using the social network Facebook as virtual motivators to physical exercise and wellness for persons living with HIV

F. Turrini<sup>1,2</sup>, M. Bonato<sup>3</sup>, L. Reiss<sup>4</sup>, L. Passeri<sup>1</sup>, L. Galli<sup>5</sup>, C. Vitobello<sup>1</sup>, A. Giordani<sup>1</sup>, S. Giuliani<sup>1</sup>, A. Meloni<sup>3</sup>, A. La Torre<sup>3</sup>, A. Lazzarin<sup>5</sup>, G. Merati<sup>3,6</sup>, P. Cinque<sup>1,4</sup>

<sup>1</sup>Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy, <sup>2</sup>Vita-Salute San-Raffaele University, Milan, Italy, <sup>3</sup>Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy, <sup>4</sup>New Media Office, Marketing and Communication Department, San Raffaele Hospital, Milan, Italy, <sup>5</sup>Department of Infectious Diseases, San Raffaele Hospital, Milan, Italy, <sup>6</sup>Centre of Sport Medicine, Don Carlo Gnocchi Foundation, Milan, Italy

### P 157 A desk for a material assistance, psychological support and work orientation for HIV-positive - LABORES

S. Negri<sup>1</sup>, M. Bagnato<sup>1</sup>, B. Bongini<sup>1</sup>, C. Falanga<sup>2</sup>

<sup>1</sup>GVMAS ONLUS, Milano, <sup>2</sup>ANLAIDS Sezione Lombarda, Milan, Italy

## TRANSLATIONAL SCIENCES

### P 158 The role of HIV protease inhibitors on mesenchymal stem cells in vitro differentiation

S. De Rose<sup>1</sup>, A. Cazzaniga<sup>2</sup>, V. Romeo<sup>2</sup>, J.A.M. Maier<sup>2</sup>, S. Rusconi<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, <sup>2</sup>Clinical and Biomedical Sciences Department, University of Milan, Italy



**P 159 Analyses of protective genetic polymorphisms in HIV-infected cART treated patients**

*E.M. Lori<sup>1</sup>, A. Cozzi-Leperi<sup>2</sup>, M. Biasin<sup>1</sup>, V. Mercurio<sup>1</sup>, S. Lo Caputo<sup>3</sup>, F. Castelli<sup>4</sup>, A. Castagna<sup>5</sup>, A. Gori<sup>6</sup>, G. Marchetti<sup>7</sup>, C. Venditti<sup>8</sup>, M. Clerici<sup>9,10</sup>, A. d'Arminio Monforte<sup>7</sup>*

<sup>1</sup>Department of Biomedical and Clinical Sciences, University of Milan, Milan, <sup>2</sup>Institute for Global Health, University College London, London, United Kingdom, <sup>3</sup>Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy, <sup>4</sup>University Department of Infectious and Tropical Diseases, ASST degli Spedali Civili di Brescia, University of Brescia, Brescia, Italy, <sup>5</sup>Department of Infectious Diseases, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy, <sup>6</sup>Department of Infectious Diseases, ASST di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, <sup>7</sup>Clinic of Infectious and Tropical Diseases, ASST Santi Paolo and Carlo, Department of Health Sciences, University of Milan, Milan, Italy, <sup>8</sup>UOC Microbiologia, Banca Biologica e Cell Factory, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, <sup>9</sup>Department of Physiopathology Medical-Surgery and Transplantation, University of Milan, Milan, Italy, <sup>10</sup>Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy

**ANY OTHER ISSUE**
**P 160 Prevalence, risk factors and subtypes of Blastocystis spp. in HIV infected patients in Italy**

*L. Fontanelli Sulekova<sup>1</sup>, M. Maiorano<sup>1</sup>, S. Gabrielli<sup>2</sup>, G. Iaiani<sup>1</sup>, C. Fimiani<sup>1</sup>, M. De Angelis<sup>1</sup>, E. Biliotti<sup>1</sup>, R. Esvan<sup>1</sup>, D. Palazzo<sup>1</sup>, M. Spaziante<sup>1</sup>, M. Rivano Capparuccia<sup>1</sup>, G. Taliani<sup>1</sup>*

<sup>1</sup>Department of Clinical Medicine, "Sapienza" University of Rome, Italy, <sup>2</sup>Institute of Public Health and Parasitology, "Sapienza" University of Rome, Italy

**P 161 Vaccination coverage in HIV positive adult patients in ASL 1 Imperia**

*I. De Macina<sup>1</sup>, R. Furnari<sup>2</sup>, D. Zollo<sup>2</sup>, M. Duberti<sup>2</sup>, A. Riccio<sup>1</sup>, C. Dentone<sup>1</sup>, M. Mela<sup>2</sup>*

<sup>1</sup>Infectious Diseases Unit, Sanremo Hospital, <sup>2</sup>Hygiene Unit, ASL 1 Imperia, Italy




10° CONGRESSO NAZIONALE



Italian Conference on  
AIDS and Antiviral Research



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



GENERAL  
INFORMATION



## GENERAL INFORMATION

### Conference Venue

#### Ergife Palace Hotel

Largo Lorenzo Mossa, 8 – 00165 Rome



### How to reach the Conference Venue



#### Public transportation

**Bus n. 246 e 247** Aurelia/da Rosate stop

**MEA** Cornelia stop (1,3 km from the venue)



#### Car

4 km from G.R.A. - Grande Raccordo Anulare di Roma



#### Airport

30 km from Fiumicino airport



#### Railway Station

12 km from Termini Railway

## Official languages

Italian and English. No simultaneous translation provided.

## Pre-conference advanced courses and Congress dates

**Pre-conference advanced courses:** Tuesday, May 22 from 13.30 to 16.00

**Congress:** from Tuesday, May 22 at 16.30 to Thursday, May 24 at 17.00

## Conference Secretariat opening times

Tuesday, May 22	Wednesday, May 23	Thursday, May 24
from 09.00 to 20.30	from 08.00 to 18.45	from 08.00 to 17.00

## Lunches

Tuesday, May 22	Wednesday, May 23	Thursday, May 24
only for Courses participants from 12.30 to 13.30	from 12.30 to 14.30	from 12.30 to 14.30

## Exhibition Area opening times

Tuesday, May 22	Wednesday, May 23	Thursday, May 24
from 13.30 to 20.30	from 08.00 to 18.45	from 08.00 to 17.00



## GENERAL INFORMATION

### Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least 2 hours before the session. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power-point presentations
- Last minute changes of power-point presentations
- Being supported by technical staff
- Uploading power-point presentation in the dedicated session conference room

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide**

### Oral Communication Sessions

Selected abstract will be presented in Oral Communication Sessions. The Authors of the selected abstract are requested to attend those sessions and provide max **8/10 (Microsoft Power Point) slides** resuming their poster. **Time allowed for presentation: 10 minutes followed by 2 minutes for discussion.**

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**

### Poster Discussion Sessions

Selected abstract will be presented in Oral Discussion Sessions. The Authors of the selected abstract are requested to attend those sessions and **provide max 5 (Microsoft Power Point) slides** resuming their poster. **Time allowed for presentation: 5 minutes followed by 2 minutes for discussion.**

**All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.**

Authors can set up their posters according to the number received from the Organizing Secretariat on **May 22, 2018 from h. 9.30 and remove them on May 24, 2018 at the end of the Congress.**

### Poster Exhibition

ICAR Poster exhibition will take place within a dedicated area of the Congress Center. Dimensions should not exceed 70x100 cm. Authors can set up their posters according to the number received from the Organizing Secretariat on **May 22, 2018 from h. 9.30 and remove them on May 24, 2018 at the end of the Congress.** See pages 82-85




## Quick test for HIV and HCV

At Piazza di Spagna on:

- **Saturday, May 19, from 11.00 to 17.00**
- **Sunday, May 20, from 11.00 to 17.00**

Healthcare personnel from Fondazione Villa Maraini will perform free rapid testing for HIV and HCV at the request of citizens in a confidential and anonymous way. The test is noninvasive, requires few minutes and is highly reliable.

*Realizzato con il supporto di Janssen  
e in collaborazione con Meridian Bioscience*



## RaccontART HIV

- **Tuesday May 22, Conference venue, Auditorium, from 13.30 to 16.30**

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through various forms of expression. Before the Conference Opening Session the winners will be awarded by the Jury composed of leading representatives of the national cultural world, ICAR Scientific Coordinators and Patients' Community. *See page 26.*





## OFFICIAL EVENTS



## ICAR-CROI Awards

**As tradition, the Young Italian Investigators will be awarded during the ICAR 2018 Opening Session in Auditorium, on Tuesday May 22, from 19.00 to 19.30. See page 28.**



## ICAR 2018 Best Poster Award

Among abstracts accepted as "Poster", 15 have been selected to participate in the "ICAR 2018 Best Poster Award". The winner will be announced on **Thursday, May 24, 2018 from 16.15 to 16.45 in Auditorium.**

The 15 selected posters will be recognizable in the Conference Venue through a cockade. A dedicated Commission will judge the posters in two time-slots during the Conference:

- **Wednesday, May 23, from 12.30 to 13.30**
- **Thursday, May 24, from 12.30 to 13.30**

Authors are requested to be close to their posters to meet the Commission during the time-slots above.



## SIMIT-ICAR special Awards

The 10th ICAR Chairs, Scientific Secretariat and Organizing Secretariat wish to thank SIMIT for the Special Awards addressed to Young Investigators:

**5 Awards** of € 2.000,00 each for the best abstracts accepted as Oral Communications in Clinical HIV (3 Awards), Clinical HCV (1 Award), Virology and Immunopathogenesis (1 Award), presented by young Investigators (under 40 aa), regularly registered to SIMIT for years 2017 and 2018.

**Abstracts will be selected at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2018 Special Awards Session, scheduled in Auditorium, on Thursday May 24, from 16.15 to 16.45.**



## Community Village

A specific area of the Congress Venue dedicated to the Community Village: a meeting point for all the participants to visit the booths of HIV/AIDS and Hepatitis patient associations and meet the Community activists. See page 83.



## Nice to ICAR you

The Secretary Meeting point where all registered participants can ask for ICAR T-shirt.



## Poster-4-you

A free service for selected posters' Authors to create and print their own posters and pick them up at the Poster exhibition area inside the Congress Venue. **Poster-4-you** USB Pendrive can be requested showing the coupon at the Gilead Sciences booth.

*Unrestricted educational grant of Gilead Sciences*



## Abstract USB Pendrive

All registered participants can ask for the **ICAR Abstract USB Pendrive** showing the coupon at ViiV Healthcare booth: it contains all accepted abstracts.

*Unrestricted educational grant of ViiV Healthcare*



## Website and Web Repository

After the Congress, the ICAR official website ([www.icar2018.it](http://www.icar2018.it)) will publish the ICAR 2018 web repository with abstracts, presentations, oral communications, accepted posters, podcasts and photo gallery.

## Social Media





## CME ACCREDITATION



## Conference

The 10th ICAR Conference has been accredited to the Italian Ministry of Health for **14,7 CME Credits**.

Every single day has been accredited for the following professionals:

<b>Id ECM Number</b>	<b>Credits</b>	<b>Professionals</b>
Tuesday, May 22 <b>150-220725</b>	<b>2,8</b>	<b>Medical Doctor</b> Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine, Gastroenterology, Hematology, Oncology <b>Healthcare Assistant, Biologist, Pharmacist,                      Nurse, Medical laboratory technician, Psychologist</b>
Wednesday, May 23 <b>150-220729</b>	<b>6,3</b>	
Wednesday, May 24 <b>150-220736</b>	<b>5,6</b>	

## Pre-conference advanced Courses

The 10th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

<b>Id ECM Number</b>	<b>Credits</b>	<b>Professionals</b>
HIV Reservoir <b>150-224919</b>	<b>2</b>	<b>Medical Doctor</b> Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine, Gastroenterology <b>Biologist, Medical laboratory technician</b>
Le infezioni opportunistiche: sfide diagnostiche e problematiche cliniche <b>150-224922</b>	<b>2</b>	<b>Medical Doctor</b> Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine, Gastroenterology <b>Biologist</b>
La gestione della terapia antiretrovirale: nuove opzioni diagnostiche <b>150-224926</b>	<b>2</b>	<b>Medical Doctor</b> Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine, Gastroenterology <b>Biologist, Hospital Pharmacist</b>
Prendere decisioni in sanità: l'approccio GRADE <b>150-224908</b>	<b>2</b>	<b>All CME professionals</b>
Competenze avanzate degli infermieri <b>150-224933</b>	<b>2</b>	<b>Professional educator, Psychologist,                      Neurophysiology technician, Medical Doctor</b> Infectious and Tropical Diseases; Hygiene, Epidemiology and Public Health; Internal Medicine

## Obtaining CME credits

### Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day

### Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see Participants).

### Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

### CME Certificates

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.



## REGISTRATION FEES

### Pre-conference advanced Courses

Free of charge (registrations available on a “first come, first served” basis).

**Registration includes:** congress kit (delegate bag, badge, certificate of attendance), CME registration and materials, working brunch and coffee breaks during the day of the course.

### Conference

#### Conference Registration Fees (22% VAT non included)

Physicians	€ 700,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologis	€ 310,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

**The registration fee includes:** congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on May 22, coffee breaks and lunches on May 23 and 24, CME registration, Conference USB/abstract and poster.

#### Daily Conference registration fees (22% VAT not included)

Physicians	€ 300,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologis	€ 150,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

**The registration fee includes:** attendance to the sessions of the day, congress kit (delegate bag, badge), Conference USB/abstract and poster, coffee break and lunch for the day, certificate of attendance for the sessions of the day.




10° CONGRESSO NAZIONALE



Italian Conference on  
AIDS and Antiviral Research



22-24  
MAGGIO  
2018  
ERGIFE  
PALACE HOTEL,  
ROMA



CONGRESS  
MAP




SCIENTIFIC PROGRAMME

**PIANO TERRA**

- SEGRETERIA ORGANIZZATIVA
- NICE TO ICAR YOU
- GUARDAROBA
- SALA PERGAMO
- SALA VOLUBILIS
- AGORA' VIIV
- AGORA' COMMUNITY
- LUNCH AREA




<b>H</b>	Anlaidis	<b>N</b>	ASA ONLUS	<b>R</b>	CICA
<b>I</b>	PLUS	<b>O</b>	NPS	<b>S</b>	Caritas Italiana
<b>L</b>	LEGA ITALIANA PER LA LOTTA CONTRO L'AIDS	<b>P</b>	RECOPALENDA	<b>T</b>	Coordinamento Romano HIV
<b>M</b>	ARCIGAY	<b>Q</b>	mariomielli	<b>U</b>	Fondazione Villa Maraini O.N.L.U.S.
				<b>V</b>	



**PIANO -1**

- AREA POSTER
- SALA CESAREA
- VILLAGGIO COMMUNITY
- SALA POLA
- SALA ORANGE 1
- SALA SPALATO
- SALA SIMIT
- SALA ICAR
- UFFICIO STAMPA
- DESK SIMIT
- AGORA' GILEAD






SCIENTIFIC PROGRAMME

10° CONGRESSO NAZIONALE  
**ICAR** 22-24 MAGGIO 2018  
 ERGIFE PALACE HOTEL, ROMA  
 Italian Conference on  
**AIDS and Antiviral Research**

**PIANO -2**

AREA ESPOSITIVA  
 AREA POSTER  
 AUDITORIUM  
 LEPTIS MAGNA  
 CENTRO SLIDE







## THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

---

### PLATINUM



---

### GOLD



---

### SILVER



---

### OTHER





## **PROVIDER AND ORGANIZING SECRETARIAT**

### **Effetti srl**

Via G.B. Giorgini, 16 - 20151 Milan, I  
Phone +39 02 3343281 - Fax +39 02 33496370  
icar2018@effetti.it

## **CONGRESS VENUE**

### **ERGIFE Palace Hotel**

Largo Lorenzo Massa, 8 - 00165 Rome, I

## **QUICK LINKS**

**Organizing Secretariat** [icar2018@effetti.it](mailto:icar2018@effetti.it)

**Abstract Secretariat** [abstract.icar2018@effetti.it](mailto:abstract.icar2018@effetti.it)

**ICAR Website** [www.icar2018.it](http://www.icar2018.it)



[www.facebook.com/ICAR2018Roma](http://www.facebook.com/ICAR2018Roma)



[twitter.com/ICAR2018Roma](https://twitter.com/ICAR2018Roma)